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ABSTRACT
STRATEGIES FOR THE MODULATION OF PROTEASE ACTIVATED
RECEPTORS (PARs)

Disha M. Gandhi, B.Pharm, M.Pharm

Marquette University. 2018

Protease-activated receptors (PARs) are class A G protein-coupled receptors
(GPCRs) with 4 subtypes (PAR 1 – 4) and with a unique mode of action. PARs are
cleaved by extracellular proteases at the N-terminus, creating a new tethered ligand that
activates the receptor and transduces biological signals into the cell. PARs have been
implicated in various productive and pathological signals, including those related to
thrombosis, inflammation, reperfusion injury, and cancer cell metastasis. Despite the fact
that PARs are attractive as drug targets, their intramolecular mode of activation makes it
challenging to modulate them with drugs in a selective manner, and only one PARtargeting therapy, the PAR1 antagonist and antiplatelet drug vorapaxar, is currently
approved by the FDA. Previously in the Dockendorff lab, compounds with a 1,3diaminobenzene scaffold, called parmodulins, were identified as biased ligands of PAR1
that selectively inhibit Gαq-mediated signaling of PAR1 without significantly inhibiting
Gα12/13-mediated signaling leading to platelet shape change. More recently,
cytoprotective and anti-inflammatory effects of parmodulins in endothelial cells were
identified that could be fruitful for the treatment of sepsis and myocardial infarction. We
developed a Gαq-mediated intracellular Ca2+ mobilization (iCa2+) assay in endothelial
cells to perform medium-throughput screening and characterization of parmodulins, and
we demonstrated that they are reversible, negative allosteric modulators of PAR1, unlike
ligands such as vorapaxar. We also extended structure-activity relationship (SAR) studies
of parmodulins to identify analogues with potentially improved properties using
medicinal chemistry, and these parmodulins are promising leads for safer antithrombotic
and sepsis drugs. Additionally, we commenced investigations into the role of heteromeric
PAR complexes in proliferative disorders such as restenosis and cancer cell metastasis.
We synthesized a novel class of bivalent ligands targeting putative PAR1/2 heteromers
and characterized them using our iCa2+ assay with endothelial cells (EA.hy926) and the
breast cancer cell line MDA-MB-231. Such bivalent PAR ligands hold promise for the
selective treatment of cancer and other proliferative disorders.
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Chapter 1

Introduction of GPCRs and PARs

1.1. Overview of GPCRs

Figure 1.1. Heterotrimeric G-protein associated intracellularly with GPCR.

G-protein coupled receptors (GPCRs) are the largest and most diverse family of
membrane proteins in eukaryotes (Figure 1.1). Structurally, GPCRs are the single
polypeptides with seven folds located at cell membrane. The polypeptide possesses Nterminus at extracellular site and C-terminus at intracellular site along with heterotrimeric
G-protein. They act like messengers to communicate with peptides, hormones, small
molecules, etc. to mediate most cellular responses. They are responsible for the vast array
of functions in human body like vision, olfaction, and taste. They are also involved in
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normal heart function to neuronal activity and widely present in every organ of the body.
Hence, mutation to GPCRs have been reported to triggering many diseases like cancer,
cardiovascular dysfunction, neuronal disorders, diabetes, inflammation and pain, and
have been identified as potential drug targets for a majority of the best selling drugs and
overall of 40% of prescribed pharmaceuticals till this date. 1
GPCRs, based on sequence homology and structural similarities, are commonly
classified in 6 different families. Family A, rhodopsin receptor family is by far the largest
family, which accounts for approximately 85% of GPCR genes and over 50% of these are
involved with the olfaction.2 Rhodopsin family is further subdivided to three classes
based on their mode of activation. Class 1 (A1) includes small ligands activated
rhodopsin and β-adrenergic receptors. Class 2 (A2) includes the receptors activated by Nterminal peptides and class 3 (A3) includes GPCRs for glycoprotein ligands. Family B,
secretin receptor family shares similar morphology to A3 family but has different
sequence homology. Hormones like growth hormones, calcitonin, secretin, glucagon,
etc., also activate this family of GPCRs. Family C, metabotropic glutamate receptor
family mainly includes mGluR, olfactory, taste, Ca2+ sensing and GABA receptors.3 This
family by so far is the most potential target for CNS disorders due to involvement of
excitatory glutamate hormone binding to mGluR and inhibitory GABA binding to GABA
receptors. Both Family D and E, fungus pheromone receptor family and cAMP receptor
family, don’t found in vertebrates. Family F, frizzled/Smoothened receptor family: This
family recruits 10 frizzled (FZD) and smoothened (SMO) receptors. Theses receptors are
involved in the embryonic development. The FZDs are activated by lipoglycoproteins,
whereas SMO is activated by transmembrane proteins.4
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1.2.

Structure and mode of action of GPCRs

A.

B.

C.

D.

Figure 1.2: Selected examples of GPCR crystal structure in ribbon cartoon. A) human beta2 adrenergic
receptor;5 B) dopamine D3 receptor;6 C) morphine opioid receptor (uOR);7 D) 5-HT1B receptor.8

GPCRs, also known as seven transmembrane receptors (7TMRs), are structurally
a single polypeptide arranged in 7 folds that compose a cylindrical/barrel shape in the cell
membrane. These folds are arranged as alternative transmembrane α-helices (TM1 -
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TM7), connected by intracellular loops (IL 1-3) and extracellular loops (EL 1-3), with an
extracellular N-terminus and an intracellular C-terminus and a heterotrimeric G-protein at
the intracellular side (Figure 1.1). X-ray characterization of few GPCRs has been
reported in literature (Figure 1.2). Due to their cylindrical/barrel shape, GPCRs make a
cavity within the cell membrane that is open on the extracellular side, which is known as
ligand binding pocket/active site, from where GPCRs serve as the essential nodes of
Inactive

Active

Figure 1.3. Activation of β2AR receptor by adrenaline: After binding with adrenaline, receptor changes its
conformation to activate heterotrimeric G-protein complex by exchanging GTP from cytosol to GDP.
Heterotrimeric complex dissociates and GTP-Gα activates adenylate cyclase to activate cAMP from ATP
and therefore activates protein kinase A. Activation of receptor also leads to phosphorylation by G-proteincoupled receptor kinase (GRK) and thus coupling with β-arrestin. Arrestin is signaling regulatory protein
that promotes activation of extracellular signal regulated kinases (ERK) and promotes internalization of the
receptor.
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communications between extracellular and intracellular cell environment. First a ligand
binds to the GPCRs at the active site, changes the receptor conformation in a way to
stimulate the associated heterotrimeric G proteins, which in turn leads to the modulation
of downstream effector proteins. The conformational change in the heterotrimeric Gprotein releases guanosine diphosphate (GDP) from the G α subunit in exchange for
guanosine triphosphate (GTP). The GTP bound G α subunit then dissociates from the Gβγ
dimer subunit, and both GTP-Gα, and Gβγ can trigger several cellular signaling pathways.
For example, β2-adrenergic receptor (β2AR) is a subtype of adrenergic GPCRs and
belongs to family A (Subfamily A17, cAMP receptors) of GPCRs. 9 Binding of the
hormone adrenaline to β2AR leads to the activation of G αs subunit, which activates
downstream signaling pathways. In this case, activated Gαs activates cAMP-dependent
phosphorylation of protein kinase A (PKA) via stimulation of adenylate cyclase, and
ultimately triggers smooth muscle contraction (Figure 1.2). 2

D+ R+G

K

RG

E (Active)

L

M

D+

Low afﬁnity
DR + G

K'

E (Inactive)
DRG
High afﬁnity

Figure 1.4: A ternary complex model (D- Agonist. R- Receptor, G- G protein, E-Enzyme, K, K`, L, MRate constants)10
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Over past 40 years, extensive efforts have been undertaken to investigate the
mode of action of GPCRs and their involvement in normal and pathological processes.
For instance, Lefkowitz and co-workers proposed a ternary complex model10 to
understand the allosteric mode of activation of G-protein mediated signal transduction
pathway. The ternary complex model (Figure 1.4) involves an agonist (D, e.g., hormone,
neurotransmitters), 7-TMR (R) and G-protein (G) as activated signaling unit. The agonist
binds to an extracellular region (the binding pocket) of the 7-TMR to form a low affinity
binary [DR] complex which further leads to a conformational change of the receptor and
associates with guanine nucleotide G at the intracellular region to form DRG, a high
affinity ternary complex. For example, adrenaline binds to β2AR and G-protein forming a
high affinity ternary complex, which in turn exchanges GDP for GTP. The resultant
GTP-Gɑ complex activates adenylate cyclase. In other words, after ligand binding,
GPCRs lead to the conformational change, transduce the signal via heterotrimeric G
proteins to various downstream effectors via G-protein dependent and independent
pathways and each pathway can stimulate a variety of intracellular signaling cascades to
mediate physiological responses.

1.2.1. GPCR-mediated signaling

1.2.1.1.

G-protein dependent signaling

G-proteins exist in complex heterotrimeric forms. They are comprised of a G α
subunit and Gβγ dimer. After agonist binding to GPCR, the conformational change in the
GPCR leads to activation of the G-protein causing nucleotide exchange of GDP for GTP
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in the Gα subunit (Figure 1.2).11-13 The active GTP-bound Gα subunit then dissociates
from the receptor and Gβγ dimer and activates/inhibits downstream effector proteins, and
regulators of G-protein-signaling (RGS) proteins. For example, RGS proteins, containing
GTPase-activating protein, attenuate GTPase activity of G α subunits and thereby decrease
its signal amplitude and duration. 11 RGS proteins, containing guanine nucleotide
dissociation protein, inhibit dissociation of Gα subunits and thereby inhibit Gα mediated
signaling.

Gα subunit: Structurally, Gα subunits are 39-45 kDa proteins, modified at the N-terminus
by the covalent attachment of myristate/palmitate fatty acids. The lipophilic portion is
mainly responsible for the specific signal transduction of G α subunits. Palmitolyation is
responsible for the stable attachment of Gα with the receptor, whereas myristolyation is
responsible for membrane localization of G α. Based on sequence similarity, Gα proteins
are divided into four major class: G α(s/olf), Gα(i1/i2/i3/o/z/gust/t-cone/t-rod/), Gα(q/11/14/16) and Gα(12/13).
Functionally, Gα subunits are responsible for targeting from the specific membrane region
of the receptor and interactions with other effector proteins like stimulate or inhibit
kinase and adenylyl cyclase or regulate small G-protein like RhoA.14

Gβγ subunit: The Gβγ subunit is a heterodimer of Gβ and Gγ polypeptides. There are 5
known genes encoding Gβ and 12 known genes encoding Gγ, leading to potential
combinations of Gβγ polypeptide dimers. Gβ contains seven WD40 units (tryptophan –
aspartic acid repeats for 40 times), and these seven units are arranged anti-parallel in βstrands, while the N-terminus of Gβ forms α-helix. Unlike the Gα subunit, the C-terminus
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of the Gγ subunit is prenylated either with 15-carbon farnesyl or 20-carbon
geranylgeranyl moiety. Similar to Gα, this lipophilic portion of Gγ is responsible for the
membrane localization of the Gβγ heterodimer. As of now, there are more reported in vitro
assays measuring Gα function, but Gβγ-mediated signal transduction has gained attention
to better understand the roles of Gβγ heterodimer in downstream effector activation. In
addition, Gβγ doesn’t change conformation like G α when it dissociates from heterogenic
trimer unit and doesn’t activate any effectors when it’ associated with G α.14

1.2.1.2.

G-protein independent / β-arrestin-mediated signaling

Figure 1.5. GPCR activation after ligand binding activates the heterotrimeric G-protein and β-arrestin.
Activated β-arrestin desensitizes or internalizes the dissociated GTP bound receptor and shuts down Gprotein mediated signaling. Alternatively, β-arrestin transduces its own signal.

β-arrestins are ubiquitously expressed in mammalian tissues. They play a key role
in the termination of GPCR signals by desensitization and internalization (Figure 1.5).15
Following agonist binding and phosphorylation of the C-terminus of the receptor by G-
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protein-coupled receptor kinases (GRKs), β-arrestin can form a complex with the
receptor, and prevent further activation of G-proteins, effectively turning off G-proteinmediated signaling (also termed GPCR desensitization). β-arrestin desensitizes GPCRs
either by blocking GPCR – G-protein interactions or by the recruitment of enzymes to
degrade secondary messenger molecules.16
β-arrestin also plays an important role in receptor internalization, the process of
transporting GPCRs into intracellular compartments. β-arrestin-mediated internalization
is a first crucial step in the recycling of desensitized receptors. Internalized receptors are
then involved in the receptor trafficking where they either recycled to plasma membranes
or degraded by enzymes.16, 17
In recent studies, β-arrestin has also shown to transduce signal through G-protein
independent pathway in the regulation of cardiovascular function15 and could be an
important tool for the treatment for heart failure. More rigorous investigations are
underway to understand β-arrestin signaling mechanism, and its ultimate significance in
finding novel drug targets.

1.2.2. Interaction of ligands with GPCRs

GPCRs are one of the best targets to develop medications and have maintained
popularity amongst medicinal chemists because of their broad spectrum of interactions
with ligands. In a traditional way, a ligand that activates the receptor is called agonist,
and a ligand that blocks the activation of the receptor is known as antagonist. However,
ligand – receptor interactions are not limited to only activation or inhibition, but they are
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also dependent on the binding site and kinetics of binding (Figure 1.6). A ligand can
interact with the receptor either binding to an orthosteric site (natural ligand binding-

Receptor - Ligand interactions

Based on signaling pattern

Agonism (ligand that
activates the receptor)

Antagonism (ligand that
block the activation of the
receptor)

Based on interaction site

Based on reaction kinetics

Orthosteric site (active site)

Competitive (reversible)
binding

Allosteric site

Non-competitive
(irreversible) binding

Figure 1.6. Categorizations of ligand-receptor interactions

pocket) or to an alternative (allosteric) site. Orthosteric antagonists bind to the agonist
active site typically in a competitive or non-competitive fashion and shut down all
signaling, whereas allosteric antagonists bind to an alternative site of the receptor relative
to the agonist, altering the receptor conformation in a way that can shut down some or all
of the defined signaling through the receptor.
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Figure 1.7. Differences between full/partial agonist, antagonist, and inverse agonist signaling

Traditionally, apart from full agonists and antagonists, a ligand can stimulate the
receptor with a lower efficacy compared to a full agonist. Such ligands are termed partial
agonists. GPCRs may also have basal activity even in the absence of a ligand. In such
cases, if a ligand binds to the receptor as an agonist but produces an opposite
pharmacological response, i.e. the response is less than the basal level, it is termed an
inverse agonist (Figure 1.7). The agonist activity is measured in terms of EC50 (the
concentration of agonist at which the response is half its maximal value), and antagonist
activity is measured in terms of IC50 (the concentration of antagonist which inhibits the
response to half its maximal value).
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A) Orthosteric ligands of GPCRs.

Figure 1.8: Schematic representation of orthosteric binding of agonist and antagonist at ligand binding
pocket

As discussed in earlier sections, 7-TMRs can transduce the signal via either Gprotein or β-arrestin pathways. Therefore, ligands are categorized by their interactions
with GPCRs and the resulting signals. The ligand-binding pocket, exposed to the
extracellular site, is termed active sit. In general, antagonists, full agonists, partial
agonists and inverse agonists interact with GPCR at active site, resulting in the complete
activation of all G-protein mediated signals. Such ligands are termed as orthosteric
agonists. In contrast, ligands that shut down all G-protein signaling are termed as
orthosteric antagonists (Figure 1.8).
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B) Allosteric modulators and biased ligands of GPCRs.

Figure 1.9: Schematic representation of biased signaling of GPCRS: A) Balanced/non-biased signaling; B)
Biased agonist favors only one G-protein mediated signaling; C) β-arrestin biased agonist potentiated only
β-arrestin signaling; D) PAM in presence of an orthosteric agonist prefers only one G-protein mediated
signaling; E) NAM in presence of an orthosteric agonist inhibits only one G-protein mediated signaling.

Allosterism of GPCRs has gained popularity amongst the researchers due to the
diverse signaling pattern. Allosteric modulators possess different binding site than
orthosteric ligands and can alter the selectivity, affinity, efficacy and potency of
orthosteric ligands via modulating conformational changes. In literature, allosteric
modulators are identified as negative allosteric modulators (NAM) and positive allosteric
modulators (PAM). NAMs decrease the efficacy or affinity to the orthosteric binding site
of the agonists. Conversely, PAMs increase the efficacy or affinity of the agonists at the
orthosteric site. However, it’s been reported that the presence of an orthosteric agonist is
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necessary to exhibit effects of PAMs. 18, 19 In some cases, ligands bind at the active site of
the receptor, but exerts biased signaling pattern like NAMs and PAMs. These ligands
favors either only one G-protein mediate signaling or β-arrestin mediated signaling or
such ligands are called as biased ligands (figure 1.9). These ligands stabilize receptor
conformation in a way to affect only one signaling over others but the exact reason for
such biased behavior is unknown. Investigations in studying ligand-receptor interaction
will provide vital information about how we can modify such type of interactions in
designing of drugs.
Focusing on allosteric nature and biased signaling pathways of GPCRs, this
project work mainly enlightens structural and functional insights of PARs to understand
ligand interaction and selectivity with the receptor in a biased way to modify GPCR
signal and to utilize this application in drug discovery.

1.3

Protease Activated Receptors (PARs): A novel family of GPCR as potential

therapeutic targets

Protease Activated Receptors (PARs), are a novel family of GPCRs with a unique
mode of action. Instead of being stimulated with ligands (endogenous ligands like
hormone, neurotransmitters, small molecules, etc,) binding at the active site, this family
of receptors is activated by the cleavage of the extracellular N-terminus by serine
proteases, generating a new tethered ligand that interacts with the extracellular loop of the
receptor and activates the downstream signaling pathways. 20
There are four different types of PARs (PAR1-4), which have been identified in
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part based on unique N-terminal cleavage sites. Amongst these, human PAR1,21,
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PAR3,23 and PAR424, 25 can be activated by the serine protease thrombin and activated
protein C (APC). PAR2 is activated by trypsin26 and tryptase27 as well as by coagulation
factors VIIa and Xa,28 but not by thrombin.29 PAR1 is the main “thrombin receptor” in
human platelets. PAR1 is also expressed in endothelial cells, fibroblasts, monocytes, and
smooth muscle cells. PAR2 and PAR3 are expressed in endothelial cells, but notably not
in human platelets. Similar to PAR1, PAR4 is also expressed in human platelets but
possesses lower affinity for thrombin. 30 In platelets, thrombin cleaves the extracellular Nterminus of PAR1 and PAR4 receptors at low and high concentration respectively, which
activates Gαi mediated granule secretion and G12/13 mediated platelet aggregation.

1.3.1. Platelets as therapeutic targets for antithrombotic agents

Platelets are disc-shaped cells found in the blood and plasma that can become
activated upon vascular injury and help to form clots to prevent blood loss from
hemorrhage. The activation of platelets is an essential function during haemostasis.
Haemostasis is the physiological response of the blood vessels to maintain blood fluidity
and to limit the damage from hemorrhage by forming blood clots. After an injury,
thrombin activates platelet aggregation at the site of an injury to prevent blood loss. The
adhered platelets recruit more platelets, which aggregate to form an armored plug
covering the injury. Although blood clotting is an essential function to prevent blood loss
upon tissue injury, excess or undesired thrombus formation must be avoided. For
example, upon vascular damage, such as rupture of an arteriosclerotic plaque, plateletmediated thrombosis of a coronary artery can result in acute myocardial infarction (MI),
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and thrombosis of a cerebral artery can results in acute ischemic stroke. These thrombotic
events are the leading cause of morbidity and mortality in the industrialized world 31 and
platelet aggregation inhibitors play a vital role in the prevention of such adverse
cardiovascular events.

1.3.2. PAR1 as a therapeutic target

Thrombus formation occurs via activation of platelets, and coagulation cascade.
At the end of coagulation cascade, thrombin activates fibrin and thus activates platelets.
There are numerous anti-thrombotic agents in clinical use to prevent thrombus formation
or dissolve existing one. These drugs either target coagulation cascade to prevent
thrombin formation or target platelets aggregation. Hence, current anti-thrombotics bear
the risk of excess bleeding. In addition, the application of current anti-platelet therapy has
significant limitations like inadequate platelet response, delayed onset of action and
increased bleeding risks.32, 33 Moreover, poor oral bioavailability of this class of drugs has
limited their use. These limitations have provided the motivation to fulfill an unmet
clinical demand of antiplatelet therapy with better pharmacokinetic and pharmacological
profile. Now, as described earlier, thrombin also activates PAR1 and hence, acts as a dual
activator of platelets. Therefore, PAR1 could be better therapeutic target to selectively
block only one pathway of platelet aggregation that could be beneficial in providing the
treatment with less bleeding risk and maintain hemostatic balance. Furthermore, recently
FDA approved, orally active, orthosteric antagonist of PAR1 (vorapaxar) has opened the
doors to PAR targeted therapies for the development of safe and orally active
antithrombotic agents.
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1.3.3. Mode of action

Figure 1.10. Activation of PAR1 by cleavage of its N-terminal tethered ligand by thrombin. Upon
activation by thrombin, PAR1 signals through Gαq and Gα12/13, causing granule secretion and platelet shape
change, both of which are important for clot formation. PAR1 can also activate β-arrestin in endothelial
cells, which may have cytoprotective effects.

PAR1 is activated by an unusual proteolytic mechanism. Thrombin recognizes the Nterminal exodomain of PAR1 and cleaves the peptide bond between Arg41 and Ser42
residues. The resultant SFLLRN sequence functions as a tethered ligand and binds to the
receptor intramolecularly to transduce signaling. Thus PAR1 is a peptide receptor that
carries its own ligand, the latter being active only after receptor cleavage (Figure 1.10).34

1.4

Orthosteric antagonism of PAR1

PAR1 inhibitors could serve as important antiplatelet drug candidates by
inhibiting thrombin-induced platelet activation but not thrombin-induced cleavage of
fibrinogen (the final step in coagulation) and thus may provide an optimal balance
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between a reduced risk of thrombosis and an increased risk of bleeding. Therefore, many
investigations are underway to target PAR1-mediated platelet aggregation with the
promise of providing anti-platelet

agents with better pharmacodynamic and

pharmacokinetic profiles. However, PAR1 carries its own agonist for activation, which
makes it difficult to develop small molecules as PAR1 antagonists since they need to
compete with the high effective concentration of the tethered ligand at the PAR1 binding
site. However, several efforts were attempted to develop orthosteric antagonists of PAR1.
Amongst them, 3 distinct approaches have been reported to develop orthosteric
antagonists of PAR1: peptidomimetic antagonist and non-peptide antagonist.

1.4.1 Peptidomimetic antagonists

Figure 1.11. Peptidomimetic antagonist: 1- RWJ-56110 and 2- RWJ-58259, reported IC50 in TRAP
induced (SFLLRN-NH2, 2 µM) receptor binding assay.

Thrombin cleaves the N-terminus of PAR1 at Arg41-Ser42 and exposes
SFLLRN, which acts as an agonist of PAR1. 35 Therefore, the design of peptidomimetics
can be based on the structure of SFLLRN. The structure-function requirements for these
peptides are a terminal free amine, adjacent to an aromatic ring (such as phenylalanine),
and a basic residue such as arginine. Based on these requirements, initially 6-aminoindole
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Pharmaceuticals.36 The 6-aminoindole template meets the required spatial arrangement of
the pharmacophore and hence, it was selected as a scaffold for the development of
orthosteric antagonists of PAR1. The first potent molecule based on the 6-aminoindole
template was RWJ-56110 (1, Figure 1.10), which showed an IC50 of 0.16 µM in a
SFLLRN-NH2-induced platelet aggregation assay.37 However, RWJ56110 showed
hypotensive effects in guinea pig models, which led to the development of RWJ-58259
(2, Figure 1.11),38 using the related 6-aminoindazole scaffold. RWJ-58259 was the most
potent analogue in this series with 0.11 µM IC50 in the SFLLRN-NH2-induced platelet
aggregation assay, however, RWJ-58259 was not advanced to the clinical trials because
of poor oral bioavailability and short half-life.38

1.4.2

Non-peptide based antagonist

Anh and coworkers at Schering-Plough discovered a series of pyrroloquinazoline
PAR1 antagonists (Figure 1.12). They introduced SCH-79797 (3) and its N-methylated
derivative SCH-203099 (4) as the first high-affinity PAR1 ligands with nanomolar
potencies (IC50 70 and 45 nM respectively in TRAP – thrombine receptor activated
peptide induced binding assay). Both ligands were the new embankment to achieve nonpeptide based PAR1 antagonists where entropic restrictions of PAR1 tethered peptide
didn’t hamper binding with PAR1. Unfortunately due to the lack of sustained inhibition,
both ligands could not proceed further. 39
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Figure 1.12. Non-peptide based antagonist: reported IC50 in TRAP (SFLLRN-NH2) assay.

Benzimidazole derivatives (5, figure 1.12) with modest affinities were reported by
Schering-Plough.40 Urea 641 and phenyl-isoxazole 742 were also reported by Merck with
sub-micromolar potencies. Schering-Plough and Eisai reported cyclic guanidine and
amidine30 based molecules 8 and 9 with nanomolar potencies. Both antagonists were
advanced to clinical trials for the treatment of acute coronary syndrome (ACS,) the latter
was in phase II clinical trial.43
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Himbacine (10, Figure 1.12) is a tetracyclic piperidine alkaloid isolated from the
bark of the Australian pine tree of the Galbulimima species. It was discovered to be a
potent inhibitor of the M2 muscarinic receptor.44 The original therapeutic interest for
himbacine was to treat cognitive defects from Alzheimer’s disease, and it had no activity
against PAR1. During the SAR studies of himbacine, the more basic piperdine ring was
replaced with the less basic pyridine, resulting in analogue 11 (Figure 1.13). Decreasing
the basicity resulted in a loss of muscarinic activity in 11, but an unrelated, later screen
led to the discovery that it inhibited PAR1 with an IC50 of 300 nM in the TRAP induced
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binding assay, and that was the first breakthrough in the development of the first orally
available PAR1 antagonist.45 The resolution of racemic 11 to 11a (Figure 1.13) showed
the activity against PAR1 was greater for the ent-himbacine analogue with an IC50 of 150
nm. Further SAR investigations led to development of 12 (SCH-205831) with the biaryl
group attached to the tricyclic core. 12 was highly potent, with an IC50 of 11 nM in the
TRAP assay, and Ki of 2.7 nM. However, 12 was subjected to enzyme induced
metabolism in monkeys and the tricyclic core of 12 was oxidized in vivo to 13 (SCH219122). 13 was less potent than 12 but has considerable potency with an IC50 of 17 nM
in TRAP assay and Ki was 11 nM. Unfortunately, 13 had a poor clearance profile in
monkeys (80% clearance observed after 30 days with IV dose 1 mg/kg) and needed
further SAR investigations.46 SAR studies on the tricyclic core led to the development of
14 (SCH-530348, also known as vorapaxar and Zontivity®, Figure 1.13). It is the
carbamate analogue of 13 with the best pharamacokinetic and pharmacodynamics profile
of this series. 14 (vorapaxar) inhibited SFLLRN-NH2-induced platelet aggregation with
an IC50 of 15 nM and Ki of 8.5 nM in a competitive binding assay. 14 showed prolonged
inhibition of platelets (100% inhibition for 24 h), and was orally active with 86%
bioavailability.47 Later, 14 was approved by FDA as the first PAR1 antagonist, for use as
an anti-thrombotic agent for the treatment of secondary prevention of MI and PCI
(percutaneous coronary intervention).48

1.5 Allosteric antagonism of PAR1 and project aim

As discussed in earlier section, several orthosteric antagonists were synthesized
for PAR1 but only 2 candidates proceeded to clinical trials were 9 and 14, the latter was
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approved by FDA in 2014.48 9 is in phase II clinical trail for treatment of ACS, however,
9 showed a higher rate of TIMI (thrombolysis in myocardial infarction) bleeding in high
doses.49 In addition, 9 showed dose-dependent increase in liver transaminases and QTcF
prolongation.49, 50 On the other hand, 14 showed increased risk of intracranial bleeding
and it cannot be used in patients with history of stroke. 50-53 Therefore, safe and effective
treatments for patients with coronary artery diseases (CAD) are still needed.

Figure 1.14: High resolution (2.2 Å) crystal structure of modified PAR1 with vorapaxar 14 (in green).54

Coughlin and co-workers reported a crystal structure of 14 bound to PAR1
(Figure 1.14).54 14 binds to PAR1 at the orthosteric site near the extracellular surface, in
contrast to other GPCR ligands that usually penetrate more deeply into the
transmembrane core. PAR1 carries its own agonist as a tethered ligand. When 14 binds to
PAR1, it can be covered with excess tethered ligand of PAR1, to prevent 14 from leaving
the receptor easily. Indeed, evidence supports binding of 14 to PAR1 in a virtually
irreversible manner with a very low off rate that may be one of the possibility to cause
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excess bleeding effects associated with 14 (Figure 1.14).54

Figure 1.15: Concentration-response curves of SFLLRN-NH2 in the presence of different concentrations of
vorapaxar (14, VOR). Insurmountable response dependent on dose of 14 indicates irreversible binding of
14 to PAR1.54

In summary, the high risk of irreversible binding and complete shutdown of Gprotein mediated signaling by orthosteric antagonists to PAR1 could explain possible
excess bleeding risks and undesired side effects associated with the use of these antithrombotic agents. Selective inhibition of G-protein downstream signaling could be
beneficial, and it could be achieved by binding a ligand at an allosteric site, which could
also offer more reversible effects. This is one of the main topics for our project.
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Project snapshot:

Figure 1.16: Comparison of 14 (as orthosteric antagonist, A) and parmodulin (as allosteric modulator, B)
on downstream singling of PAR1 and its ultimate pharmacological effect.

This project emphasizes the design and development of allosteric modulators of
PAR1, termed “parmodulins”. Parmodulins are functionally biased ligands of PAR1 and
could be beneficial to provide a safer and more effective ways of inhibiting platelet
activation. Preliminary studies suggested that parmodulins ligands antagonizes Gαi and
Gαq mediated downstream signaling, but have no effect against G α12/13 or β-arrestin
mediated signaling50 and could be superior anti-thrombotics compared to orthosteric
PAR1 antagonists, which inhibit all modes of signaling via PAR1.
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Chapter 2:

Background information on 1,3-diaminobenezen scaffold as biased antagonists /
negative allosteric modulators of PAR1

As discussed in the earlier sections, PAR1 plays an important role in activation of
platelets and has been studied as an anti-platelet drug target for the prevention of adverse
cardiovascular events. Several efforts have been made to develop orthosteric PAR1
antagonists. Amongst them, vorapaxar (1, an orthosteric PAR1 antagonist) has been
approved by the FDA for the secondary prevention of myocardial infarction (MI) and
percutaneous coronary intervention (PCI). Although 1 showed a decreased risk of adverse
cardiac events in patients with acute coronary disease during phase III clinical trials, it
showed an increased risk of bleeding events including intracranial hemorrhage (ICH) and
fatal bleeding. For this reason, allosteric modulation of PAR1 could be a promising
venture to selectively inhibit PAR1 and to overcome the liabilities associated with current
anti-platelet drugs.
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2.1.

Discovery of 1,3-diaminobenzene scaffold

Figure 2.1: PAR1 inhibition by A) vorapaxar (1), an FDA approved orthosteric PAR1 antagonist, and B)
ML161 (2), an allosteric, biased antagonist of PAR1, and the lead compound for our studies. IC50 was
measured using a haTRAP (SFLLRN-NH2, 2 μM) binding assay for 1 and in a platelet P-selectin assay (Pselection expression on human platelets induced by 5 μM SFLLRN-NH2) for 250.

Platelets undergo phenotypic changes like dense granule secretion and shape
change in response to injury. After a vascular injury, diverse array of agonists (e.g.,
thrombin, thromboxane-A2, ADP, etc.) trigger phenotypic changes via interaction with
platelet surface receptors. To identify a novel, small molecule inhibitor of platelet
activation, a high throughput screening (HTS) of 302,457 molecules with 7.5 µM
concentration was performed at Broad Institute.55 The primary screening assay measured
platelet activation via dense granule secretion. In this assay, SFLLRN-NH2 (thrombin
activating peptide) was used to activate platelets, which undergo phenotypic changes that
include dense granule secretion. Activated platelets were quantified via amount of ATP
(stored in dense granules) released after dense granule secretion using

a

luciferin/luciferase detection system. After primary screening, 661 candidates were
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considered as hits based on > 50% inhibition of ATP generation. A secondary screen was
performed using the primary assay on a selection of 1584 compounds of the original set
that included 661 hit molecules and their structural analogs. From this set, 651 molecules
tested as active, with measured IC50 < 10 µM. To rule out potential false positives,
inhibitors of the luciferin/luciferase detection system were determined and excluded from
the set of hits. From the results of these assays, 28 candidates were selected for additional
characterization, by measuring the inhibition of P-selectin surface expression, a
transmembrane cell adhesion molecule that is stored at the inner wall of α-granules in unactivated platelets. Upon platelet activation, P-selectin is released onto the surface of
platelets and can be measured by flow cytometry.56 After additional studies, 3 probe
molecules were nominated. Of these probes, ML161 (2, also known as parmodulin 2 or
PM2) inhibited PAR1-mediated platelet aggregation. Therefore, compound 2 with the
1,3-diaminobenzene pharmacophore was considered for further pharmacological
investigations to characterize 2 (ML161) as a hit molecule.
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2.2.

Pharmacology of 1,3-diaminobenzene scaffold

Figure 2.2: ML161 selectively inhibited PAR1 receptor. A) P-selectin assay: 3 µM ML161 to inhibit
platelet activation in response to 5 µM SFLLRN-NH2, 0.2 µM PMA, 100 µM AYPGKF, 1 µM U46619, or
10 µg/ml collagen. Inhibition was observed only with PAR1 agonist SFLLRN-NH2; B) PM2 selectively
inhibited PAR1 mediated secretion of VWF in endothelial cells; C) GPCR profiling: PM2 (10 µM) was
tested in HEK cells with reference compounds for agonist and antagonist activity; agonist activity was
compared with SFLLRN-NH2 in iCa2+ flux and with isoproterenol in cAMP assay; antagonist activity was
measured with control inhibitors of represented receptors.57

P-selectin surface expression assay was considered as a functional assay to
characterize 1,3-diminobenezene scaffold. ML161 (2) was moderately potent with IC50 of
0.26 µM in the SFLLRN-NH2 mediated P-selectin assay. Inhibition of platelets by
ML161 was investigated using different platelet activators, to consider the selectivity of
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ML161. Assays were performed on washed human platelets, separately treated with the
peptide AYPGKF (a PAR4 agonist), PMA (a protein kinase C activator), U46619 (a
thromboxane receptor agonist), and collagen (an agonist of collagen receptors), and
ML161 showed little or no inhibition of platelet activation via the receptors other than
PAR1 (Figure 2.2A). In endothelial cells, ML161 selectively blocked only PAR1mediated VWF (Von Willebrand Factor, glycoprotein involved in haemostasis) secretion
when tested against other receptor agonists (Figure 2.2B). Additional assays were
performed for GPCR profiling of ML161 where it selectively inhibited some, but not all,
Gɑ mediated signaling cascades (Figure 2.2C).

Figure 2.3: ML161 inhibited Gαq mediated signaling but not Gα12/13 mediate signaling. A) Gαq mediated
signaling of PAR1: N/A is vehicle; PM1-4 represents different parmodulins where PM2 is ML161; V =
vorapaxar, A = atopaxar, S = SCH-79797, B = BMS-200261; V,A,S,B are orthosteric antagonists; Conc.
were used – 10 µM PM1, 3 µM PM2, 10µM PM3, 10 µM PM4, 0.3 µM V, 0.3 µM A, 1 µM S, 3 µM B and
5 µM SFLLRN-NH2; Platelets were incubated with parmodulins and orthosteric antagonists and iCa2+ flux
was measured after incubation with SFLLRN-NH2. B) Gα12/13 mediate signaling of PAR1: Conc. of PM2,
V and A were similar to A; Platelet shape change is not affected by ML161; black trace is vehicle, red trace
is SFLLRN-NH2 agonist before wash and blue trace is SFLLRN-NH2 agonist after wash.57

Although ML161 was moderately active relative to orthosteric antagonists such as
vorapaxar, it exhibited some unusual characteristics as a PAR1 ligand. In general,
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activation of PAR1 by thrombin leads to multiple downstream effects like β-arrestin
activation and G-protein activation, leading to phenotypic changes (Gαq stimulation for
granule release and Gα12/13 stimulation for shape change). A traditional orthosteric
antagonist, vorapaxar (1), blocks all phenotypic changes. But ML161 showed inhibition
of Gαq-mediated granule secretion but no effect on Gα12/13-mediated platelet shape change
(Figure 2.3). These preliminary results were suggestive of ML161 as a biased ligand for
PAR1. Additionally, the insurmountable antagonism by ML161 of SFLLRN-NH2-driven
P-selectin expression suggested ML161 (2) could be either a negative allosteric
modulator or an irreversible biased antagonist of PAR1 (Figure 2.4).

Figure 2.4: SFLLRN-NH2 Induced P-selectin expression in presence of varying concentrations of ML161.
Instead of a rightward shift of the dose− response curve (as expected of an orthosteric inhibitor) ML161
demonstrated insurmountable antagonism at higher doses, consistent with allosteric inhibitory
mechanism.50

Moderate potency, selectivity for PAR1, biased signaling, and the possibility of
an allosteric mode of action were promising criteria to consider ML161 as a “lead”
molecule to develop anti-thrombotics with improved safety profiles. Therefore, the 1,3diaminobenzene scaffold was considered for further SAR explorations.
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2.3

Identify the binding site of parmodulins on PAR1

Figure 2.5: Identification of binding site of ML161. The effect of vehicle (N/A), 10 µM parmodulin 1
(PM1), 3 µM parmodulin 2 (PM2), and 1 µM SCH79797 (S) on agonist-induced iCa2+ flux was evaluated
in COS-7 cells transfected with (B) wild-type (WT) PAR1, (C) WT PAR4, (D) the ΔH8 PAR1 mutant, (E)
a chimeric PAR1 in which il2 was replaced with il2 of PAR4, and (F) a chimeric PAR1 in which il3 was
replaced with il3 of PAR4. iCa2+ flux was evaluated after stimulation with either 5 µM SFLLRN-NH2
(B,D-F) or 300 mM AYPGKF (C).57

The preliminary studies showed biased mode of action by ML161 but didn’t
specify the binding site of ML161 on PAR1 and the reason for its signaling bias. Our
collaborators, Robert Flaumenhaft and co-workers, attempted to determine the putative
binding site of ML161. Their work with chimeric PAR1 receptors suggests that ML161 is
binding on the cytosolic face near intracellular loop 3 (Figure 3.10).57 They demonstrated
that replacement of the 3rd intracellular loop of PAR1 with that of PAR4 (Figure 3.10E)
leads to a drastic decrease in PM2 activity in a iCa2+ flux assay with COS-7 cells with
SFLLRN-NH2 as agonist There are very rare examples available in the literature where
small molecules bind to intracellular site of GPCRs. In a recent study, Kuliopulos and co-
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workers developed a modified peptide series, termed as pepducins, as PAR modulators. 58
Pepducins modeled after 1 st intracellular loop of PAR1 and they act as either agonists or
antagonists, in a manner which is not fully understood yet. It may be possible for
parmodulins to share a similar site and can modulate the signal in a way act as either
agonist or antagonist. In such cases, it’s very important to learn about mode of action of
parmodulins.
Kobilka and co-workers presented x-ray structure of PAR1 embedded with
Vorapaxar, unfortunately they heavily modified intracellular loop 3 and disordered the Cterminus to facilitate crystallization, making it difficult for us to identify putative binding
site via computational studies.

2.4

Parmodulins as cytoprotective agents

Initially, PAR1 was focused as the anti-platelet target for the treatment of
cardiovascular diseases but recent studies suggest that PAR1-mediated cytoprotective
and/or anti-inflammatory signaling could be beneficial for the treatment of conditions
such as sepsis and reperfusion injury. The activation of PARs is unique among GPCRs as
they not only carry their own ligands for activation, but also trigger different signaling
cascades based on cell type and proteases by which they are cleaved. For example, in
platelets PAR1 is cleaved at the Arg41 residue on the N-terminus by thrombin, leading to
platelet activation. In endothelial cells, PAR1 triggers pro-inflammatory and barrier
disruption in presence of thrombin. 59 In contrast, APC (activated protein C)-mediated
PAR1 activation triggers the opposite anti-inflammatory and barrier stabilizing effects. 60
The conundrum of completely contrasting effects of PAR1 agonism was answered by
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separate efforts of Mosnier and Trejo. Mosnier and co-workers demonstrated that APC
cleaves PAR1 at Arg46 instead of Arg41.61 Trejo and co-workers demonstrated that APC
binds to EPCR (endothelial protein C receptor) to form APC-EPCR complex, which can
cleave the N-terminus of PAR1 at Arg46 and activate biased PAR1 signaling via βarrestin, which exerts cytoprotective effects.62 These contrasting observations make
PAR1 an interesting target anti-inflammatory target in endothelial cells, in addition to
being an anti-thrombotic target in platelets. This functionally biased phenomenon of
PAR1 adds to the difficulty of developing orthosteric antagonists for PARs. It was found
that parmodulins blocked thrombin generation mediated by inflammatory mediators LPS
(lipopolysaccharide, an endotoxin) and TNF-α (tumor necrosis factor alpha, a cytokine
involved in inflammation) in endothelial cells. The anti-inflammatory effects of
parmodulins are exerted via PAR1 and are independent of anti-platelet activity. In other
words, parmodulins blocked pro-inflammatory responses and exhibited APC-like
cytoprotective effects, thus emerging as a new class of cytoprotective agents for the
treatment of sepsis.

2.4.1 Biased mode of action of parmodulin 2 in endothelial cells and their
evaluation as cytoprotective agents.

Previously, the advantage of parmodulins as functionally biased PAR1 ligands
was discussed. During the course of our studies, our collaborator Flaumenhaft and coworkers studied the cytoprotective effects of parmodulins in endothelial cells. In
platelets, vorapaxar blocked all PAR1 signaling pathways whereas ML161 inhibited only
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PAR1-mediated pro-thrombotic responses by inhibiting Gαq but not significantly
inhibiting G12/13.57More recently, they demonstrated that ML161 (aka PM2) selectively
inhibited Gαq mediated signaling over G12/13 in endothelial cells (Figure 2.6).

Figure 2.6: Parmodulins demonstrated biased signaling in endothelial cells. A) Parmodulins blocked Gaq
mediated iCa2+ flux; B) Orthosteric antagonists blocked Gaq mediated iCa2+ flux; C) vorapaxar but not PM2
blocked G12/13 mediated RhoA-GTP activation.57

To further evaluate the effects of vorapaxar and PM2 in endothelial cells, they
incubated human umbilical vein endothelial cells (HUVECs) with vorapaxar and PM2
and observed apoptosis in a dose-dependent manner. Increasing the length of exposure of
vorapaxar from 24 h to 48 h leads to increasing rates of apoptosis even at lower
concentrations. The similar effect was observed with other orthosteric antagonists like
SCH-79797, atopaxar and BMS-200261 (figure 2.7A). In contrast, no increase in
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apoptosis was observed with parmodulins even at micromolar concentrations (Figure
2.7B).

Figure 2.7: Effect of orthosteric antagonists and parmodulins on apoptosis in endothelial cells.

A previous study showed that APC (a vitamin K‐dependent plasma protein) can
reduce the rate of mortality associated with sepsis. 63 APC was studied in clinical trial for
the treatment of severe sepsis; however, it was retracted owing to increased rate of
mortality.64 Later exhaustive efforts were made in understanding the mode of activation
of APC that suggested that the distinct anti-thrombotic effects of APC are due to
inactivation of factors (F) Va and VIIIa, 65 and cytoprotective effects are due to
compartmentalization with PAR1 and later β-arrestin activation.62
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Figure 2.8: Vorapaxar blocks APC mediated cytoprotection in endothelial cells. A) Mock and PAR1
siRNA transfected HUVECs were incubated with buffer (NA) or APC before the treatment with TNF-α; B)
HUVECs were incubated with PM2 (10 µM) or vorapaxar (0.3 µM) for 30 min, followed by treatment with
57
PAC for 4 h and at last with TNF-α.

Because vorapaxar and PM2 inhibited PAR1, and APC mediates its
cytoprotective effects with PAR1 agonism, our collaborators investigated vorapaxar and
PM2 effects on APC mediated cytoprotection. They demonstrated that application of
APC before TNF-α exposure significantly reduces apoptosis (Figure 2.8A). Next, they
treated HUVECs with PM2 or vorapaxar prior to APC and observed inhibition of APCmediated cytoprotection by vorapaxar but not PM2 (figure 2.8B). These results indicated
parmodulins can interfere thrombin formation without blocking APC-mediated
cytoprotective effects, and possibly could show anti-inflammatory activity through βarrestin activation like APC.
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2.4.2 Profiling of parmodulin as cytoprotective agents

Figure 2.9: Inhibition of thrombin generation by A) ML161 (3 µM) and B) APC (10 nM) in endothelial
cells. Thrombin generation was detected by fluorogenic thrombin substrate in HUVECs incubated with
LPS mixture (100 ng/mL LPS, 10 ng/mL LBP, 100 ng/mL sCD14) or TNF-α (10 ng/mL) with or without
ML161 and APC.66

Parmodulins inhibited thrombin formation mediated by inflammatory factors like
LPS and TNF-α in endothelial cells and demonstrated APC-like cytoprotective effects.
LPS and TNF-α are inflammatory mediators to induce thrombin formation in endothelial
cells. ML161 was incubated with LPS or TNF-α in HUVECs for 4 h and inhibited 70%
of LPS induced thrombin activation and 54% of TNF-α induced thrombin activation
(Figure 2.9A). In a similar assay, APC also exerted inhibition of thrombin activation via
LPS and TNF-α (Figure 2.9B).
Next, factor Va (FVa) and factor Xa (FXa) assays were performed investigate the
mode of cytoprotective effects of PM2 and APC. In the factor V assay, parmodulins
showed no effect on FVa generation whereas APC significantly inhibited it (Figure
2.10A). In contrast, parmodulin 2 inhibited LPS- and TNF-α-induced FXa generation
significantly, whereas APC showed no effect (Figure 2.10B). These evidences suggested
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the possibility to cleave tissue factor pathways inhibitor by APC, 67 and thereby
preventing tissue factor inhibition.

Figure 2.10: Effect of PM2 and APC in FVa and FX generation in endothelial cells: A) FVa generation:
HUVECs were incubated with APC (10 nM) for 15 min and PM2 (10 µM) for 4 h, followed by
measurement of FVa generation as a function of time.66

To demonstrate anti-thrombotic effect of parmodulins 2 via cytoprotective
pathways, they exposed endothelial cells with TNF-α before the whole blood and let
platelets accumulate on endothelial cells. After that they treated these endothelial cells
with parmodulin 2 and observed no effect on platelet accumulation on endothelial cells.
In contrast, after incubating parmodulin 2 with endothelial cell for 4 h followed by TNFα exposure lead to inhibition of TNF-α induced platelet accumulation (Figure 2.11).
These evidences suggested the anti-thrombotic activity of parmodulin 2 mediated through
inflammatory factors, demonstrating that parmodulins stimulate cytoprotective signaling
in endothelial cells.
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Figure 2.11: Parmodulin 2 mediates anti-thrombotic activity via a cytoprotective pathway in endothelial
cells: A) HUVECs cell surface micrographs; B) quantification of TNF-α induced platelet aggregation.66

Additionally, they exposed HUVECs to TNF-α and staurosporine after incubation
with parmodulin 2 and APC, and measured the apoptosis rate (figure 2.12A-B), which
confirmed the cytoprotective effects of parmodulin 2. To eliminate the possibility of any
off target effect on apoptosis by parmodulins, they performed PAR1 knockdown studies.
They inhibited PAR1 expression by siRNA directed to F2R (coagulation factor II
receptor, in human encoded as F2R gene). Abrogation PM2 activity demonstrates
cytoprotective activity via PAR1 (figure 2.12C). They also performed time course of
PM2 mediated cytoprotection in HUVECs (figure 2.12D)
of at least 2 h is required for cytoprotection effects.

that showed pre-incubation
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Figure 2.12: Parmodulin 2 induces cytoprotective effects in endothelial cells. A) HUVECs were exposed
to vehicle, PM1 (10 µM), PM2 (3 µM) and APC (10 µg/mL) for 4 h followed by treatment with buffer
(NA), TNF-α (10 ng/mL), staurosporine (10 µM) or thrombin (1 U/mL). Quantification of % apoptotic
cells demonstrated APC like cytoprotective effects by PM2; B) HUVECs were exposed to vehicle, PM1
(10 µM), PM2 (10 µM) and APC (5 µg/mL) for 4 h followed by treatment with buffer (NA), TNF-α (50
ng/mL). Apoptosis was evaluated using cleaved caspase-3 antibody; C) PAR1 knockdown studies
performed in similar fashion like (A); D) Time course of PM2 mediated cytoprotection from staurosporine
induced apoptosis.66

We originally designed and developed a small library of functionally biased
parmodulins as to find safer and more effective alternatives to current anti-thrombotic
agents and tested them in the P-selectin assay, in collaboration with the Flaumenhaft lab.
However, the cytoprotective properties of the parmodulins encouraged us to emphasize
the development of cytoprotective agents. In the literature, PAR1 showed barrier
protection through β-arrestin activation in endothelial cells. We hypothesize that the
biased signaling and resulting endothelial barrier protection from parmodulins is due to
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their allosteric site of interaction on PAR1 in endothelial cells. Similar to P-selectin assay
in platelets, we needed to develop Gaq mediated signaling assay in endothelial cells, as a
primary tool to study the biased mode of activation of PAR1 by parmodulins, and to
study their SAR to find a potent anti-inflammatory agent to treat sepsis. Our progress was
hindered due to the lack of a standard protocol for such an assay. In order to achieve an
easy and reproducible measurement for functional bias, we planned to develop Gaq
driven intracellular Ca2+ flux assay in endothelial cells.
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Chapter 3

Gɑq driven intracellular Ca2+ flux bioassay optimization in endothelial cells

3.1 Introduction and mode of action of Gɑq driven intracellular Ca2+ flux
In addition to maintaining bone structure and function, intracellular calcium ions
(Ca2+) serve as secondary messengers to control numerous cellular processes like cell
division and differentiation, transcription factor activation, apoptosis, vasodilation and
vasoconstriction, hormonal secretion, nerve transmission, muscle function, etc. 68,

69

During resting conditions, concentration of Ca2+ ions is ~ 100 nM that can increase
roughly to 1000 nM upon activation.68 This increase could be due to the i) transport of
extracellular Ca2+ through voltage gated or receptor operated Ca2+ channels, or ii) release
of stored Ca2+ ions from endoplasmic reticulum (ER) or lysosome related stores. 70 Later,
the elevated intracellular Ca2+ level is regulated by Ca2+ buffer system, Ca2+ ATPase
transporters or Na+/Ca2+ exchangers to restore the normal cytosolic concentrations. 71
Precedent to ligand-receptor interaction, activated receptor can increase influx of
Ca2+ via Ca2+ channel pumps or sequester the stored Ca2+ from the endoplasmic
reticulum. In case of GPCRs, activated receptor stimulates heterotrimeric G-protein (Gɑ
and Gβγ subunits). Based on sequence homology of GPCRs, there are 4 types of Gɑ
protein Gα(s/olf), Gα(i1/i2/i3/o/z/gust/t-cone/t-rod/), Gα(q/11/14/16) and Gα(12/13). Upon activation with
ligand, different GPCRs triggers signal through different heterotrimeric G-proteins.
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When GPCRs transduces signal through a series of Gɑq protein, GTP bound Gɑq activates
phospholipase β (PLCβ). The later catalyzes the hydrolysis of phosphatidylinositol-4,5bisphosphate (PIP2) into 1,4,5–inositol triphosphate (IP3) and diacylglycerol (DAG). The
released IP3 binds to IP3 sensitive Ca2+ channels on endoplasmic reticulum (ER) to
release Ca2+ ions into the cytosol (Figure 3.1).72 Therefore, cell based functional assays to
monitor the intracellular Ca2+ concentrations have provided the grate platform in high
throughput screening and pharmacological characterization of ligands with GPCRs and
have been widely used in academia and pharmaceutical industries.

Figure 3.1: Gαq mediated intracellular Ca2+ flux fluorescent assay mechanism: Upon interaction of agonist
with GPCR (a), the activated receptor exchanges GDP for GTP and dissociates heterotrimeric Gɑ and Gβγ
subunit (b). The released Gɑ protein activates PLCβ (c) that catalyses hydrolysis of PIP2 into IP3 and DAG
(d). Diffused IP3 than binds with IP3 sensitive Ca2+ channel on ER (e) and releases free Ca2+ into cytosol
(f). Upon the treatment of cells with a fluorescent dye (e.g. Fluo-4-AM), the released free Ca2+ then binds
with anionic fluorescent dye (e.g., Fluo-4) and the fluorescence of the resultant complex can measured by
fluorescent detectors (e.g, fluorometric imaging plate reader - FLIPR).
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3.2

Fluorescent indicators for the measurement of intracellular Ca2+ concentration

The very first approach to measure intracellular Ca2+ level was performed by
Ridgway and Ashley who used a photoprotein aequorin, isolated from the jellyfish
Aequorea Victoria. Aequorin is a 21 kDa polypeptide with 3 potential Ca2+ binding sites
that upon binding with free Ca2+ emits photons at 470 nm.73 However, due to the
complicated application of photoproteins, a range of Ca2+ sensitive fluorescence synthetic
indicators were developed including Rhod-2, Indo-1, Fura-2 and Fura-3.74-76 These
indicators are based on the structures of Ca2+ chelators like EGTA, incorporated with a
fluorescent moiety and lipophilic acetoxymethyl (AM) ester. AM ester facilitates
transportation into the cells, where it gets hydrolysed to free carboxylic acid to retain the
indicator inside the cell and to chelate with intracellular Ca2+.77
Based on biochemical properties, synthetic indicators have been classified as
ratiometric (e.g. Fura-2, Indo-1, etc) and non-ratiometric indicators (e.g. Fluo-3, Fluo-4,
etc). Ratiometric indicators like Fura-2 exhibit dual excitation wavelength in Ca2+ bound
and free forms. For example, Fura-2 has excitation wavelength 340 nm in Ca2+ bound
form and 380 nm in Ca2+ free form. Upon binding with Ca2+, excitation at 340 nm
increases and 380 nm decreases, and the ratio can be used to quantitate Ca2+
concentrations.72 In contrast, non-ratiometric indicators emit brighter fluorescence upon
binding with Ca2+.72 The most widely used non-ratiometric Ca2+ indicators for biological
purposes are Fluo-3 developed by Tsien and co-workers,76 and Fluo-4 developed by
Johnson and co-workers.78 In vivo, fluo-4 exhibits high rate of cell permeation, high
fluorescence emission, and can be used at lower Ca2+ concentrations.

46
3.3

Optimization of Calcium mobilization assay

Figure 3.2: iCa2+ flux assay protocol: A) EA.hy926 cells were seeded to costar 96-well plate for ~40 h and
imaged under EVOS microscope, followed by media removal with HBSS-HEPES buffer; B) Fluo-4 dye
incubation for 1 h and imaged under EVOS microscope, followed by dye replacement with HBSS-HEPES
buffer; C) fluorescent trace with antagonist, followed by agonist addition. A spike in fluorescence is
observed after agonist addition indication PAR1 activation leading to increased iCa2+ from endoplasmic
reticulum.79

All assay work was carried out at the Blood Research Institute, Milwaukee in our
collaborator Dr. Hartmut Weiler’s lab. During the initial phase of our study, EA.hy926
cells were cultured by Irene Hernandez, however, afterwards we cultured our own batch
of EA.hy926 cells. The assay development described here represent my combined efforts
with my colleagues Dr. Mark Majewski and my advisor Dr. Chris Dockendorff.
To initiate our study, the transformed endothelial cell line (EA.hy926) 80 was our
primary choice for measuring calcium mobilization in adherent endothelial cells.
EA.hy926 cell line is widely used in PAR-related studies and could be cultured to
extended number of passages and grown reliably in tissue culture-treated 96 well plates.
Frozen vial of EA.hy926 cells was purchased from ATCC and cultured up to 14 passages
during the course of our study. The culture protocol was adopted from ATCC. 79, 81 We
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chose Corning Costar (#3603) with black wall, flat and clear bottom. Black wall plates
are recommended for fluorescent assays, flat bottom aids in even distribution of cells and
clear bottom permits direct microscopic analysis. These plates are available as tissue
culture treated to adhere cell line to the plate. The cell seeding density was set to 25000
cells per well followed by incubation period of 42-48 h to reach maximum confluency
(figure 3.2A). We chose Fluo-4 dye to quantify iCa2+ flux. Fluo-4 offers a brighter
fluorescence emission due to its greater absorption at 488 nm and also offers a high rate
of cell permeation than other dyes. It has been highly recommended for fluorometric
analysis in high throughput screening assays. 78 Fluo-4 was dosed as its acetoxymethyl
ester (Fluo-4/AM) and generated emission signals at 525 nm in our assay. Pluronic F-127
was used to dissolve Fluo-4 dye. Both of Pluronic F-127 and probenecid (Fluo-4 anion
efflux inhibitor) were purchased directly from vendor. The cells were incubated with dye
for 60 – 75 min during our initial studies (figure 3.2B). PerkinElmer EnSpire plate reader
was used to take fluorescent measurements. The major limitation of EnSpire plate reader
is to imagine one well at a time instead all wells concurrently like with FLIPR
instrument.82 A representative trace of response versus time is shown in figure 3.2C. For
initial studies, we used normalized response of each well with difference between
maximal response and average of baseline. PAR1 agonist TFLLRN-NH2, PAR2 agonist
SLIGKV-NH2, PAR1/2 agonist SFLLRN-NH2, PAR1 orthosteric antagonist vorapaxar
and PAR1 allosteric antagonist ML161 were chosen to optimize the assay conditions.
During our initial attempts, we observed acceptable signal/noise measured
concentration response curves with PAR1 and PAR2 agonists. However, the results were
not reproducible in case of PAR1 antagonists. Initially, PAR1 antagonists were loaded
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with 100% DMSO (1% final concentration of DMSO in assay) but adverse effects of
DMSO on endothelial cells (retraction) was observed. DMSO concentration was
minimized from 1% to 0.1-0.2% but high deviations were observed. Considering the poor
solubility of our molecules to be a root of high deviations, we tested several excipients to
keep parmodulins in solution form. We tested different excipients like Tween-20, Tween80, Triton X-100, BSA, and Pluronic F-127 in final concentration range of 0.01 – 0.1%.
These excipients were incorporated with antagonists in vehicle. Although the excipients
had improved solubility, it didn’t help in improving inconsistent results. In case of Tween
20, Tween 80 and Triton X-100, dye was leaked extracellularly after 5 -10 minute of
incubation period whereas in case of BSA and Pluronic F-127, dye leaking was observed
over 45 – 60 min incubation period. Therefore, we eliminated poor solubility of
parmodulins as a cause for inconsistent results and fixed to use DMSO concentration 0.01
– 0.02% for the rest assay development.

Figure 3.3: Micrograph of EA.hy926 cells. A) Under transmission light without any dye; B) After dye
incubation of45-60 min; C) No probenecid; D) & E) after manual liquid exchanges.
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We next examined volume of antagonist addition, dye and antagonist incubation
period, dye loading amount with any profound effects form probenecid and pipetting
technique. When we eliminated the probenecid from experiments, we observed the no
retention of dye inside the cells (figure 3.3C), which confers the necessity of probenecid.
Our antagonist loading volume was 2 µL. We reasoned that lower volume may be the
cause for high deviation due to inadequate pipetting. We tried different volume of
injection ranging from 2 µL to 50 µL keeping antagonists solution temperature 37°C. We
tried different pipetting techniques like forward/reverse pipetting to avoid air-bubble
formation. Unfortunately, these efforts were not successful. We gained access to single
channel automated liquid handler for addition but the process to add 1 well at a time in a
96-well plate for inadequate timewise and Fluo-4 dye was significantly leaked outside
causing lower calcium maxima signals. We next analyzed incubation period of dye and
antagonists and decreased Fluo-4 dye concentration. But dye was leaking slowly over
prolonged period of time and that cannot be fruitful in longer experiments. We serum
starved our cells, yet observed similar results.

Figure 3.4: ML16 concentration response curves: A) With PAR1 agonist TFLLRN-NH2 (3.16 µM) using
manual media exchanges; B) With PAR1 agonist TFLLRN-NH2 (5 µM) using automated liquid handling.79
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During the course of assay optimization, we observed inconsistency of cells in
some of the wells. When tracked the results with inconsistent wells, we observed high
variability associated with them. To reason with the source of inconsistency, we imagined
confluency of cells before first media wash (figure 3.4A), and observed fully confluent
cells. However, when we imagined cells after replacing the media with dye and the later
with the fresh HBSS-HEPES buffer, we observed inconsistency in few of the wells
(figure 3.3D-E). It turned out that we used “flicking” for our liquid exchanges and that
dislodged the cells from the plate causing high variability in assay results (figure 3.4A).
When we performed liquid exchanges using 8-channel automated liquid handler
(Beckman Coulter), our inconsistent results disappeared. Agonists and antagonists
concentration response curves were reproducibly obtained with low deviations with use
of Beckman Coulter (figure 3.4B).

3.4

Results and discussion of bioassay results

3.4.1 Z-factor calculation for assay reliability

Figure 3.5: Z- Calcium mobilization responses- with PAR1 agonist 5 μM TFLLRN-NH2 and plus with
optional PAR1 antagonists 10 μM ML161 or 0.316 μM Vorapaxar and 10% DMSO-Wash buffer as
vehicle.
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Table 3.1 Z- Calcium mobilization responses

Positive

Negative
Z’-factor

Control

Control
Vehicle (10%

Agonist Assay

TFLLRN-NH2

(n=12)

(5 µM)

DMSO-

0.720

HBSS/HEPES)
ML161 (10
Antagonist Assay

µM) +

TFLLRN-NH2

(n=12)

TFLLRN-NH2

(5 µM)

0.618

(5 µM)

Z-factor is a statistical effect size measurement and widely used for high
throughput screening. As this assay was developed to screen parmodulins, we determined
to measure Z-factor for reliability of our assay. Z-factor value between 0.5 – 1.0 indicates
an excellent assay.83
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3.4.2 Concentration response curves for PARs agonists and antagonists
A. TFLLRN-NH2

B. SLIGKV-NH2

EC50 = 4.77 μM

EC50 = 5.79 μM
C. SFLLRN-NH2

EC50 = 2.38 μM
Figure 3.6: PAR agonist concentration-response with EA.hy926 cells: A) TFLLRN-NH2 (PAR1)-mediated
iCa2+ mobilization; B) SLIGKV-NH2 (PAR2)-mediated iCa2+ mobilization; C) SFLLRN-NH2 (PAR1/2)mediated iCa2+ mobilization.79

With a reliable assay in our hand, we started pharmacological profiling of our
molecules. We first determined concentration response curve of 3 agonists: PAR1 agonist
(TFLLRN-NH2; EC50 = 4.77 μM; figure 3.6A); PAR2 agonist (SLIGKV-NH2; EC50 =
5.79 μM; figure 3.6B) and PAR1/2 agonist (SFLLRN-NH2; EC50 = 2.38 μM; figure
3.6C).
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A. Vorapaxar

B. Atopaxar

IC50 = 0.032 μM

IC50 =0.033 μM
C. RWJ-58259

IC50 = 0.020 μM
Figure 3.7. Concentration-response for PAR1 antagonists in the TFLLRN-NH2-mediated iCa2+
mobilization assay (5 µM) with EA.hy926 cells: A) vorapaxar, B) atopaxar, (C) RWJ-58259.79

Using EC50 of agonists, we obtained concentration response curve for PAR1
orthosteric antagonists vorapaxar (IC50 = 0.032 μM; figure 3.7A), atopaxar (IC50 = 0.033
μM; figure 3.7B), and RWJ-58259 (IC50 = 0.020 μM; figure 3.7C).
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A. ML161

B. RR-90

IC50 = 0.847 μM

IC50 = 0.978 μM

C. DG-5

D. EMG-21

IC50 = 94 μM

IC50 = 3.31 μM

Figure 3.8: Concentration-response for ML161 analogs (parmodulins) in the TFLLRN-NH2-mediated (5
µM) iCa2+ mobilization assay with EA.hy926 cells: A) ML161; B) RR90; C) DG5; D) EMG21. 79

We obtained concentration response curve for several parmodulins ML161 (IC50
= 0.847 μM; figure 3.8A), RR90 (IC50 = 0.978 μM; figure 3.8B), DG5 (IC50 = 94 μM;
figure 3.8C) and EMG21 (IC50 = 3.31 μM; figure 3.8D).
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Figure 3.9. Concentration-response for the PAR2 antagonist TJF5 (Fairlie’s PAR2 antagonist; IC50 = 1.66
μM) in the SLIGKV-NH2-mediated (5 μM) iCa2+ mobilization assay.79

Fairlie reported TJF5 as PAR2 antagonist, 84 which was synthesized in solution
phase in our lab as a standard for PAR2 antagonist. We obtained concentration-response
curve for TJF5 with IC50 of 1.66 μM in presence of PAR2 agonist SLIGKV-NH2 (5 μM),
indicates versatility of our assay for other PARs (figure 3.9).

3.5

Conclusion

A protocol to measure Gaq mediated intracellular Ca2+ was successfully
developed in adherent endothelial cells. This assay can be used to measure concentrationresponses for a variety of PAR1 and PAR2 ligands in a reproducible manner. This assay
is suitable for both orthosteric and allosteric PAR1 and PAR2 ligands and provides a
good platform to small academic labs to perform preliminary pharmacological evaluation
in the absence of automated high throughput screening instruments. We also developed a
protocol for medium throughput screening of parmodulins and studied their
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pharmacological behavior with PAR1 using this assay. In addition, it has provided a good
tool to evaluate behavior of our heterobivalent ligands.
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Chapter 4:

Design and development of negative allosteric modulators of PAR1

4.1.

Early SAR studies

Figure 4.1: SAR summary of the 1,3-diaminobenzene scaffold50

A brief summary of SAR study on 1,3-diaminobenzene pharmacophore was
published in 201250 (Figure 4.1). To track SAR trends, the structure of ML161 was
divided into 3 sections:

west region, central ring system and eastern region. All

molecules were tested in the platelet P-selectin assay.
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Figure 4.2: SAR of selected eastern modified analogues

Preliminary SAR studies suggested that the maximal activity was observed with
eastern arenes with ortho substituents; meta and para substituents had neutral or negative
effects on potency. Some compounds with di-substitution on the eastern benzene retained
activity but did not improve potency. Small electron withdrawing or neutral groups at the
ortho position were the most potent, with the ortho bromide (e.g. as in ML161, IC50 =
0.26 µM in P-selectin assay) so far being the most potent compound of the series.
Increasing bulkiness at the ortho position (e.g. phenyl) or replacing the eastern arene with
heterocycles (e.g, furan, pyridine, quinoline) led to poorly active or inactive compounds.
The arrangement of amide was also necessary to retain the activity. When the position of
the amide was reversed, the analogue lost activity. When at the east side, amide nitrogen
was methylated, indicating the possibility of this functional group acting as a hydrogen
bond donor with the receptor (Figure 4.2).
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Figure 4.3: SAR of selected western modified analogues

Keeping the east side fixed, the alkyl group at the west side was explored (Figure
4.3). Optimal potency was observed with a 3-carbon chain (ML161). Some potency was
observed with 2-carbon chain but 4-carbon chain analogue was inactive. Poor plasma
stability issue of ML161 was answered with replacing normal alkyl chain to branched
alkyl chain with similar potency like ML161. The overall modifications at west side of
1,3-diaminobenzene pharmacophore offered some flexibility, which were utilized in this
thesis. During early SAR studies, modifications at central ring system was not fully
explored however, replacement of 1,3-disubstituion to 1,4-disubstituion caused loss in
activity.
Previous SAR study highlighted possible sites for modification but additional
investigations are needed to understand mode of action of this pharmacophore and where
it is binding to PAR1. In addition, ML161 has dianilide groups, which can have potential
to undergo enzymatic hydrolysis to yield toxic aniline derivatives. It has moderate
solubility (40 µM in PBS) and it suffers from poor mouse plasma stability (2% left after 5
h). It was evident from SAR data that branched alkyl chain improved plasma stability yet
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other liabilities associated with ML161 need an equal attention to develop a drug
candidate. A part of this thesis work has been dedicated to explore SAR study to answer
all liabilities associated with ML161.

4.2.

Extended SAR studies of 1,3-diminobenezene scaffold

Figure 4.4: 1,3-diaminobenzene core.

This section highlights how the 1,3-diaminobenzene based scaffold was utilized
to explore SAR studies. The first part will discuss the design, synthesis and biological
evaluation of western parmodulins. The second part will discuss the design, synthesis and
biological evaluation of central parmodulin analogues. The third part will discuss the
design, synthesis and biological evaluation of eastern parmodulins. The fourth part will
discuss the attempts made to investigate binding site to PAR1. At last, the fifth part will
discuss results of iCa2+ assay in endothelial cells.
To track SAR, 1,3-diminobenzene based scaffold was divided into 3 parts: west
side, central ring, and east side (Figure 4.4). Designing of these molecules were done by
myself and in part of the efforts from colleague Ricardo Rosas Jr. under the guidance of
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advisor Dr. Chris Dockendorff. I optimized reaction conditions of intermediate,
synthesized few west side analogues and mainly focused on synthesis of complex central
heterocycles. The rest of the library was prepared by other graduate students Ricardo
Rosas Jr. and Eric Greve, and undergraduates (specifically, Meredith Kuhn, Teresa
Yeung, Andrew Kreatsoulas, Allison Stephan, Kaitlin Kentala, Ben Plehaus, Alaa Shana,
Khia Kurtenbach, Trevor Foster, Vlada Kot and N’Gussen Diby) under my, Ricardo and
Eric’s direct supervision.
Screening of parmodulins using P-selectin assay of platelets was performed at
Beth Israel Deaconess Medical Center (Harvard Medical School, Boston, Massachusetts)
institute in our collaborator Dr. Robert Flaumenhaft’s laboratory. Analogues were tested
by Dr. Omoz Aisiku in P-selectin expression assay at 10 µM concentration. Table 3.1 –
3.3 represents P-selectin assay data. For initial screening, only %inhibition was measured
at 10 µM concentration. IC50 was measured for molecules typically with >80% of
inhibition.
For iCa2+ flux assay of endothelial cells, we discussed and demonstrated the
reliability of assay to measure concentration-response curve of PARs agonists and
antagonists in previous chapter 3. We screened our parmodulins library in this Gaq
mediated iCa2+ flux assay to identify ‘potent” parmodulins and further characterize as
PAR1 biased ligands in endothelial cells for their cytoprotective effects.
Medium throughput screening was carried out at Blood Research Institute,
Milwaukee in our collaborator Dr. Hartmut Weiler’s lab. Screening protocol was
designed by me. Screening of all parmodulins in this thesis was performed by myself and
further characterization of “potent” parmodulins will be carried out as combined efforts
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of me and graduate student Ricardo Rosas Jr. under the guidance of my advisor Dr. Chris
Dockendorff.
In 96-well plate, screening was mapped out for 18 parmodulins (n=4) at a time,
along with Vorapaxar as positive control. Concentration parmodulins were set to 10 µM
final concentration with 0.03% final concentration of DMSO for initial screening.
TFLLRN-NH2 was selected as PAR1 selective agonist and concentration was set to 5
µM. All liquid exchanges and antagonists’ addition were performed using automated
liquid handler. Final agonist addition was done via multichannel pipette to minimize
variations at the best. Z-factor was measured for each plate using agonist response as
negative control and Vorapaxar response as positive control to verify validity of
screening.

4.3

Design, synthesis and biological evaluation of western ML161 analogues

Figure 4.5: Planned SAR studies on west side of 1,3-diaminobenzene core

Figure 4.5 illustrates key points of structure where modifications can be done.
From previous results, we knew that 3-carbon chain to amide is optimal for activity.
However, insertion of heteroatom to the west side chain was not fully explored.

63
Heteroatoms can boost solubility and can make addition H-bods with the target that can
improve potency. Therefore, keeping the east side fixed, we designed ether, carbamate
and malonate derivatives at the west side chain. Additionally, we inserted amine to this
chain to make molecule more basic and it is expected to be protonated at physiological
pH which can improve solubility of ML161. Branched alkyl chain was reported with
improved plasma stability, but the resultant molecule has poor solubility. We designed to
insert alcohol on branched chain to improve solubility and we reversed the position of
amide to observe tolerance in activity. Insertion of F-atom is widely popular among
medicinal chemists due to similar size of F compared to H-atom and fluorinated
molecules are tend to be more metabolically stable. Due to limited availability, cost and
efforts to synthesize fluorinated starting materials, we have designed only one molecule
and this area needs further investigations.

4.3.1 Synthesis of west side analogues

Scheme 4.1: Synthesis of west side intermediate and analogues.
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To build a library of western analogues, commercially available nitro aniline 4.1
was acylated with commercially available 2-bromo benzoyl chloride under anhydrous
conditions to give nitro-anilide 4.2 in >90% yield. Previously, reduction of nitro-anilide
4.2 to aniline 4.3 was reported using sodium dithionite as reducing agent in 60% yield
with 16 h of reaction time. However, the major drawback for this step was formation of
N-sulfate by product that required additional treatment to hydrolyze N-sulfate to aniline
4.3. We optimized this step with 80% yield and 2 h of reaction time using Sn(II)Cl2 as
reducing agent. Aniline 4.3 was prepared in 5-10 of quantity and stored as HCl salt to
prevent carbamate formation. Aniline 4.3 was then peptide coupled with carboxylic acid,
or acylated with acid chloride or acid chlorofomate to synthesize the western analogues
(Scheme 4.1).

4.3.2 Representative reductive amination to synthesize amine analogues

Scheme 4.2: Synthesis of amine / aniline analogues.

To prepare amine analogues, aniline 4.3 was condensed with aldehyde or ketone
to imine. Imine then reduced to secondary or tertiary amine using sodium triacetoxy
borohydride (Scheme 4.2).
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Table 4.1: SAR at west end

#ID

Structure

P-selectin assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

Alkyl chain analogues
ML161

>99%; 0.26

82% ± 1.7%;
-6.1 ± 0.10

CJD125

99%; 0.29

82% ± 1.5%

EMG21

95%; 1.7

54% ± 2.7%;
-5.5 ± 0.26%

EMG23

<1.0%

23%d ± 5.1%

EMG22

91%; 0.52

65% ± 1.5%

Amine analogues
RR90

99%; 0.34

85% ± 1.6%;
-6.0 ± 0.19

KMK22

Inactive

13% ± 1.7%

KMK18

Activec

-12% ± 5.7%
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P-selectin assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

TY14

Inactive

43%d ± 5.7%

DG75

3%

17% ± 5.9%

VAK11

N.D.

3.0% ± 2.9%

#ID

Structure

Branched alkyl, fluorinated and reverse amide analogues

DG119

27%

21% ± 1.7%

DG121

65%

48% ± 13%

DG120

16%

25% ± 5.0%

AS1

100%c

27% ± 6.4%

NDRD25

N.D.

88%c ± 0.7%

RR71

94% b

63% ± 4.0%

Ether, malonate and carbamate analogues

NDRD27

N.D.

39% ± 4.8%
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P-selectin assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

RR72

Inactive

58% ± 7.2%

TY13

88%, 2.7

57% ± 3.6%

VAK12

N.D.

38% ± 4.9%

DG14

12%

11% ± 12%

DG17

5%

37% ± 11%

DG37

14%

36% ± 13%

VAK9

N.D.

42% ± 12%

VAK10

N.D.

60% ± 3.7%

#ID

Structure

Heterocyclic / aromatic derivatives
VAK7

N.D.

92%c ± 0.3%

NDRD21

N.D.

90%c ± 0.4%

NDRD23

N.D.

82%c ± 1.0%
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P-selectin assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

NDRD22

N.D.

58% ± 4.4%

AS2

100%, 0.99

42% ± 2.9%

AS4

11%

44% ± 1.9%

KMK15B

Inactive

4% ± 5.7%

KMK14B

Inactive

63% ± 3.9%

KMK15A

Inactive

-8% ± 5.7%

KMK14A

Inactive

65% ± 4.4%

KMK17

Inactive

-60% ± 8.1%

#ID

Structure

Notes: a. %Inhibition and IC50 was measured at 10 μM concentration in P-selectin expression on
human platelets induced by 5 μM SFLLRN-NH2; b. %Inhibition was measured at 10 μM
concentration in iCa2+ assay in EA.hy926 cells induced by 5 μM TFLLRN-NH2 and n=4, unless
otherwise noted; c. IC50 measurements are pending; d. n=3; e. %Inhibition and IC50 was measured at
1 μM concentration in P-selectin expression on human platelets induced by 5 μM SFLLRN-NH2;
N.D.= Not Determined.
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4.4

Design of central ML161 analogues

Figure 4.6: Planned SAR studies on central region of 1,3-diaminobenzene core

From previously published SAR data, we didn’t have evidences for the
importance of central aromatic ring as pharmacophore. Therefore we expanded our
efforts in modifying central pharmacophore by addition of heteroatoms and replacing
central ring with urea derivatives or heterocycles (Figure 4.6). First, we replaced central
aromatic ring with urea and saturated piperidine ring. We investigated the tolerance of
additional substitutions at central aromatic ring and here we are reporting 3 analogues.
We have planned to add heteroatoms on central aromatic ring (e.g., pyridine, pyrimidine,
pyrazine, etc.). However, unavailability, high cost and limited literature precedence on
aromatic heterocyclic starting materials have limited our efforts at this time.
Majority of marketed drugs and natural products contain heterocycles. Many
times, heterocycles are incorporated to confer more stability of a ligand or to improve
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ADMET profile of a ligand. With similar concept in mind, we designed basic and
electron-rich -N containing heterocycles like indole, indazole and benzimidazole.

4.4.1 Representative synthesis of urea analogues

Scheme 4.3: Synthesis of urea analogues.

East side intermediate 4.4 was reacted with CDI to yield intermediate urea 4.5. In
some cases, intermediate urea 4.5 was isolated and reacted with amine to final urea
analogues. Depends on stability of intermediate urea 4.5, was carried forward into the
reaction without any isolation (Scheme 4.3).
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4.4.2 Synthesis of piperidine based central analogues

Scheme 4.4: Synthesis of piperidine based central analogues.

Commercially available N-boc-3-amino piperidine 4.6 was acylated with benzoyl
chloride to N-boc piperidine amide 4.7 in >95% yield. Boc group was deprotected to give
piperidine – HCl salt 4.8 (70% yield) using 4M HCl in dioxane. Piperidine – HCl salt 4.8
was acylated with commercially available butyryl chloride to give piperidine analogue
4.9 (71% yield). All piperidine based central analogues were synthesized in a similar
fashion (Scheme 4.4).
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4.4.3 Synthesis of Benzimidazoles

Scheme 4.5: Synthesis of benzimidazole central analogues (unoptimized reaction conditions).

We attempted condensation of 4-nitro-O-phenylenediamine 4.10 and butanal to
imine, followed by nucleophilic attack of aniline to imine to ring closure nitro
benzimidazole 4.11. However, the attempt was unsuccessful. We than followed a
literature procedure to form benzimidazole from diamine 4.10 and butyric acid in
presence of 4 N HCl and refluxed the reaction. 85 Unfortunately, the reaction didn’t
proceed and we recovered the starting material. Another literature search lead us to
acylation of diamine 4.10 with butyryl chloride and then to condense in presence of conc.
HCl and ethanol as solvent.86 This attempt yielded 12% of benzimidazole 4.10 along with
some by products. Later, we found a paper to synthesize nitro benzimidazole 4.11 from
phenylenediamine 4.10 and butyric acid using POCl3 as solvent.87 This reaction was gave
nitro bnenzimidazole 4.11 in 23% yield (unoptimized). Nitro-Benzimidazole 4.11 was
then reduced to aniline 4.12 in hydrogen gas environment in the presence of 2 mol%
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Pd/C. Amine 4.12 was acylated with 2-bromobenzoyl chloride to give benzimidazole
analogue 4.13 in 45% yield (unoptimized, Scheme 4.5).

4.4.4 Synthesis of Indazoles

Scheme 4.6: Synthesis of indazole central analogues.

Synthesis of nitro-indazole 4.15 was first attempted by conversion of nitro aniline
4.14 to diazonium intermediate followed by ring closure in aqueous acidic condition
using 1M HCl. In this reaction starting material was recovered back. Later we followed a
literature procedure to make diazosalt in glacial acetic acid followed by cyclisation at
room temperature.88 Reaction worked well to give analytically pure crude nitro-indazole
4.15 in 82% yield. Nitro-indazole 4.15 was then alkylated with 1-bromobutane to give
alkylated nitro-indazole isomers 4.16 and 4.17, which were separated easily by normal
phase flash chromatography and characterized by 2D NMR to assign the structure.
Alkylated nitro- indazole 4.17 was reduced to aniline 4.18 using 10 mol% Pd/C under the
complete hydrogen gas environment in 60% yield. At last, aniline 4.18 was acylated with
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2-bromobenzoyl chloride to final indazole analogues 4.19 in 81% yield. The rest of
indazole based analogues were synthesized in similar fashion (Scheme 4.6).

4.4.5 Synthesis of Indoles

Scheme 4.7: Synthesis of indole central analogues (unoptimized reaction conditions)..

A literature procedure of similar analogue to nitro-indole 4.24 was followed.89
First acylation of commercially available nitro-aniline 4.20 was performed to make amide
4.21 with 68% yield. The Phenol group in amide 4.21 was converted to triflate 4.22 with
47% yield. Triflate 4.22 was subjected to Sonogashira cross coupling with 1-pentyne to
give alkyne 4.23 and flowed by heteroannulation to nitro-indole 4.24 under basic
conditions. Nitro-indole 4.24 was reduced using 10 mol% Pd/C under the complete
hydrogen gas environment to obtain aniline 4.25 which was further acylated with 2-
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bromobenzoyl chloride to final indole analogue 4.26 with 18% yield (unoptimized,
Scheme 4.7).

Table 4.2: SAR at central region

#ID

Structure

P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

Piperidine based analogues at central region

DG81

25%

5% ± 3.7%

DG82

Inactive

76% ± 3.0%

RR3

Inactive

-5% ± 15%

RR5

N.D.

-2% ± 4.5%

Replacement of central aromatic ring with urea

TY7

11%

48% ± 2.7%

TY10

4%

-27% ± 5.4%
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#ID

Structure

P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

Heterocycleic analogues at central region

DG26

47%

3% ± 4.7%

RR2

Inactive

1% ± 6.8%

DG45

30%

14% ± 3.1%

DG9

Inactive

6% ± 5.7%

DG51

42%

31% ± 12%

Additional substitutions on central aromatic ring

a-b

MK7

13%

8% ± 2.9%

TY9

10%

70% ± 2.2%

See table 4.1 foot notes.
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4.5

Design of eastern ML161 analogues

Figure 4.7: Planned SAR studies on east side of 1,3-diaminobenzene core

SAR at east side was extensively explored previously. Therefore, to fill in the gap,
we designed few mono- and di-substituted analogues (Figure 4.7). In addition, loss of
potency was observed when phenyl ring was replaced with pyridine. We hypothesized
that perhaps loss of activity was associated with the protonation of pyridine at the
physiological pH. Therefore, keeping the west side fixed, we added –F atoms to the east
ring to decrease pH of the molecule. Further, the order of amide at east side was
necessary to retain the activity. However, other functional group tolerance was not tested
yet. Therefore, keeping the sequence of “–N and –CO” of amide, we replaced amide
group with urea to improve solubility and hence, potency.
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Figure 4.8: Promising ML161 analogues.

We had two promising analogues (Figure 4.8) from the combined SAR study
before and after published results. CJD125 offered improved plasma stability whereas
AS2 was unique heterocycle with a fixed position of oxygen atom responsible for the
activity. Many times, changing one part of molecule can affect the activity of entire
pharmacophore. Keeping in mind, we decided to reinvestigate the east side with fixed
west branched chain of CJD125 and tetrahydrofuran of AS2.

4.5.1 Synthesis of east side analogues

Scheme 4.8: Synthesis of east side intermediate and analogues.
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Strategically similar to western analogues, commercially available nitro aniline
4.1 was acylated with commercially available butyryl chloride to nitro-anilide 4.27 in
90% yield. Nitro-anilide 4.27 was reduced under complete hydrogen gas environment
using 10 mol% Pd/C catalyst to aniline 4.28. Aniline 4.28 was stored as HCl salt to avoid
carbamate formation. Aniline 4.28 was then peptide coupled with carboxylic acid, or
acylated with acid chloride or acid chlorofomate to synthesize the eastern analogues
(Scheme 4.8).

Table 4.3: SAR at east region

#ID

Structure

P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

Replacing amide to urea and sulfonamide

BWP27

Inactive

38% ± 4.4%

BWP13

Inactive

8% ± 5.5%

BWP14

Inactive

11% ± 11%

BWP10

Inactivee

-2% ± 9.4%
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P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

BWP8

Inactivee

13% ± 7.6%

BWP9

16%e

18% ± 10%

ACK41

9.9%

3%d ± 1.9%

#ID

Structure

Incorporating -F and pyridine at east side

MEM1

Inactivee

40% ± 8.9%

BWP22

Inactive

13% ± 9.0%

BWP6

28%e

15% ± 4.7%

BWP25

7%

42% ± 6.5%

BWP24

Inactive

38% ± 5.6%

BWP20

Inactive

4% ± 14%
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P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

BWP23

Inactive

13% ± 6.4%

BWP18

16%

22% ± 4.8%

BWP21

12%

17% ± 4.9%

#ID

Structure

Additional substitutions at east side

KMK19

100%c

24% ± 5.6%

KMK21

Actived

9.0% ± 8.6%

AFS5

N.D.

70% ± 2.5%

DG64

22%

46% ± 2.9%

DG67

Inactive

12% ± 5.8%

ACK42

N.D.

-44% ± 13%
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P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

AFS11

Inactivee

-8% ± 10%

AFS4

12%e

3% ± 11%

AFS12

Inactivee

21% ± 21%

AFS15

N.D.

-11% ± 5.7%

AFS16

N.D.

37% ± 3.3%

RR31

58%, 0.74

89% ± 0.3%

#ID

RR33

Structure

47% ± 3.3%
Inactivee

Fixed branched chain analogues

BWP48

N.D.

77% ± 4.4%
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P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

BWP49

N.D.

21% ± 7.9%

BWP54

N.D.

56% ± 3.7%

BWP55

N.D.

61% ± 2.0%

BWP57

N.D.

37% ± 5.7%

#ID

a,b.e

Structure

See table 4.1 foot notes.

Table 4.4: Fixed tetrahydrofuran analogues at west side

P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

KEK1

N.D.

45% ± 6.2%

KEK2

N.D.

32% ± 7.7%

#ID

Structure

84
P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

KEK3

N.D.

58% ± 3.4%

KEK4

N.D.

47% ± 6.5%

KEK6

N.D.

54% ± 3.3%

KEK7

N.D.

61% ± 3.6%

KEK9

N.D.

60% ± 5.1%

KEK10

N.D.

41% ± 7.5%

KEK11

N.D.

56% ± 3.9%

KEK8

N.D.

62% ± 4.2%

#ID

a-b

See table 4.1 foot notes.

Structure
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Table 4.5: Fixed branched chain analogues at west side

P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ±
SEM;
Log IC50 ± SEM

BWP45

N.D.

54% ± 3.0%

BWP48

N.D.

77% ± 4.4%

BWP49

N.D.

21% ± 7.9%

BWP54

N.D.

56% ± 3.7%

BWP55

N.D.

61% ± 2.0%

BWP57

N.D.

37% ± 5.7%

#ID

a-b

See table 4.1 foot notes.

Structure
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4.6

Design of photoaffinity probes

Figure 4.9: Design of photoaffinity probes for PAR1

In previous chapter 3, we discussed about the experiments in Flaumenhaft’s lab
with chimeric PARs.57 Replacement of 2 nd and 3rd intracellular loop of PAR1 with PAR4
and mutant helix 8 of PAR1 lead to a considerable decrease in inhibition of SFLLRNNH2 induced Ca2+ flux by ML161. These results suggested that ML161 acts
intracellularly at the cytosolic face of PAR1. Kobilka and co-workers reported x-ray
structure of PAR1 bound to vorapaxar.54 However, 3rd intracellular loop was highly
modified and C-terminus was disordered to facilitate crystallization, and that made
difficulty in determining putative binding site. To identify the precise binding site of
parmodulins and mode of action of PAR1, we designed azide and alkyne based
parmodulins (Figure 4.9).

We planned to adopt Nakanishi, Ernst and co-workers

protocol of photo affinity studies of rhodopsin, where azide moieties possess photo labile
nature so we can irradiate using UV lamp whereas alkyne could be useful in fluorescent
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labeling via click chemistry to facilitate pull-down experiments to isolate labeled
peptides.90
For photo affinity studies, we planned to incubate aryl azide with the isolated
human platelets membranes containing PAR1, followed by irradiation at >300 nm using
UV lamp. Next, the membranes will be solubilized and the proteins will be separated
from the membrane phospholipids.91 The collected proteins will be treated with trypsin,
and filtered off to collect the complex peptide mixture. The peptide mixture will be next
treated with azido – biotin conjugate and copper catalyst according to Ernst’s protocol. 90,
92

The result mixture will be flushed with buffer over avidin-agarose column to remove

unlabeled peptides. Labeled peptides will be separated by HPLC, quantitated and
sequenced by mass spectrometry to identify putative binding site.

4.6.1 Synthesis photoaffinity ligands of 1,3-diminobenezene scaffold

Scheme 4.9: Synthesis of photoaffinity ligands.

The amine of anthranilic acid 4.29 was transformed to azido acid 4.30 using
Sandmeyer reaction conditions. Azido acid 4.30 was acylated with aniline 4.28 to give
azide analogue 4.31 in 80% yield (Scheme 4.9).

88
Table 4.6: Photo affinity ligands assay data in P-Selectin assay

P-selectin
assay:
%Inhibitiona;
IC50 (µM)

iCa2+ assay:
%Inhibitionb ± SEM;
Log IC50 ± SEM

DG5

87%; 4.28

38% ± 2.9%

RR10

100%c

34% ± 12%

RR34

N.D.

Inactive

#ID

a-e

Structure

See table 4.1 foot notes.

We expect that the designed analogues will bind to intracellularly at cytosolic face
of PAR1. Unfortunately, the azide and alkyne analogues we screened were not active
enough to perform this photo affinity experiment. The most likely complication in our
study could be rearrangement of photoaffinity probes upon photoactivation before
binding to PAR1. More potent and selective for PAR1 analogue may facilitate these
studies and thus, we can answer mode of action of PAR1 bound to parmodulins.
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4.7

Summary of P-selectin assay results

Figure 4.10: Extended SAR of parmodulins in P-selectin assay.

From the assay data, we concluded that the east side of 1,3-diamino benzene
scaffold must be present to retain the activity (Figure 4.10). Severe modifications at the
east side have adverse effect on activity. We have not fully explored central region,
however, moderate activity of indazole and indole ring suggests a promising site with
functional group tolerance. Replacing the central aromatic region with urea could be
indicative of sensitivity of this scaffold over the marginal distance between two aniline
nitrogen atoms.
We put extensive efforts in developing the west side analogues.

From the

previous data the length of alkyl chain was necessary to retain the activity. We put
additional branch and heteroatoms to alkyl side to improve solubility and plasma
stability. But the assay data suggests that protonation at physiological pH (specifically
amines) could hamper the activity. Among this set of the molecules, we found 2tetrahydrofuran ring (AS2) as one of promising scaffold with 0.99 µM IC50 and 100%
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inhibition. Changing the position of “O” or replacing “O’ with “N” didn’t retain any
activity. This could be indicative of specific H-bonding with the receptor and
physiological property may be influencing the activity to a great extent. Unfortunately,
these analogues were less potent than ML161 but still show reasonable activity.

4.8

Summary of iCa2+ flux assay

Figure 4.11: SAR of parmodulins in iCa2+ assay.

We didn’t screen the complete set of previously published parmodulins, however,
SAR profile of current set of parmodulins was similar to P-selectin assay with few
exceptions (Figure 4.11). Such as, at the west side, 4-carbon chain was necessary. 3- and
5- carbon chain analogues were poorly active. Another striking difference between both
assay data was activity of 2- and 3- tetrahydrofuran analogues (AS2 and AS4) in both
assays. In P-selecting assay, AS2 and AS4 showed 100% and 11% inhibition,
respectively. These results suggested that position of “O” may be really important to
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retain the activity. However, in iCa2+ flux assay, both AS2 and AS4 showed similar
activity with moderate 42% and 44% inhibition, respectively.

Figure 4.12: “Hit molecules” from PAR1 mediated iCa2+ screening at 10 µM concentration of parmodulins
in the presence of 5 µM TFLLRN-NH2 agonist

An interesting note to the observation was, unlike P-selectin assay, addition of
heteroatoms was well tolerated at the west side. From this screening, we found 4 “hit
molecules” along with ML161 and RR90, which will be further characterized using iCa2+
flux assay (Figure 4.12). Characterization of these 4 hit molecules is pending in Pselectin assay.
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4.9

Pharmacological profiling of parmodulins

4.9.1 Selectivity of parmodulins

A. PAR1 activity

B. PAR2 activity

Figure 4.13. Selectivity data of antagonists in A) PAR1 (TFLLRN-NH2) and B) PAR2 (SLIGKV-NH2)driven iCa2+ mobilization. ML161, RR90, Q94, TJF5 (Fairlie’s PAR2 antagonist) were used at 10 µM;
Vorapaxar, Atopaxar, and RWJ-58259 were at 0.316 µM. TFLLRN-NH2 and SLIGKV-NH2 were used at
3.16 µM; Vehicle (V) = 10% DMSO–HBSS/HEPES wash buffer.79

We demonstrated here that parmodulins are selective PAR1 receptor over PAR2
receptor (Figure 4.13). To our knowledge, PAR1 orthosteric antagonists have not been
tested against PAR2 because of the absence of PAR2 receptors in human platelets. We
chose Ml161 and RR90 as parmodulins representatives because of their potency both in
iCa2+ mobilization and P-Selectin assay. TJF5 was chosen as PAR2 representative and
Vorapaxar and RWJ-58259 were orthosteric antagonists. We additionally incorporated Q94 (a commercially available PAR1allosteric modulator). However, in our study it was
found to be inactive. For rest of the compounds, we observed that parmodulins and
orthosteric antagonists exhibited an excellent selectivity for PAR1 whereas TJF5 was
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selective for PAR2. We tested these compounds against PAR4 receptor; however, PAR4
receptor agonist AYPGFK-NH2 didn’t show any activity even at 100 µM concentration.

4.9.2 Interactions of parmodulins with PAR1.

A.

B.

C.

D.

Figure 4.14. Concentration-response of the PAR1 agonist TFLLRN-NH2 in the presence of increasing
concentrations of (A) vorapaxar, (B) RWJ 58259, (C) ML161, (D) RR90. 79

We discussed earlier about possible binding site of parmodulins at intracellular
loop may be the reason for their biased signaling. ML161 showed non-competitive
binding in SFLLRN-NH2 mediated P-Selectin assay. In addition, it doesn’t affect binding
of high affinity [3H]TRAP to platelet membranes. 57 In contrast, Vorapaxar showed noncompetitive antagonism with very slow off rate to PAR1. 54 To demonstrate mode of
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action of parmodulins, we measured concentration-response curve of TFLLRN-NH2 in
varied concentration of parmodulins and orthosteric antagonists. We observed dosedependent decrease in TFLLRN-NH2 efficacy with Vorapaxar (Figure 4.14A), ML161
(Figure 4.14C) and RR90 (Figure 4.14D). This observation could be suggestive of either
irreversible interaction or negative allosteric modulation. In case of RWJ-58259 (Figure
4.14B), we noted right forward shift indicating competitive antagonism, however, agonist
concentration was not high enough to reach at maximum response.

Figure 4.15: Reversibility studies of the PAR1 antagonists vorapaxar, RWJ-58259, ML161, CJD125, and
RR-90. Cells containing antagonists were optionally washed with buffer prior to treatment with the PAR1
agonist TFLLRN-NH2 (5 μM). Vorapaxar and RWJ-58259 were used at 0.316 µM. ML161, CJD125, RR90
were used at 10 µM.79

To determine whether parmodulins are irreversible inhibitors or negative
allosteric modulators, we performed “wash” studies. We treated antagonists with
endothelial cells and measured the response before and after buffer wash (Figure 4.15).
As indicated in literature, Vorapaxar binds to extracellular loop 2 of PAR1 and is
virtually irreversible antagonist.54 Consistent with the literature, even after 2 times buffer
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wash, Vorapaxar completely shuts down TFLLRN-NH2 mediated PAR1 signal.
However, RWJ-58259, ML161, CJD125, and RR90 lost their activity for PAR1
significantly. Hence, we concluded that at least ML161, CJD125 and RR90 are negative
allosteric modulators of PAR1.

4.10

Conclusion

A set of parmodulins, specifically concentrating at west side of ML161, was
synthesized using optimized synthetic protocol. SAR was investigated using P-selectin
assay to develop anti-thrombotic but the modifications at west side and central region did
not improve potency of ML161. Next, we developed Gɑq mediated iCa2+ flux assay in
EA.hy926 endothelial cell lines to characterize parmodulins in endothelial cells as PAR1
selective ligands. This assay is suitable for medium throughput screening and obtaining
concentration-responses for PAR1 and PAR2 ligands. We observed that ML161 and
RR90 were highly selective for PAR1, decreasing the maximal signal of TFLLRN-NH2
(PAR1 agonist) in concentration dependent manner in iCa2+ flux assay and binding to
PAR1 with reversible interaction. This behavior characterized ML161 and RR90 as
negative allosteric modulators of PAR1. Whereas FDA approved PAR1 inhibitor
vorapaxar binds with PAR1 in irreversible manner and is non-competitive orthosteric
antagonist. During the course of study, parmodulins were evaluated to exert APC like
cytoprotective effects. Therefore, these results suggested that parmodulins could be
potential towards the development of anti-inflammatory agents for the treatment of sepsis
like disorders. With that aim, we screened ~100 molecules in iCa2+ flux assay and we
found 4 hit molecules from this screening with modification at west side of ML161. Our
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future work is to characterize new hit molecules as negative allosteric modulators for
PAR1 and to perform another screening in cytoprotection assay which is under
development at this stage.
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Chapter 5

Introduction of GPCR oligomers and project aim

5.1

GPCR oligomerization

5.1.1. GPCR oligomers

Figure 5.1: GPCRs as A: as monomers; B: as homomers; C: as heteromers.

Traditionally, GPCRs were considered only as monomers, where ligand binds,
resulting in conformational change to activate only G-protein, trigger secondary
messenger pathway and ultimately result in receptor phosphorylation, desensitization and
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internalization.93-95 In last two decades, several mechanisms to regulate GPCRs mediated
signaling were published which highlighted the cross-talk with neighboring cell
membrane receptors, suggesting multimeric GPCRs conformations. 96, 97 GPCRs can exist
as dimers (homomers or heteromers) or highly ordered oligomers (figure 5.1). In
addition, the advancements in biochemical and biophysical tools provided indirect
evidences of GPCR oligomerization. Initially, GPCRs were reported to be as homomers,
but more intense investigations showed that some receptor subtypes can exist as
heteromers as well, which may have different signal transduction pathways compared to
homomers, and could have significant potential as novel drug targets. 98, 99
A very first example to demonstrate GPCR heteromerisation came from GABAB
receptors. GABA (γ-amino butyric acid) is an inhibitory neurotransmitter and its
inhibitory effects are mediated via GABAA-C receptors. GABAA and GABAC are ligand
gated chloride channels whereas GABAB is a GPCR. The cloned GABAB receptors,
GABABR1100 and GABABR2101-104 showed non-functional behavior105 in most
heterologous cells with GABAB receptor ligands. However, co-expression of GABABR1
and GABABR2 showed neuronal properties of GABAB receptors.106 This evidence was
suggestive of the heteromerisation of GABAB. To support the theory, extensive research
was done on both GABABR1 and GABABR2, and it was demonstrated that GABA binds
to the extracellular domain of GABABR1, but signal transmission occurs completely via
GABABR2.107, 108
Another example is sweet taste, which is believed to be due to the presence of
GPCR T1R1 and T1R2 in taste buds.109 T1R3, another GPCR, extensively homologous
with T1R1 and T1R2, was derived from Sac mice110-114 and exhibits reduced sensitivity
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toward sweet stimuli. When T1R1, T1R2 and T1R3 were expressed in heterologous cells,
neither of them was responsive to sweet stimuli. However, T1R3 was activated by
saccharin, when co-expressed with T1R2.109, 110 In same manner, co-expression of T1R3
with T1R1 was responsive towards monosodium glutamate and amino acids, 115 which
gives a very distinctive “umami” taste.109, 110, 116 These findings were highly suggestive of
the necessity of heteromerisation of T1R3 with T1R1 and T1R2 to develop sensitivity to
giving the specific tastes. Although the concept of receptor-receptor interactions of
GPCRs has been accepted, it’s unclear how these interactions result in dimer or oligomer
formation, and what proportion of receptors exist as monomer, dimer (homomers or
heteromers) or oligomer.

5.1.2 Pharmacology of GPCR heteromers and their potential as novel drug targets

GPCRs can interact and associate with same family to form homomers or can
interact with same family subtypes, or other GPCRs to form heteromers. Such
interactions can result in completely different conformation of one or both receptor,
leading to unique signaling pathway. For example, dopamine receptor heteromers D1R –
D2R altered the Gɑi mediated signaling of D1R and Gɑs mediated signaling of D2R to
Gɑq11 mediated pathway.117 Whereas the heteromerisation of δOR and µOR
predominantly switches from G-protein mediated pathway to β-arrestin mediated
pathway.118 The resulted change in conformation can alter the binding pocket for the
receptor, and thus, affinity for ligands. For example, heteromers of δOR - µOR have
decreased affinity for highly selective synthetic ligands of δOR and µOR. 119 In addition,
heteromers has been found in specific tissues and sometimes specific disease conditions.

100
For example, 5HT2A – mGluR2 receptor heteromers are specifically implicated in
psychosis.120 Another example is that of the heteromers of prostaglandin EP1 and
adrenaline receptor β2AR. The combination of EP1 – β2 AR in airway smooth muscles
results in reduced Gas coupling of β2AR followed by reduced bronchodilation by β2AR
agonist isoproterenol and ultimately leading to asthma. 121
These studies suggested that if heteromers are disease specific they could serve as
novel therapeutic targets.. In such cases, ligands acting at heteromer complexes can
modulate a specific physiological or pathophysiological process and this information
could be utilized to develop drug candidates. For example, the adenosine A2A receptor, in
brain, has an important role in the regulation of glutamate and dopamine release, and
hence serves as a potential therapeutic target for the treatment of pain, insomnia, drug
addiction, and Parkinson’s disease. SCH-442416, an A2A receptor antagonist, showed
significantly less affinity when the A2A receptor was co-expressed with the dopamine D2
receptor.122 From a pharmacological point of view, A2A-D2 receptors are located at
postsynaptic neurons.122,
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Blocking of the A2A receptor at postsynaptic neurons

produces locomotor activation because of the interaction of A2A-D2 receptors. A2A
antagonists increased the affinity of D2 receptor for dopamine and thus, A2A blockade at
postsynaptic neurons can be effective for the treatment of Parkinson’s disease.
Schizophrenia is another pathological condition where A2A-D2 heteromers can be used as
a drug target.124
Because of the improved understanding of GPCR heteromerisation and ongoing
efforts to understand the pharmacology of heteromers, it has been possible to selectively
target pathophysiology of the disorder and then undergo drug development phase. In a
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nutshell, GPCR heteromers tend to have i) unique localization; ii) distinct allosteric
properties which can offer ligand selectivity and functional selectivity (to study
functional diversity) can be used as physiological tools and additionally but can be used
as lead for development of highly selective drugs.

5.1.3 Methods to determine the existence of GPCR oligomers

Currently, a number of experimental techniques are available to detect the
existence of GPCR oligomers including biochemical, biophysical, and molecular imaging
techniques. Biochemical methods like co-immunoprecipitation (IP) and Western blotting
(WB) are considered as a good starting point to show oligomers even though this
technique requires cell lysis and specific antibodies for the receptors of interest.
Biophysical methods like resonance energy transfer (FRET, BRET, etc.) provide
evidence about the receptors proximity to each other. Currently, no definitive method
exists to determine GPCR oligomers because each method has its own advantages and
disadvantages that are highly dependent on the receptor of interest.

5.1.3.1 Biochemical methods

Co-immunoprecipitation and Western blot were the first biochemical tools to
detect monomers and oligomers. This technique provided the first direct evidence of
homodimers of b2AR125 and dOR126. This method requires high affinity antibodies for
the receptors of interest or incorporation of epitope tags like Flag, V5, His, Myc, etc. at
the N-terminus of the receptor. In the first stage of the process, cells expressed with the
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receptors are solubilized and the lysate is incubated with the antibody of one of the
receptors. The resultant receptor – antibody complex is treated with binding medium like
sepharose beads and unbound proteins are washed away from the lysate. In the second
stage of the process, the complex is subjected to SDS-PAGE and immunoblotted against
the antibody or epitope tag of secondary receptor. 127, 128 This method has been widely
used to provide evidences of higher order of oligomersation such as interactions of
A2AR, D2R, and mGlu5R and heteromer mediated effects on the progression of
schizophrenia and drug addiction.129 However, there are two major limitations to this
technique. First is cell lysis and solubilization step that may lead to oligomer formation or
dissociation. And second is lack of availability of specific and high affinity antibody for
the receptors of interest and specifically, when the receptors are heterogeneously
expressed.

5.1.3.2 Biophysical methods

Biochemical methods are usually targeted for non-living cells. To determine the
presence of oligomers in living cells, biophysical tools like resonance energy transfer are
widely used. In this process, higher energy donor fluorophore transfers energy to the
lower energy acceptor molecule, resulting in quenching of donor molecule and sensitized
fluorescence of acceptor molecule. There are two types of resonance energy transfer
techniques in use: Fluorescence resonance energy transfer (FRET) and Bioluminescence
resonance energy transfer (BRET). The advantage of this method is to occur energy
transfer only when two receptors are in close proximity to each other (<100 Å).130
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A)

FRET (Fluorescence resonance energy transfer):

Figure 5.2: Schematic representation of FRET method: Receptor R1 is tagged with donor CFP and R2 is
tagged with acceptor YFP at C-terminus. CFP is excited at 433 nm that emits light at 475 nm. If R1 and R2
are in close proximity <100 Å, then FRET occurs and YFP emits at 527 nm.

In this method, a high energy donor fluorescent protein is excited by
monochromatic light, followed by resonance energy transfer to a lower energy acceptor
protein if both proteins are in close proximity to each other and emission spectra of donor
overlaps with excitation spectra of acceptor protein. FRET is usually measured between
two fluorophores in a cell suspension. In this method, two receptors of interests are
usually tagged at C- terminus with the variants of green fluorescent protein (GFP), among
which a donor protein is tagged as cyano fluorescent protein (CFP) and an acceptor
protein is tagged as yellow fluorescent protein (YFP). When the pair of CFP – YFP is in
close proximity to each other (<100 Å), the energy transfer occurs after CFP excitation at
433 nm and acceptor emission at 527 nm (Figure 5.2), and FRET can be quantitated by
calculating the ratio of emission intensity FYFP(exc433/emi527)/FCFP(exc433/emi475).130 Sometimes
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additional corrector factors are needed in this process due to the leaking of donor
emission into the acceptor emission by the light used to excite the donor. For example,
Cotecchia, et al., investigated higher order of oligomerization between A1a- and A1b-AR
via FRET measurements.131 First, they excited CFP at 430 nm and measured the emission
at 450 nm, followed by calculating the ratio of excitation at 450 nm in mock transferred
and expressed cells, and used it as correction factor. Due to the difference in receptor
expression in cells, they had to perform additional experiments to measure the fluorescent
spectra of individually receptor expressed cells, adjusted by the correction factor to
normalize cell density, and then FRET efficiency was measured. 131 In addition,
photobleaching of YFP to blue – cyan fluorescence can also affect FRET accuracy. 132, 133
Time resolved FRET (TR-FRET) and photobleaching FRET (Pb-FRET) are other
reported indirect approaches to measure FRET. In TR-FRET, lanthanides like europium
or terbium are incorporated to prolong the time frame between excitation and detection of
FRET signal that allows decay of autofluoresence and provides improved signal to noise
ratio. On the other hand, Pb-FRET measures the decay of fluorescent signal upon
continued exposure to excitation by light. The donor fluorophore is photobleached by
intense light and fluorescence is measure in the presence and absence of acceptor. If the
acceptor is in proximity of the donor, FRET occurs resulting in decreased intensity of
photobleaching.128
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B)

BRET (Bioluminescence resonance energy transfer):

Figure 5.3: Schematic representation of BRET method: Receptor R1 is tagged with Renilla luciferase
(Rluc) and R2 is tagged with acceptor GFP at C-terminus. Rluc catalyses oxidation of DeepBlueC and in
return emits light ta 410 nm. If R1 and R2 are in close proximity <100 Å, then BRET occurs and GFP emits
at 515 nm.

In this method, energy transfer occurs from a luminescent donor to a fluorescent
acceptor. Renilla luciferase (Rluc) from the marine sea pansy Renilla reniformis is
commonly used as a luminescence donor and YFP or GFP are used as an acceptor
protein. The Coelenterazine substrate DeepBlue C is oxidised to excite luciferase that
emits light at 410 nm. Similar to FRET, when luciferase tagged donor protein is in close
proximity to the acceptor protein YFP, the light from the donor excites the acceptor,
followed by light emission from the acceptor at a unique wavelength (Figure 5.3). Then,
calculating the ratio of acceptor to donor light emission, the interaction of the receptors
interactions can be quantified.127,

128

This technique has played a major role in the

characterization of GPCR heteromers. For example, Franco, et al., studied a direct
interaction between D2 and AT1 receptors. First, they showed that drugs selective for
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AT1R could alter the cell signaling pathway of D2 R, which could potentially be beneficial
in the treatment of Parkinson’ disease. Second, they tagged AT 1R with Rluc and D2R
with YFP and measured BRET with and without ligand binding in HEK-293T cells.
From the BRET results, they concluded that D2R and AT1R form heteromers in HEK293T cells and the heteromer structure is unaffected upon ligand binding. 134 This could
be an important tool to investigate ligand – heteromer interactions as well and ultimately,
identifying drugs that can modify this signaling. The disadvantages of BRET are its
limitation to detect only cell-surface receptors, and overexpression drastically affects the
accuracy of BRET.
Even though these methods have certain limitations, both biochemical and
biophysical methods could be used together to predict GPCR heteromer or homomer
formation. Other techniques are also in practice like computational based methods (e.g.,
protein – protein docking, sequence based methods), or modifications of current
biophysical methods. In addition, x-ray crystallography of proteins has gained popularity
as direct evidence. Although relatively few GPCR structures have been obtained from xray crystallography, the method has not been successfully implied to support evidences
for oligomers. In summary, these methods are a good starting point to investigate the
existence of GPCR oligomers or form oligomers after ligand binding and exert unique
signaling pattern compared to monomers. Then, this information could be utilized to
design novel therapeutics with selective affinity and efficacy.
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5.1.4 Novel approaches to targeting GPCR heteromers

5.1.4.1 Monovalent ligands specific for heteromers

As discussed before, heterodimersation of GPCRs can modulate receptor function
by changing a receptor's conformation, but it may cause significant change in the ligand
binding site as well. The altered binding site can then accommodate distinct ligands. For
example, Waldhoer et al. reported that 6’-GNTI (6-guanidinonaltriindole) was originally
designed as a ƙOR agonist.135,

136

However, later it was discovered to act selectively

through ƙOR – δOR heteromers, but not either of the homomers. 6’-GNTI showed the
most potency and efficacy in ƙOR – δOR co-expressed cells in an agonist mediated iCa2+
assay, while ƙOR selective agonists showed equivalent potency in both single and coexpressed cells. Both ƙOR and δOR selective antagonists inhibited signaling of 6’-GNTI.
Another proof of concept was revealed by selective targeting of SKF-83959117 for
dopamine receptors. In animal models, SKF-83959 was found to induce a number of
behavioral effects similar to dopamine D1 receptor agonists; however, in spite of high D1
receptor affinity, SKF-83959 failed to induce cAMP production. Further investigations
showed the selectivity of SKF-83959 for the D1-D2 heteromeric complex. SKF-83959
caused an increase in intracellular calcium levels through activation of Gq/11 mediated by
the D1-D2 heteromeric complex. This effect was abolished when D1 and D2 receptors
were expressed alone. Moreover, radioligand binding studies of the D2 receptor
antagonist raclopride showed a high affinity binding site of SKF-83959 on the D2
receptor that was absent in D1 knockout models. In addition, pertussis toxin (PTX)
pretreatment (which uncouples Gi/o protein and resists Gq/11 protein) with the D2 receptor
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showed minimal difference in the high affinity binding site for SKF-83959;
demonstrating the involvement of Gq/11 mediated effects of SKF-83959. These findings
suggest that heteromers specific ligands can promote or block specific signaling
pathways that can be tuned into a specific pharmacological effect.

5.1.4.2 Bitopic/Dualsteric ligands

GPCRs have been known to adopt multiple active sites via orthosteric ligands or
allosteric modulators, giving rise to a specific cell signaling. Extension of this approach
by linking orthosteric ligands and allosteric modulators yield a new class of ligands,
known as bitopic hybrid ligands.
160209137,

138

For example, Steinfeld et al, developed THR-

(figure 5.4A), as a bitopic ligand for M2 receptor (muscarinic receptor

subtype, located in heart and responsible for slowing heart rates). In compound THR160209, 4-ABP (4-aminobenzylpiperdine) motif showed allosteric behavior and 3-BHP
(3-benzylhydrylpyrrolinyl) motif showed orthosteric behavior with M2 receptor. By
linking both motifs by heptane chain, THR-160209 exhibited higher affinity and
selectivity for M2 receptor compared to its individual components.
Linking orthosteric and allosteric moieties together not only affects affinity but
sometimes it develops bias signaling as well via unique confirmations. For example,
Christopoulos et al,139,

140

developed a biotopic ligand VCP-746 (Figure 5.4B by

connecting an orthosteric adenosine motif to thienyl motif of VCP-171 (a positive
allosteric modulator for adenosine receptor responsible for bronchoconstriction).
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Figure 5.4: Examples of bitopic ligands: A: THR-160209, M2 receptor bitopic ligand; B: VCP746, A1
receptor bitopic ligand

As a result, VCP-746 showed a distinct biased profile compared to individual
counterparts. VCP-171 was responsible for bradycardia and cytoprotection; however,
connecting allosteric VCP-171 motif with orthosteric counterpart in VCP-746, in vitro
studies of showed to protect cardiomyoblasts and cardiomyocytes against simulated
ischemia, but showed no effect on rat atrial heart rate in vivo.141 These results suggested
cytoproetction of VCP-746 without any significant effects on heart rate.

5.1.4.3 Bivalent Ligands

Portoghese and co-workers addressed the question of inter-receptor distance via
developing bivalent ligands. The concept originally thrived from P.S. Portoghese,
bivalent ligands are molecules which connect two pharmacophores with an appropriately
designed spacer. Bivalent ligands can have two identical pharmacophores for binding at
homomers or two different pharmacophore for binding at heteromers. These ligands can
target either at orthosteric sites of homomers and heteromers or target orthosteric and
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allosteric site of heteromers (Figure 5.5). These ligands may exhibit higher affinity with
the receptor complex compared to monovalent ligands, which is excellent evidence for
the presence of receptor complexes. When one pharmacophore binds with one of a
receptor dimer, it increases the local concentration of second unbound tethered
pharmacophore in the vicinity of neighboring receptor, and therefore lowers the entropy
of overall ligand – receptor complex resulting in increased affinity. 142

Figure 5.5: Schematic representation of bivalent ligand – receptor complex: A) bivalent ligand targeted to
homomers at orthosteric site; B) bivalent ligand targeted to heteromers at orthosteric site; C) bivalent ligand
targeted to heteromers at orthosteric site of R1 and allosteric site of R2.

The first reported example of a bivalent GPCR ligand comprised two units of βnaltrexamine (a μ-OR antagonist) linked by a polyethylene glycol spacer. This compound
showed showed greatly enhanced selectivity for μ-OR.143 Numerous other bivalent
ligands have been developed and characterized for a variety of putative GPCR dimers
present in the central nervous system, including opioid, muscarinic, chemokine, and
dopamine receptors.
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In summary, dimeric GPCRs exist naturally or under pathological conditions. The
growing acceptance on GPCR heteromerisation and continual efforts in invaestigation of
GPCR heteromers offer them as a potential drug targets. Further the extensive research
on bivalent ligands showed access to unique pharmacological profiles than monovalent
ligands, and therefore, employing bivalent ligand could be a feasible route to avoid
undesired signaling of monovalent counter parts, and ultimately provide safer drug. In a
similar way, PARs have been reported to form dimers under pathological conditions. This
thesis work has focused on unique signaling of protease-activated receptors for the
treatment of restenosis and breast cancer metastasis, which could be achieved by
selectively targeting PARs heteromers with bivalent ligand.

5.2

PAR oligomers and their pharmacological significance

It is now evident that GPCRs can naturally exist as oligomers or can form
oligomers via crosstalk with nearby GPCR monomers or other cell surface proteins upon
receptor activation. As a result, these GPCR oligomers can possess different
conformations and trigger a range of different signals as heteromers or dimers. There are
four subtypes of Protease-Activated Receptors (PARs 1–4) which are expressed in
numerous tissues, including platelets, smooth muscle cells, endothelial cells, astrocytes,
immune cells and microglia of the central nervous system. 144-146 PARs have been
reported to exist as dimers and heteromers and their modified signaling has been studied
in the context of different diseases states.147, 148
Small molecules or natural molecules like hormones, peptides or ions can activate
GPCRs. The majority of USFDA approved drugs are designed by synthetically
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mimicking these ligands to target GPCRs. However, PARs have unique mode of action
involving the irreversible site-specific receptor cleavage at the extracellular N-terminus,
as the exposed tethered ligand, in the presence of different proteases. The tethered ligand
does not diffuse away but the new N-terminus binds to the receptor resulting in the
conformational change and ultimately, the activation of the variety of downstream
signaling pathways like G-protein signaling, β-arrestin signaling or transactivation of
other receptors. Depending on the activated signaling pathways, PARs can play critical
role in the progression of thrombosis, hemostasis, and inflammatory and proliferative
response.147-149 Recent studies have suggested the engagement of PARs in the progression
of cancer metastasis150 and modulation of the immune response during viral infections. 151
Due to site-specific and tissue-specific signaling pattern, existence as oligomers,
evidences of interactions with the neighboring receptors, and involvement in different
disease progression, PARs have become the attractive candidates to develop bivalent
ligands as novel therapeutics.

5.2.1 Evidence of PAR crosstalk

In the early 1990s, Coughlin and co-workers demonstrated the first evidence of
self-association of the PAR1 receptor to form homodimers.144 The evidence showed that
the exposed tethered ligand of PAR1 can intermolecularly transactivate an adjacent
PAR1, but with less efficiency than intramolecular activation. Later, Brass and coworkers observed that the complete blockade of thrombin-mediated cellular responses in
HUVECs could only be achieved by blocking both PAR1 and PAR2 receptors. They
treated HUVECs with two selective antibodies and a PAR1 selective antagonist (BMS-
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200261) at previously studied inhibitory concentrations. The antibodies, which mimicked
PAR tethered peptides, completely blocked thrombin mediated cellular responses, but the
PAR1-selective antagonist was partially effective. They showed evidence of
transactivation of PAR2 by a tethered PAR1 peptide, and therefore, such transactivation
to form PAR1-PAR2 heteromers can limit the effectiveness of PAR1 monovalent
ligands.27 McLaughlin and co-workers showed evidence via BRET studies that PAR3 can
preferentially modulate Gα13 signaling of PAR1. Mosnier et al., and Madhusudan et al.,
showed that APC can cleave both PAR1 and PAR3 to promote cytoprotective signaling
and can block either of the receptor attenuated the rate of apoptosis. Interestingly, PAR3
signaling on its own is unknown until now,which therefore suggests the existence of
PAR1-PAR3 heteromers. Similar results were observed where APC-mediated PAR3
activation triggered PAR2-PAR3 heteromerization and ablation of PAR3, and completely
blocked the cytoprotective effects of APC. Cunningham and co-workers demonstrated
PAR2-PAR4 association when they observed increased trafficking of PAR4 on HEK293
cell surface after co-expression of PAR2.

Table 5.1: Selected examples of PAR oligomers and their effects on signaling

PAR oligomers

Function affected

PAR1-PAR1

Ca2+ signaling

PAR2-PAR2

Inflammatory signaling

PAR4-PAR4

Ca2+ signaling

PAR1-PAR2

Cytoprotective signaling, smooth muscle hyperplasia
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PAR1-PAR3

Gα13 biased signaling

PAR2-PAR3

Cytoprotective signaling

Numerous studies have been done that show evidence of PAR dimerization and
heteromerisation, and which reveal unique signaling patterns associated with them like
biased G-protein signaling, β-arrestin mediated signaling or more efficient G-protein
signaling (Table 5.1). However, the driving force to stimulate such co-precipitation of
two PARs together is poorly understood at this time. X-ray structures of PAR1 and PAR2
have been recently published but they do not reveal any dimer formation. It may be
possible that PARs dimers are transient in nature and could be stabilized with interacting
proteins or perhaps, small molecule ligands. This thesis work focuses specifically on
putative PAR1-PAR2 heteromers and how antagonism of both receptors could block
pathological signaling.

5.2.2 Background on PAR1 – PAR2 heteromers and project aim

The connection between thrombosis and tumor cell metastasis has been studied
from several decades. It has been reported that thrombin has significant effects in
modifying the behavior of cancer cells via activation of thrombin receptors.152 There is
strong evidence that PARs are implicated in cancer metastasis and the process is driven
by the presence of both PAR1 AND PAR2. In 2004, Mueller and co-workers reported a
study of metastasis in human melanoma cells to activate the coagulation cascade to
generate thrombin. They demonstrated that thrombin stimulates PAR1, which
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simultaneously activates PAR2 and induces motility of metastatic tumor cells.153, 154 They
reported that stimulation of PAR1 or PAR2 alone did not lead to migration of metastatic
cells but in presence of both PAR1 AND PAR2 agonists there was 12-fold increase in
tumor cell migration.27,

155, 156

These results are consistent with the greatly increased

migration of cancer cells promoted by the PAR activator thrombin. In addition, there is
complementary evidence from co-immunoprecipitation and fluorescent labeling
(FRET/BRET) studies showing that PAR1 and PAR2 are present TOGETHER as
complexes on different cell types, including breast cancer cells, and that RNA silencing
of PAR2 significantly inhibits PAR1-driven invasion of MDA-MB-231 breast cancer
cells.157 In 2011, Kuliopulos and co-workers reported the involvement of multimeric
PAR complexes in restenosis (the narrowing of arteries after stent implantation and
angioplasty). 158

5.2.2.1 Role of PAR1 – PAR2 heteromers in cancer cell metastasis.

PAR1 expression in human breast cancer cells correlates with tumor
progression152 whereas it correlates with bone metastasis in prostate cancer. 153 Mueller
and co-workers showed correlation between thrombin generation and its effect on
metastasis of melanoma cells.159,

160

They demonstrated that thrombin-mediated

melanoma cell metastasis requires not only PAR1 activation but simultaneous PAR2
activation is also necessary to induce the highest levels of metastasis. They observed
stimulation of cell migration by thrombin and then observed abolition of cell migration in
the presence of hirudin, an inhibitor of thromin, indicating that thrombin is necessary for
cell migration.
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Figure 5.6: Cell migration enhanced in presence of both PAR1 and PAR2 agonists A) M24met melanoma
cells and B) prostate cancer cells4

They observed no cell migration in presence of thrombin and a PAR1 antibody,
indicating that thrombin acts via PAR1. However, cell migration was not observed in the
presence of PAR1 selective agonist TFLLRNPNDK, indicating that thrombin may act on
other targets as well. To support the hypothesis, they expressed M24met cells with
agonists where they observed thrombin-like cell migration only in the case of coadministration of the PAR1 and PAR2 agonists (Figure 5.6).154 Additionally,
desensitizing either the PAR1 or PAR2 receptor ablated cell migration.

5.2.2.2 Role of PAR1 – PAR2 heteromers in restenosis

Neointimal hyperplasia is the major cause of restenosis, the constriction of a
blood vessel after stent implantation and/or angioplasty. A stent is a tube like structure
kept after angioplasty to prevent narrowing of blood vessels or to support weak arteries to
promote blood flow.161 However, many times blood vessels recognize stents as foreign
matter and initiate coagulation and immune processes that lead to constriction of blood
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vessels. Therefore, neointimal hyperplasia limits the effectiveness of vascular
interventions and leads to poorer clinical outcomes, and therefore new solutions are
needed for the effective treatment of cardiovascular disorders.162

Figure 5.7: Intimal hyperplasia effect of P1pal-13 in WT, PAR1 and PAR2 deficient mice. Intimal area
was calculated from cross section of arteries; Veh = vehicle; WT = wild type mice; P1pal-13 = PAR1/2
activating pepducin, PAR-/- = PAR1 deficient mice; PAR2-/- = PAR2 deficient mice. P1pal-13 significantly
increases medial hyperplasia in WT compared to PARs deficient mice. 163

Kuliopulos and co-workers examined the role of PAR1 and PAR2 together in the
rapidly changing microenvironment of damaged blood vessels. They accessed PAR1 and
PAR2 functions in vivo after artery injury. After inducing arterial injuries, they harvested
carotid arteries from WT mice and observed acute edema and cytoplasmic swelling, later
characterized as hyperplasia in smooth muscle cells. They analyzed the hyperplasia effect
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in the presence of P1pal-13, and PAR1 and PAR2 deficient mice (Figure 5.7). P1pal-13
is a pepducin agonist based on intracellular loop 3 of PAR1, which activates PAR1 and
putative PAR1 –PAR2 complexes but not PAR2.58, 155, 163 When they treated WT mice
with P1pal-13 for 21 days, a 60% increase in medial area was observed compared to
vehicle but the likewise effect was not observed in mice deficient in either PAR1 or
PAR2.
According to FRET analysis, PAR 1 and PAR2 reside in close proximity to each
other (≤100Å) on the cytoplasmic surface.27, 155, 163 They provided direct evidence through
coimmunoprecipitation studies that PAR1 – PAR2 can form stable heteromers. They
showed that PAR2 strongly associated with PAR1 when co-expressed, demonstrating the
physical interaction, possibly in the form of heteromers.

5.3

Design of Bivalent Ligands

In last 40 years, many heterobivalent ligands showed improved potency and
selectivity compared to their monomeric counter parts and hence, design of such ligands
have gained popularity in medicinal chemists. In general, a heterobivalent ligand is a
designed single molecule that combines two different selective monovalent ligands of
two different targets, suitably modified with an attached spacer (linker) (Figure 6.1).

5.3.1 Selection of pharmacophores

The ideal pharmacophore should be highly selective and potent for the targeted
monomers. The choice of the ligand also depends on the potential to introduce an
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attachment point with a linker, feasibility of chemical modification and the tolerance of
chemical modification to biological activity. The ligand should be low to medium in
molecular weight (300<MW<400),164 because of the additional bulk added with the
attached linker.

Figure 5.8: Heterobivalent ligands targeting CB1 and OX1 heteromers.

To determine the best attachment points to the pharmacophores, good
understanding of structure-activity relationships is necessary. For example, Zhang et al.
reported bivalent ligand probes of cannabinoids (CB1) and orexin (OX1) receptor
heteromers for the potential treatment of neurological disorders (Figure 5.8). To target
both receptors, they chose the marketed drug SR141716 (5.1) as the CB1 antagonist to be
modified, as its SAR was studied in depth and suggested that the piperidine ring can be
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modified without detrimental effects on affinity. On the other hand, as OX1 antagonist,
they chose ACT-078573 (5.2) with limited information on SAR. Therefore, they first
focused on detailed SAR studies of the tetrahydroisoquinoline scaffold of 5.2. From the
SAR data, they identified compound 5.3 with phenoxy group at C7 and C4’ as the most
suitable attachment point. Afterwards, they replaced the piperdine of 5.1 with a
hydrophobic linker with a tertiary amine that was later condensed with a phenol analog of
the OX1 receptor antagonist 5.3 to synthesize bivalent ligand 5.4.
Most commonly, "adapter" sites are made with carboxylic acid, 1º amine, phenol
or alcohol functional groups, and the attachment to the spacer can be achieved by
forming esters, amides, or ethers. In this thesis work, we incorporated the 1,2,3-triazole
functional group via click reaction (1,3- dipolar Huisgen cycloaddition) with easily
achieved modifications by inserting alkynes and azides to the ligands.

5.3.2 Spacer length and conformational flexibility

After the selection of the suitable ligands with tolerated modification sites, both
the length and the composition of a spacer are key features for connecting the ligands and
their respective receptors of the complex. The length of spacer may have a profound
effect in terms of selectivity and potency towards the targeted receptors. A short linker
cannot fully occupy the distance between co-expressed receptors and in that case,
bivalent ligands are likely to bind with monomers. On the other hand, a very long spacer
could occupy the free space of the ligand and in turn, cannot interact with the neighboring
receptor. As a result, the bivalent ligand could lose entropic gain and thus, could behave
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like a monovalent ligand. The optimal distance depends on the interaction of the
heteromers, however, 15 - 25 atom spacers have been reported.

Figure 5.9: MMG22: A heterobivalent ligand targeting μOR and mGluR5 heteromers in the spinal cord

For example, the antinociceptive activity of the MMG series (reported by
Portoghese and co-workers) was highly dependent on spacer length (Figure 5.9). They
developed the heterobivalent ligand MMG22 (5.7c) that targeted μOR–mGluR5
heteromers in the spinal cord. The motive to target μOR–mGluR5 heteromers was to
suppress morphine induced tolerance and dependence and to enhance morphine
antinociception. To target the μOR, they chose oxymorphone (5.5). From the literature
reported SAR data, modification at the ketone moiety was tolerated and morphine like
activity was maintained, and therefore, they transformed the ketone moiety to a primary

122
amine. They targeted the mGluR5 receptor by extending the phenoxy ether linkage of the
potent mGluR5 -antagonist M-MPEP (6). In both cases, modification retained the activity
of targeted receptor and they connected the phenoxy oxygen of 5.6 with the spacer
through the amino group of 5.5 to facilitate the synthesis of the heterobivalent ligands
5.7a – 5.7d (Figure 6.3). They observed that the activity of the heterobivalent ligands was
highly dependent on the length of the spacer. With the 17 atom spacer (5.7a), the bivalent
ligand was not tolerated whereas the bivalent ligands with 18 (5.7b) and 22 (5.7d) atom
spacers had no tolerance but were less potent. Ultimately, the 20 atom spaced bivalent
ligand (5.7c) was the most potent (ED50 = 9 fmol per mouse) without any signs of
tolerance after 24 h of i.t. administration. 2013PortoPNAS In addition, 5.7c exhibited lack of
tolerance and possessed >106 therapeutic ratio (ratio of administered dose to effective
dose) compared to 5.5. These findings established 5.7c as a tool candidate for the
treatment of anti-inflammatory pain without tolerance development.
The other key factor in bivalent ligand design is the chemical composition of the
spacer. Both structural rigidity and conformational flexibility have been reported to
contribute to the ligand binding and potency. Typically, a hydrophobic spacer like a long
alkyl chain is the choice because of its flexibility, readily availability, easy to bind with
ligand without many chemical transformative steps and advantage of “one-atom”
increments to determine the optimum distance between heteromers. But its application is
usually limited to spacers with 10 – 12 atoms due to solubility issues. This issue can be
addressed by linking an additional hydrophilic portion like a 2º or 3º amine or amide to
aliphatic chains. Hydrophobic linkers may be important when the ligand interaction site
lies at a hydrophobic transmembrane domain. On the other hand, many GPCRs have an
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extracellular binding site and in such cases, bivalent ligands could benefit from
hydrophilic spacers like polyethylene glycols (PEGs) or polyamides. Although long chain
PEGs are expensive and cannot provide the benefit of “one-atom” increments, PEGs can
offer a great deal of solubility in aqueous media and are the best to maintain
conformational flexibility in aqueous environment. Alternatively, higher rigidity can
selectively increase interactions between the bivalent ligands and the receptors. In such
cases, diynes, piperazine rings or aromatic rings are incorporated to gain rigidity via
reducing number of rotatable bonds.
Indeed, chemical composition and length of the spacer play a key role in binding
of bivalent ligands and ultimately, potency. Design of such spacers can be tailored based
on the nature of the ligand, binding interactions, and distance between both receptors.
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Project snapshot (Figure 5.10):

Figure 5.10: Project snapshot: Tissue selective antagonism of PAR1 – PAR2 heteromers could be
beneficial in the treatment of restenosis and breast cancer.

Based on reported literature data about the involvement of PAR – PAR2
complexes in the progression of restenosis and cancer metastasis, we hypothesized that
selective targeting of PAR1 – PAR2 complexes with heterobivalent ligands will permit
tissue selectivity and context selectivity to bind at putative PAR1 – PAR2 heteromers to
inhibit cancer cell metastasis and restenosis (Figure 5.10) while minimizing inhibition of
normal PAR1 and PAR2 signaling. We planned to target PAR – PAR2 heteromers by
making PAR1 – PAR2 bivalent antagonists. Targeting vascular GPCR heteromers, rather
than those in the CNS, has rarely been performed. Thus, the development of PAR
bivalent ligands could be an attractive strategy to selectively engage PAR1/2 complexes
to block pathological signaling to treat restenosis and cancer metastasis.
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Chapter 6

Design and development of bivalent ligands to investigate PAR1-PAR2 heteromers
for the treatment of cancer metastasis

6.1

Design and synthesis of PAR1 – PAR2 bivalent ligands

Based on published SAR data and the potential for diverse modifications, we
elected to utilize the PAR1 antagonist RWJ-5825932 and trisubstituted piperdine analogue
by Bayer pharmaceuticals as PAR1 scaffolds to be modified by attachment to an alkyne
"adapter" for connection to a spacer for the bivalent ligands. We selected the
imidazopyridazine scaffold reported by Vertex37 for use in the construction of PAR2
antagonists which could have a free terminal carboxylic acid functionality for connection
to the spacer. To connect the monovalent ligands, we selected commercially available
PEG-based spacers with a variety of lengths. PEG-based spacers can improve aqueous
solubility and can be flexible in extracellular environment compared to hydrophobic
spacers. They may provide extra "slack" and may pay less of an entropic penalty upon
binding. Commercially available PEG linkers with dual functionalities, azide and free
primary amine, were chosen to perform convenient copper-catalyzed alkyne/azide
cycloadditions (CuAAC)39 and peptide coupling under mild conditions.
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6.1.1 Design and synthesis of PAR1 antagonists

F
F
F
O
N
H

O
N

HO

6.1
IC50 = 33 nM
PAR1 [3H]haTRAP binding assay
Reported by
Schering and Plough Pharmaceuticals

O
H
N

F
NH
O

N
NH

H
N

F

O

NH2

O

N

O

N

NH

N
N
Cl

Cl

6.2 (RWJ-58259)
IC50 = 110 nM
platelet aggregation assay
Reported by
Johnson and Johnson Pharmaceutical

N

OH
6.3
IC50 = 34 nM
HEK293 PAR1 Ca2+ flux
Reported by
Schering and Plough Pharmaceuticals

Figure 6.1: Selected PAR1 orthosteric antagonists to construct PAR1 – PAR2 heterobivalent ligands

Several orthosteric PAR1 ligands have been reported in literature. Based on PAR1
potency, synthetic feasibility, and SAR data, we elected to investigate the benzamidine
6.1,37,
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the peptidomimetic 6.2 (RWJ-58259),38 and the reported piperidine scaffold

6.3165, 166 as starting points for our efforts to prepare bivalent ligands (Figure 6.1). The
synthesis of scaffold 6.1 was undertaken by Dr. Chris Dockendorff and by me. The
synthesis of 6.2 was performed by me with assistance from undergraduate Kaitlin
Kentala and Dr. Mark Majewski. The synthesis of 6.3 was initiated by me and has since
been studied extensively by Ricardo Rosas Jr., and therefore has not been included in this
thesis.

6.1.1.1 Design and synthesis of Schering-Plough benzimidine scaffold

Benzimidine 6.1 was reported by researchers at Schering-Plough as a potent
inhibitor of platelet aggregation induced by the PAR1 agonist haTRAP (IC50 of 33 nM).
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Several molecules with modifications at the east side of the scaffold showed moderate
potency. We hypothesized that could be an ideal attachment point for a linker and thus,
we designed alkyne analogue 6.11 (Figure 6.2) via a convergent 5-step synthesis.

Figure 6.2: Proposed alkyne analogue of 6.11

Scheme 6.1: Synthesis of west side intermediate of 6.11

Friedel-Crafts acylation of commercially available phenol 6.4 was initially
attempted with acetyl chloride and AlCl3 as Lewis acid. However, instead of acylation at
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the 4-position of the phenol (6.5b), an unexpected rearrangement product 6.5a was
observed with 100% conversion. Later, acylation of 6.4 to desired product 6.5b was
achieved with acetic acid in the presence of trifluoroacetic anhydride as solvent.
Bromination of acetophenone 6.5b was first performed in the presence of stoichiometric
Br2 and a catalytic amount of p-toluene sulfonic acid (PTSA) in the aprotic solvent
dichloromethane, causing a sluggish and low yielding reaction. However, performing the
reaction in the protic solvent ethanol gave faster conversion to 6.5b, in 91% yield.

Scheme 6.2: Synthesis of east side intermediate of 6.11 with alkyne tether

Commercially available 1,4-diol 6.7 was mono-alkylated to 6.8 using propargyl
bromide in 33% yield (Scheme 6.2). Benzyl alcohol 6.8 was tosylated with poor yields.
Therefore, Appel reaction conditions were utilized to convert benzyl alcohol 6.8 to the
highly reactive benzyl bromide electrophile 6.9 in 79% yield.
Synthesis of 6.11 was first attempted by alkylation of commercially available 2amino benzimidazole with excess bromoketone 6.6 to give 6.10a in 43% yield, followed
by alkylation with benzyl bromide 6.9. However, the following alkylation step (6.10a to
6.11), gave a complex mixture (Scheme 6.3, route A).
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Scheme 6.3: Attempted synthesis of 6.11

After the failure of route A, the synthesis of 6.11 was attempted in the reverse
order. Benzyl bromide 6.9 was monoalkylated with excess 2-aminobenzimidazole to give
intermediate 6.10b in 28% yield. An unsuccessful attempt was made to alkylate 6.10b
with bromoketone 6.6 (Scheme 6.3, route B). Reactions for both routes A and B were
screened with different bases (K2CO3 and DBU), additives (KI and TBAI), and solvents
(acetone, dioxane, ethanol, acetonitrile, and toluene) to yield complex and unidentifiable
mixtures, which we speculate may be due to the instability of the desired product under
basic conditions in the presence of oxygen. Therefore, the work on the development of
6.11 was halted.
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6.1.1.2 Design and synthesis of peptidomimetic scaffold RWJ-58259

Figure 6.3: Proposed alkyne analogue of 6.2 (RWJ-58259)

RWJ-58259 (6.2) is a potent and selective antagonist of PAR1 with IC50 of 110
nM in a platelet aggregation assay. RWJ-58259 was derived from extensive medicinal
chemistry efforts to develop peptidomimetics based on the tethered ligand peptide for
PAR1. Initially, an indole-based template was proposed from extensive computer
modeling. After extensive SAR studies, an indazole analog (6.2) was synthesized which
showed an improved in vivo cardiovascular safety profile. The SAR data suggested the
requirement of indazole template along with urea and crucial phenyl ring that fitted into
the spatial rearrangement of peptide SFLLRN-NH2. However, several modifications were
reported at the benzyl group at the west side of 6.2, and also at the 1° amine residue. Due
to the ease of chemical modifications at the 1° amine residue, we attempted to attach an
alkyne "adapter" here.
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Scheme 6.4: Synthesis of RWJ-58259 alkyne analogue 6.24

We synthesized RWJ-58259 with a slightly modified protocol from the literature
reports. The commercially available amino acid 6.12 was sequentially coupled with acid
and amine building blocks with standard coupling conditions using EDC and Fmocremoval conditions using piperdine, to yield intermediate dipeptide 6.16. According to
the protocols reported by Zhang and Maryanoff, commercially available 6-nitro indole
6.17 underwent nitrosation and rearrangement to give analytically pure 3-formyl indazole
6.18 with 95% yield. 3-formyl indazole 6.18 was subjected to reductive amination to give
pyrrolidine indazole 6.19 with 70% yield. Pyrrolidine indazole 6.19 was alkylated with
benzyl bromide derivative to give nitro-indazole 6.20, along with an inseparable bisalkylated byproduct. Several attempts were made to separate 6.20 from the byproduct
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without success, so the mixture was carried forward in the synthesis. Nitro-indazole 6.20
was reduced to amino-indazole 6.21 using several conditions, including SnCl2 and FeCl3
as reducing agents. The reported protocol using catalytic FeCl3 and stoichiometric
hydrazine gave amino-indazole 6.21 with moderate yield but high purity after flash
chromatography.

The

originally-reported

synthesis

of

urea

6.22

from

4-

nitrophenylchlorformate was low yielding and unreproducible in our hands. We initially
adopted the low yielding conditions using triphosgene and propylene oxide as acid
scavenger, reported by Herranz. Finally, high purity urea 6.22 was reproducibly obtained
in moderate yields via a slow addition of triphosgene to 6.21, followed by the addition of
dipeptide 6.16 in the presence of DMAP as base (as reported by Caddick) and stirring the
reaction initially at –5 °C for 30 min., and then gradually warming to room temperature.
Boc removal of urea 6.22 was performed using HCl in dioxane to give RWJ-58259 as
HCl salt 6.23a or as format salt 6.23b after purifying with semi-preparative HPLC. We
attempted the conversion of 1° amine to 2° amine, urea, or amide using several
conditions to attach alkyne with failure. Finally, coupling of the 1° amine of 6.23a with
commercially available 4-pentynoic acid provided our first alkyne-linked PAR1
antagonist (6.24) in 43% yield.
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6.1.2 Design and synthesis of PAR2 antagonists

Figure 6.4: Literature reported PAR2 antagonists

Unlike PAR1, antagonism at PAR2 was not very well studied at the starting point
of this project.

Fairlie, et al. reported non-peptidic PAR2 antagonist GB83 (6.25),

however with structural limitations and unpredictability of scaffolds to behave as partial
agonist to antagonists. The other reported scaffolds either suffered from low potency or
showed agonistic activity at higher concentrations and thus, no follow up studies were
performed (6.26, 6.27 – Figure 6.4).

Figure 6.5: Vertex reported potent PAR2 antagonists
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Meanwhile, Vertex published a patent containing PAR2 antagonists with
nanomolar potencies. After careful consideration, we found that the imidazopyridazine
scaffold of PAR2 antagonists could be modified at the pyridazine position and pyrazine
position without adverse effects on potency. We selected analogues 6.28 and 6.29 from
the patent to use in our synthesis of heterobivalent ligands.

6.1.3 Synthesis of heterobivalent ligands

Scheme 6.5: Synthesis of bivalent ligands

The carboxylic acid of PAR2 antagonist 6.28, prepared in our lab by Dr. Mark
Majewski, was efficiently peptide coupled with commercially available varying lengths
of azido-amino PEG linkers using PyBOP and HOBt to give amides 6.30a-d. The azides
of 6.30a-d were subjected to CuAAC with the PAR1 ligand alkyne 31 to provide bivalent
ligands 6.31a-d. From this list, bivalent ligand 6.31b was synthesized by me and the rest
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of the ligands (6.31a, 6.31c-d, 6.33a-d) were synthesized and characterized by Dr. Mark
Majewski.

6.1.4 Synthesis of monovalent controls with PEG spacers

Figure 6.6: PAR1 control ligand 6.34 and PAR2 control ligands 6.34 and 6.36

All control ligands, composed of PAR1 or PAR2 antagonists with attached PEG
spacers, were synthesized with a similar strategy of CuAAc and peptide coupling using
PyBOP by Dr. Mark Majewski (Figure 6.6).
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6.1.5 Design of modified bivalent ligand with hydrophobic spacer

Figure 6.7. A: X-ray structure of modified PAR2 with bound allosteric ligand AZ3451 (green) and docked
ligand 6.28 (pink)

During the course of our study, Marshall and colleagues reported an x-ray
structure of modified PAR2 with two different ligands, including the inhibitor AZ3451
which binds at an allosteric site.167 We hypothesized that AZ3451 and the Vertex PAR2
antagonist 6.28 may share a similar hydrophobic binding site based on structural
similarities. We found that 6.28 docks into the lipophilic pocket of PAR2 with a similar
pose as AZ3451, with both molecules possessing a heterocyclic nitrogen capable of
accepting a hydrogen bond from Tyr210 (Figure 6.7). The position of this binding site
within the cell membrane suggests that the hydrophilic PEG spacer may be
counterproductive and could explain the greatly decreased potency at PAR2 of our PEGlinked PAR2 antagonists.
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Figure 6.8: Novel bivalent ligand 6.38 and control compound 6.37 possessing a PEG-aminoalkylamide
spacer

We addressed this potential issue by designing bivalent ligand 6.38 with a
modified spacer. We hypothesized that incorporation of an additional hydrophobic
section such as a terminal aminoalkylamide adjacent to 6.28 could lead to a higher
affinity for the cell membrane above the putative PAR2 binding site, and could facilitate
binding to PAR1 – PAR2 heteromers (Figure 6.8). Both bivalent ligand 6.38 and control
6.37 were synthesized and characterized by Ricardo Rosas, Jr.

6.2

Bioassay results and discussion
The ligands were tested in our intracellular calcium mobilization assay (iCa2+)

using the transformed human endothelial cell line EA.hy926, and this assay was also
suitable for studying the signaling of the breast cancer cell line MDA-MB-231, which
expresses both PAR1 and PAR2. Adherent cells were cultured in 96-well plates to
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confluence over 41 – 44 h, then loaded with the fluorescent calcium binding dye Fluo4/AM, according to our reported protocol. 79 Addition of the antagonists, followed by the
relevant PAR peptide agonists TFLLRN-NH2 (PAR1), SLIGKV-NH2 (PAR2), or
SFLLRN-NH2 (PAR1/2), permitted the measurement of inhibition of Gαq-driven
signaling from both PAR1 and PAR2.

6.2.1 Activity of PAR1 antagonists and spacer-linked control

A.

B.

Figure 6.9: Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated iCa2+ mobilization by monovalent
PAR1 ligand RWJ-58259 30a, RWJ-58259 alkyne analogue 31, and spacer-linked control 6.34 in
EA.hy926 endothelial cells (A) and in MDA-MB-231 cancer cells (B).

We first tested the activity of monovalent ligands in iCa2+ assay in both EA.hy926
cells and MDA-MB-231 cells. In EA.hy926 cells (Figure 6.9A), PAR1-selective
antagonists were tested in the presence of TFLLRN-NH2 (5 µM). RWJ-58259 (30a) was
active with an IC50 of 0.02 µM. The alkyne analogue of RWJ-58259 (31) was 15-fold less
active with an IC50 of 0.31 µM. Replacing the free amine of RWJ-58259 with an amide
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connected to a PEG linker (6.34) was 5-fold less potent, but the activity was still tolerated
considerably IC50 of 0.097 µM. Similar results were observed in MDA-MB-231 cells
(Figure 6.9B), but all 3 ligands were more potent with IC50 of 0.005 µM for 30a, 0.010
µM for 31, and 0.013 µM for 6.34.

6.2.2 Activity of PAR2 antagonists and spacer-linked control

A.

B.

C.

D.

Figure 6.10: Inhibition of SLIGKV-NH2 (5 µM) PAR2-mediated iCa2+ mobilization by monovalent
PAR2 ligand 6.28 and spacer-linked control 6.35 in EA.hy926 endothelial cells (A) and in MDAMB-231 cancer cells (B); monovalent PAR2 ligand 6.29 and spacer-linked control 6.36 in EA.hy926
endothelial cells (C) and in MDA-MB-231 cancer cells (D).
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Next, we tested the activity of the PAR2 ligands in the iCa2+ assay in both
EA.hy926 cells and MDA-MB-231 cells. In EA.hy926 cells, the PAR2-selective
antagonists and spacer-linked controls were tested in the presence of SLIGKV-NH2 (5
µM). The PAR2 antagonist 6.28 was active with an IC50 of 0.1 µM (Figure 6.13A).
However, replacing the free carboxylic acid of 6.28 with an amide tethered to a PEG
linker (6.35) was 70-fold less potent (IC50 = 7.0 µM, Figure 6.13A). The PAR2
antagonist 6.29 was less potent than 6.28 with an IC50 of 0.58 µM (Figure 6.13C),
whereas the spacer-linked control 6.36 showed an IC50 of 2.4 µM (Figure 6.13C). Full
inhibition of SLIGKV-NH2 was not achieved with either of the controls 6.35 or 6.36. A
similar pattern was observed in MDA-MB-231 cells. PAR2 control ligand 6.35 retained
the activity with IC50 of 0.86 µM (Figure 6.13B), and was 2-fold less potent, and less
efficacious than 6.28 with IC50 of 0.48 µM (Figure 6.13B). 6.29 was active with IC50 of
0.42 µM (Figure 6.13D), but the IC50 of 6.36 could not be estimated due to the lack of
full inhibition (Figure 6.13D). These results indicated that modifications to PAR2 ligand
were not well tolerated. It may be because 6.28 and 6.29 bind at a hydrophobic site on
PAR2, and adding a hydrophilic spacer had adverse effects on PAR2 selectivity.
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6.2.3 Activity of heterobivalent ligands

A.

B.

C.

D.

Figure 6.11: Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated iCa2+ mobilization (A); SLIGKV-NH2 (5
µM) PAR2-mediated iCa2+ mobilization (B); Inhibition of SFLLRN-NH2 (3.16 µM) PAR1/2-mediated
iCa2+ mobilization by bivalent ligands 6.31a–d (C), and individual and co-dosed monovalent control
compounds (6.34 + 6.35) in EA.hy926 endothelial cells (D).

After testing the PAR1 and PAR2 monovalent ligands and spacer-linked controls,
we proceeded to measure the activities of our bivalent ligands from the shortest ligand
6.31a to the longest ligand 6.31d in the iCa2+ assay. All four ligands 6.31a-d were
reasonably potent in the TFLLRN-NH2 (5 µM) PAR1-mediated iCa2+ assay with IC50s in
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the range of 0.03 – 0.18 µM (Figure 6.11A), with the longest bivalent ligand 6.31d as the
most efficacious compound showing full inhibition at higher concentrations.
Unfortunately, 6.31a-d showed weak antagonism in the SLIGKV-NH2 (5 µM)-PAR2
mediated iCa2+ assay (Figure 6.11B). Weak antagonism of 6.31a-d at PAR2 may be due
to higher affinity towards PAR1 and/or higher density of PAR1 in EA.hy926 cells
causing the ligands to bind only monomeric PAR1 receptor. Next, we analyzed 6.31a-d
in the SFLLRN-NH2 mediated (PAR1 and PAR2-driven) iCa2+ assay at 3.16 µM
concentration (Figure 6.11C). We selected SFLLRN-NH2 because of its activity for both
PAR1 and PAR2 receptors. Amongst 6.31a-d, only 6.31d showed significant potency
with an IC50 of 0.15 µM, with partial inhibition. We next compared the activity of the
bivalent ligands with the individual and co-dosed monovalent spacer-linked controls 6.34
and 6.35 in the SFLLRN-NH2-mediated iCa2+ assay (Figure 6.11D). The individual
ligand 6.34 was potent with an IC50 of 0.074 µM, but 6.35 showed no activity. However,
co-dosed 6.34 and 6.35 showed a similar profile to the bivalent ligand 6.31d, with an IC50
of 0.32 µM. These results suggested that inhibition of SFLLRN-NH2-mediated iCa2+
mobilization may be largely driven by the PAR1 receptor.
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A.

B.

C.

D.

Figure 6.12: Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated iCa2+ mobilization (A); SLIGKVNH2 (5 µM) PAR2-mediated iCa2+ mobilization (B); Inhibition of SFLLRN-NH2 (3.16 µM) PAR1/2mediated iCa2+ mobilization by bivalent ligands 6.33a–d (C), and Individual and co-dosed
monovalent control compounds (6.34 + 6.36) in EA.hy926 endothelial cells (D).

Next, we measured the pharmacology the of next set of bivalent ligands, from the
shortest ligand 6.33a to the long ligand 6.33c in iCa2+ assay. Unlike the first set 6.31a-d,
all three ligands 6.33a-c were less potent in the TFLLRN-NH2 (5 µM) PAR1-mediated
iCa2+ assay, with IC50s in the range of 3.3 – 6.2 µM (Figure 6.12A), with the long
bivalent ligand 6.33c as the most efficacious compound showing full inhibition at higher
concentrations. Similar to the previous results, 6.33a-c showed weak antagonism in the
SLIGKV-NH2 (5 µM) PAR2-mediated iCa2+ assay (Figure 6.12B) and in the SFLLRN-
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NH2 (3.16 µM) PAR1/2-mediated iCa2+ assay (Figure 6.12C). The behavior of individual
and co-dosed monovalent spacer-linked controls 6.34 and 6.36 in the SFLLRN-NH2mediated iCa2+ assay (Figure 6.12D) was similar to the first set of ligands. The individual
ligand 6.34 was potent with IC50 of 0.074 µM but 6.36 showed no activity. Whereas, codosed 6.34 and 6.36 showed considerable inhibition, supporting the hypothesis of largely
PAR1 driven iCa2+ mobilization with the agonist SFLLRN-NH2.

Figure 6.13: Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated, SLIGKV-NH2 (5 µM) PAR2-mediated,
and SFLLRN-NH2 (3.16 µM) PAR1/2-mediated iCa2+ mobilization of 6.31d in MDA-MB-231 breast
cancer cells.

From 6.31a-d and 6.33a-c, only 6.31d showed promising results in Ea.hy926
cells. Therefore, 6.31d was studied in the breast cancer cell line MDA-MB-231 with all
three agonists (Figure 6.13). It was most effective at the inhibition of TFLLLRN-NH2driven calcium mobilization, with an IC50 of 0.14 µM and excellent efficacy. The IC50 for
inhibition of SFLLRN-NH2 was estimated to be 3.3 µM, with lower efficacy. The
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inhibition of SLIGKV-NH2 by 6.31d was less efficient, with an IC50 estimated at 3.5 µM,
but with no inhibition observed at submicromolar concentrations.

A.

B.

C.

D.

E.

F.

Figure 6.14. Inhibition of TFLLRN-NH2 (5 µM) PAR1-mediated iCa2+ mobilization, SLIGKV-NH2 (5
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µM) PAR2-mediated iCa2+ mobilization, SFLLRN-NH2 (3.16 µM) PAR1/2-mediated iCa2+ mobilization by
bivalent ligand 6.38 in EA.hy926 endothelial cells (A) and in MDA-MB-231 cells (B); Inhibition of
SLIGKV-NH2 (5 µM) PAR2-mediated iCa2+ mobilization by monovalent control 6.37 in EA.hy926
endothelial cells (C) and MDA-MB-231 cancer cells (D); Inhibition of SFLLRN-NH2 (3.16 µM) PAR1/2mediated iCa2+ mobilization by co-dosed control 6.34 and 6.37 in EA.hy926 endothelial cells (E) and
MDA-MB-231 cancer cells (F).

Finally, the bivalent ligand 6.38 (possessing a more hydrophobic spacer) and
control with hydrophobic spacer 6.37 were tested for possible improved activity at PAR2
in both Ea.hy926 and MDA-MB-231 cell lines (Figure 6.14). Unfortunately, attachment
of the more hydrophobic spacer had adverse effects on both PAR1 and PAR2 inhibition.

6.3 Conclusion

We designed and synthesized the first heterobivalent ligands targeting putative
PAR1 – PAR2 complexes. To our knowledge, this is the first example of PAR1 – PAR2
bivalent ligands reported in literature on the vascular receptors. We analyzed their
behavior in endothelial Ea.hy926 cells and in breast cancer MDA-MB-231 cells. We first
tested monovalent ligands and then controls having monovalent ligands coupled to PEG
spacers in iCa2+ flux assays in both cell lines. The decrease in potency was observed with
controls for PAR1 and significantly for PAR2 receptor. From the current set of bivalent
ligands, 6.31d showed a similar potency to two co-dosed monovalent controls in the
presence of the PAR1/2 agonist SFLLRN-NH2. 6.31d showed inhibition of TFLLRNNH2-mediated signaling (PAR1 agonist), but was poorly active against SLIGKV-NH2
medicated signaling (PAR2 agonist). These resultas suggested that modification of the
PAR2 pharmacophore in the current set of bivalent ligands might cause a loss of affinity
for PAR2 receptor. Therefore, we don’t yet have evidence for the presence of PAR1/2
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heteromers in Ea.hy926 endothelial cells and MDA-MB-231 cancer cells and their
selective inhibition with our bivalent ligands. Performing binding assays with the range
of picomolar to micromolar concentrations may provide evidence of binding to
heteromers, such as biphasic concentration curves which would indicate selective binding
to heteromers. We plan to synthesize labeled ligands to perform binding assays. In
addition, PAR-driven cell migration assays (e.g. scratch assay) are underway to explore
the effects of bivalent ligands relevent to metastasis. In summary, the use of PAR1 –
PAR2 bivalent antagonists is a novel approach to target the pathological signaling of
PARs while retaining their productive signaling. This approach is promising for the
development of safer treatments for restenosis, breast cancer cell metastasis, and other
proliferative disorders.
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Chapter 7

Project summary and future work

7.1 PAR1 monovalent ligands

Figure 7.1: “Hit molecules” from PAR1 mediated iCa2+ screening at 10 µM concentration of parmodulins
in the presence of 5 µM TFLLRN-NH2 agonist

We designed and synthesized ~100 parmodulin analogues focusing on detailed
exploration of the western region of the 1,3-diaminobenzene scaffold. We screened them
in a Gαq mediated iCa2+ flux assay for PAR1 in endothelial cells. From this screen, we
selected 6 “hit” molecules (Figure 7.1) that will be further characterized in this and other
assays. We will perform experiments to demonstrate selectivity of these analogues for
PAR1 and negative allosteric modulation at PAR1 with the iCa2+ flux assay in an
identical manner to ML161 and RR90. We also plan to test these analogues in a Gα12/13-
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mediated RhoA activation assay in endothelial cells to demonstrate signaling bias. In this
assay using agarose beads conjugated to GST-Rhotekin-Rho binding domain to
precipitate and quantify GTP-bound RhoA,168 in the lab of Dr. Robert Flaumenhaft at
Beth Israel Deaconess Medical Center and in β-arrestin assay in the lab of Dr. Bryan
Roth at University of North Carolina at Chapel Hill.
We hypothesize that modifications to ML161 should not affect cytoprotective
effects and the SAR profile of parmodulins should be consistent with G αq mediated iCa2+
flux assay.

To test the hypothesis, we are currently developing a FXa mediated

cytoprotection assay in the lab of Dr. Hartmut Weiler at Blood research Institute. We
have planned to screen all parmodulins in this assay.
Promising molecules will also be profiled for drug-like properties. These
molecules will tested in the lab of Dr Alexander Arnold at University of Wisconsin –
Milwaukee for water solubility, plasma stability, plasma protein binding, microsomal
stability, and membrane permeability. Depending on data, the promising analogues will
be reinvestigated with additional SAR studies or could go additional PK and selectivity
studies to develop clinical candidate for the treatment of sepsis.
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7.2 Heterobivalent PAR ligands

We designed and synthesized first generation of heterobivalent ligands targeting
putative PAR1 – PAR2 complexes. We analyzed their behavior in functional iCa2+ flux
assay in endothelial EA.hy 926 cells and in breast cancer MDA-MB-231 cells, although
we didn’t find evidences to binding to PARs heteromer. Therefore, we have planned to
adopt TR-FRET based approach to demonstrate first the existence of PAR1 – PAR2
complexes (figure 7.2).

Figure 7.2. FRET-paired ligands for PAR heteromer detection

We have planned to tether PAR1 and PAR2 antagonist with PEG linker (having
terminal azide and amine) via alkyne – azide cycloaddition, and the resultant terminal
amines will be acylated with commercially available N-hydroxysuccinimide (NHS) esters
of FRET donors and acceptors such as Lumi-4-Tb (a terbium cryptate from CisBio Inc.)
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and AlexaFluor-647. Lumi-4-Tb at PAR1 will be excited at 345 nm (that emits light at
550 nm). If PAR2 is nearby (< 100 A) then FRET will odducr at AlexaFluor-647 at
PAR2 that emits at 665 nm and FRET ratio will be calculated. The long-lasting
fluorescence emission from lanthanide cryptates permits time-resolved FRET (TR-FRET)
to minimize background signals and provide optimal signal/noise .
Next, we will develop competitive binding assay for PARs. Competitive binding
assay for PAR1 has been reported only for platelets. Whereas our PAR2 anatgonist binds
at an allosteric site of PAR2, that means we may not have competitive binding at PAR2.
Therefore, we will use lanthanied tagged PAR1 and PAR2 ligands to perfom competitive
binding assay against PAR1 and PAR2 agonists. The dye-labeled ligands will be
confirmed for their ability to selectively inhibit iCa2+ mediated by PAR1 or PAR2
agonists, then they will be tested for their ability to bind to the endothelial and breast
cancer cells. From this assay, supposed biphasic binding dose-response curves will be
obtained that will support bivalent ligand binding to the putative PAR1 – PAR2 complex.
After demonstrating the existence of PAR1 – PAR2 complexes and bivalent
ligand binding, we will measure the migration and invasion of metastatic cancer cells
using our bivalent ligand. The scratch wound assay in MDA-MB-231 cells is under
development stage. MDA-MB-231 cells are grown in 96-well plates, “scratched” with an
automated scratch tool to remove cells and create a defined gap, and imaged to measure
the relative rates at which each cell line migrates with or without antagonists.
After the assay development and analyzing the first generation of bivalent ligands,
we will study the SAR of bivalent ligands with different spacers, and different
pharmacophore. At present, development of another PAR1 antagonist reported by Bayer
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Pharmaceuticals is under progress. This piperidine scaffold will require fewer synthetic
steps and offer more flexibility for attaching various adapters to connect PEG spacers.
We discussed earlier about an allosteric binding site for PAR2 antagonists. we will
replace the current allosteric PAR2 antagonist with literature reported orthosteric PAR2
antagonist. Additionally, both PAR1 and PAR2 pharmacophores will be linked with a
variety of alternative spacers with variable with variable flexibility and length. to profile
these promising ligands for treatment of restenosis and breast cancer.
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Chapter 8

Experimental procedures

8.1

General information on Assays

Water for solutions was deionized and filtered through charcoal (Milli-Q by
Millipore) to a resistance of 18 MΩ. TFLLRN-NH2 (PAR1 agonist) was obtained from
AnaSpec (cat# AS-62937) or was synthesized (as the TFA salt) by Trudy Holyst, Blood
Research Institute Protein Chemistry Core. SFLLRN-NH2 (TFA salt) (PAR1/2 agonist)
was obtained from Bachem (cat# H-2936.0005) or was synthesized (as the TFA salt) by
Trudy Holyst, Blood Research Institute Protein Chemistry Core. SLIGKV-NH2 (TFA
salt) (PAR2 agonist) was obtained from Bachem (cat# H-5042.0025) or AnaSpec (cat#
AS-60217-1). AYPGFK-NH2 (TFA salt) (PAR4 agonist) was obtained from AnaSpec
(cat# AS-60218-1). Atopaxar (E5555 HBr) was obtained from Axon Medchem (cat#
2030). Vorapaxar (SCH 530348) was obtained from Axon Medchem (cat# 1755). Q94
(HCl) was obtained from Axon Medchem (cat# 2055).
Adherent Ea.hy926 cells (ATCC CRL-2922) and MDA_MB-231were used for
assays. The cells were cultured using the suggested protocol from the manufacturer
(ATCC), except that 150 cm2 tissue culture flasks were used, and DMEM complete
media was prepared as described below. Cells were frozen in 40% fetal bovine serum
(FBS), 50% complete media, and 10% DMSO in liquid nitrogen, and used between
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passages 2 and 11. All manipulations prior to the assays were performed in a sterile
laminar flow cell culture hood.
Cell counting was performed with an automated cell counter (Countess,
Invitrogen) using Invitrogen cell counting chamber slides and trypan blue stain. All
assays were run in 96-well plates (Corning Costar #3603, polystyrene black wall, clear
bottom). Unless otherwise noted, media exchanges with 96-well plates were performed
using an automated liquid handler (Beckmann-Coulter, Biomek 3000) with 220 µL
pipette tips. Cells were imaged with an Evos Fl inverted microscope. All assays were
run on a multimode plate reader (Perkin Elmer EnSpire). Data was exported to Microsoft
Excel for nominal processing, then analyzed with GraphPad Prism (versions 5 or 6).

8.2

Preparation of stock solutions

Complete cell media (for Ea.hy926 cells).
Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose (500 mL)
was supplemented with 200 mM L-glutamine (10 mL, 4 mM final conc.), 100 mM
sodium pyruvate (2.5 mL, 1 mM final conc.), 7.5% (w/v) sodium bicarbonate (5.0 mL,
0.75 g/L final conc.), 100X penicillin and streptomycin (Corning #30-002-CI, 2.0 mL)
and heat inactivated FBS (50 mL). The prepared media was stored in a refrigerator (5 °C)
until needed.
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Complete cell media (for MDA-MB-231 cells).
Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L glucose (500 mL)
was supplemented with 200 mM L-glutamine (5 mL, 2 mM final conc.), 1M HEPES
buffer (5 mL, 10 mM final conc.), 100X penicillin and streptomycin (Corning #30-002CI, 2.0 mL) and heat inactivated FBS (50 mL). The prepared media was stored in a
refrigerator (5 °C) until needed.

Probenecid solution (250 mM, aqueous).

Probenecid (Alfa Aesar, catalog # B20010-88, 36 mg) was added to a 1 mL
microcentrifuge tube and dissolved in 0.6 M NaOH (500 μL). NaOH (0.6 M) was
prepared by dissolving NaOH (480 mg) in H2O (20 mL). This solution was made the day
of the experiment and was sufficient for up to 50 mL of buffer (for 2 96-well plates).

HBSS–HEPES wash buffer.

HEPES (1.19 g) was added to a 500 mL bottle of Ca/Mg/phenol red-free HBSS to
make a 10 mM solution in HEPES. MgCl2 (1 M solution, 500 μL) and CaCl2 (1 M
solution, 500 μL) were added and the solution was stored in the refrigerator. Before use,
the desired amount (46 mL total per 96 well plate) was warmed to room temperature and
added to a 50 mL centrifuge tube, then supplemented with 250 mM probenecid solution
(1:100, i.e. 46 mL of buffer needs 460 μL of probenecid solution) to give a 2.5 mM
probenecid solution. The pH was adjusted to 7.4 if necessary by adding aq. HCl.
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10% Pluronic F-127 in DMSO.

Pluronic F-127 (Sigma Aldrich, 20 mg) was added to a 1 mL microcentrifuge tube
and dissolved with DMSO (200 μL), to make a 10% w/v solution. This solution was
stored at room temperature.

Fluo-4/AM loading buffer.
Fluo-4/AM (Invitrogen via Fisher, catalogue # F23917, 50 μg) was dissolved in
DMSO (24 μL), then 6 μL of the solution (light-sensitive) was transferred to a 200 μL
microcentrifuge tube and mixed with 6 μL of 10% pluronic F-127 in DMSO (sufficient
for 1 96-well plate). The remainder of the Fluo-4/AM solution was stored in the freezer at
–30 ºC. The solution was then transferred to a foil-covered 14 mL centrifuge tube already
containing HBSS–HEPES wash buffer (6 mL) and vortexed for 5 seconds. 50 μL of this
prepared dye solution (2 μM) can be added to each well of a 96-well plate containing
adherent cells.

Preparation of agonist/antagonist solutions.

Prior to the assay, stock solutions of PAR1 and PAR2 agonists were prepared by
dissolving the agonists in 100% H2O (sterile, deionized) to give stock solutions (10 mM,
5 mM, or 1 mM depending on agonist). These were aliquoted into sterile microcentrifuge
tubes and stored in a –30 ºC freezer, and thawed before use. Stock solutions of
antagonists were prepared by dissolving with 100% DMSO, generally in glass vials, to

157
give stock solutions (31.6 mM, 10 mM, or 1 mM depending on antagonist used) that were
stored in the freezer at –30 ºC, and thawed in a desiccator before use.
Agonist solutions: Prepared as 10 mM stock solutions in 100% water (sterile, deionized).
Diluted solutions were then prepared with water to give half log concentrations.
Antagonist solutions: Vehicle (diluent) was prepared by mixing 1:9 DMSO:HBSSHEPES wash buffer. An aliquot from the antagonist stock solution (in 100% DMSO) was
then diluted 10x with vehicle to give a 10% DMSO solution, then subsequent dilutions
were made with vehicle to give a consistent concentration of DMSO (1%).

8.3

Protocol for calcium mobilization assay with adherent endothelial cells

Cell Preparations (Aseptic Conditions).

Unless otherwise noted, EA.hy926 cells were plated at 25,000 cells per well in
100 μL, which corresponds to 250,000 cells/mL and MDA-MB-231 cells were plated at
15,000 cells per well in 100 μL, which corresponds to 150,000 cells/mL. Complete cell
media (25 mL per plate) was transferred to a 50 mL centrifuge tube and warmed to 37 °C
in a water bath. A vial of frozen EA.hy926 cells (ATCC CRL-2922) or MDA-MB-231
cells was taken from liquid N2 storage and warmed to 37 °C in a water bath for 5 min.
Complete cell media (1 mL) was added dropwise to the vial and the contents were mixed
and transferred to a 14 mL centrifuge tube. The cells were centrifuged at 130 g for 3 min
and the supernatant was removed via aspiration with a Pasteur pipet. The cells were resuspended in complete cell media (2 mL) and the suspension was mixed thoroughly with
a pipette to gently break up the cell pellet to give an evenly distributed suspension in the
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tube. A small fraction of this suspension (25 μL) was mixed with 25 μL of trypan blue
solution and a cell count was taken. Based on the cell count, an appropriate volume of
complete cell media was added to the 2 mL of cell suspension to assure that each well of
the 96-well plate would have 25,000 cells. The suspension was gently mixed, and the
contents of the tube were slowly poured into a sterile disposable pipetting reservoir. This
suspension containing the cells was then added (column by column, 100 μL per well) to a
96-well plate (Corning Costar #3603, black wall, clear bottom) with a multichannel
pipette. The plate was gently rocked back and forth to get even coverage of cells and the
plate was incubated at 37 °C (5% CO2) for 40–48 h.

Loading of Fluo-4/AM dye.

The 96-well plate was removed from the incubator after 40–48 h and then
checked with an EVOS Fl microscope and optionally imaged (20X magnification) to
confirm that cells were >80% confluent and viable. Note: All media exchanges were
performed with the Biomek 3000, unless otherwise noted. The complete cell media was
removed and HBSS–HEPES wash buffer (100 μL) was added to each well. The plate was
left to sit at room temperature for 5 min. to allow the probenecid to be absorbed, then the
media was removed. Fluo-4/AM solution (50 μL per well) was added (in the dark), and
the plate was incubated at 37 °C (5% CO2) for 40–50 min. The dye solution was removed
from each well and the wells were washed with HBSS–HEPES wash buffer (50 μL/well)
twice. HBSS–HEPES wash buffer (200 μL/well) was added to each well and the plate
was imaged with the EVOS Fl microscope (20X magnification, GFP setting) to verify
that the dye had been absorbed into the cells.
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Running the assay.

Basic plate reader info and settings:
a. Instrument: Perkin Elmer EnSpire plate reader
b. Temperature: 37°C
c. Excitation wavelength: 485 nm
d. Emission wavelength: 525 nm
e. Measurement height: 7.8 mm (optimized)
f. Number of flashes: 100
g. Number of repeats: 250, every 5 sec. Experiment was halted after the emission
signal starts to decrease from the maximum.
Vehicle or antagonists (2 μL) were added (single or multichannel pipette) to each
well, and the plate was incubated in the plate reader for 15 min at 37 °C. Response to
agonists was measured 2 columns at a time, since this plate reader scanned wells
individually, but plate readers that measure wells concurrently could optionally support
assays with all agonists added concurrently, for higher throughput. Upon starting the
assay, the basal level of the 2 columns was measured (20 scans) prior to the addition of
the agonist. The agonist (2 μL) was then added (over 10 seconds with a multichannel
pipette or over 90–120 seconds with a single channel pipette), and the wells were
analyzed with the plate reader using the settings above.

160
Data analysis.

Concentration-response curves were obtained by measuring the maximal increase
in emission intensity (Δ Relative Fluorescence Units, RFU) from basal levels (average of
20 scans prior to agonist addition), then dividing by the average basal levels to give Δ
RFU/basal. From this data, % stimulation was obtained by normalizing Δ RFU/basal for
each column of the plate with a well from the same column where vehicle had been
added instead of antagonist solution. The Δ RFU/basal value from the vehicle well was
considered to be 100% stimulation for each column. This normalization was necessary
due to increasing background signal over time, presumably due to dye efflux. Data (%
stimulation versus log concentration) was then plotted for 3 or more repetitions and
analyzed using GraphPad Prism (versions 5 or 6). All concentration-response curves were
fitted using 4-variable non-linear regression, showing the standard error of the mean
(SEM) for each concentration.

8.4

Reversibility Assay Protocol

Preparation of Plate for Assay.

Cell preparations (under aseptic conditions), loading of probenecid and Fluo-4
dye, the washing/removal of dye, and the replacement with HBSS-HEPES buffer solution
(200 µL) were performed as detailed above.
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Wash Procedure.
Vehicle or antagonist (2 μL) was added to the wells of interest (already containing
200 µL of HBSS-HEPES wash buffer) and the plate was incubated in the plate reader for
20–30 min. The wash buffer was carefully removed from the wells with a multichannel
pipette, replaced with fresh HBSS-HEPES wash buffer (200 µL) and incubated in the
plate reader for 10 min. at 37 °C. Wash buffer was carefully removed from the wells
again with a multichannel pipette and replaced with fresh HBSS-HEPES wash buffer
(200 µL). The plate was incubated again in the plate reader for 10 min., and then the
assay was performed according to the regular protocol above. Note that the washing steps
can alternatively be performed with the automated liquid handler.

8.5

Instructions for Screening

General notes.

a. Vehicle: Water
b. Agonist TFLLRN-NH2 concentration was set to 5 µM.
c. This map was designed for n = 4 of parmodulins.
d. Parmodulins were designated according to ELN entry.
e. For 1 mM dilution of PMs and addition of agonist solution, multichannel
pipette was used.
f. To add 100 µL of PMs to the assay plate, automated liquid handler was used.
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Preparation of Vehicle and solutions.

Vehicle was 100% Water to prepare 1 mM PMs solution. All other solutions like
HBSS-HEPES wash buffer, probenecid solution, and Fluo-4 dye solution were prepared
as described above.

Preparation of 10 µM solution of PMs:
a. 0.2 – 0.4 mg of PMs were dissolved in 100% DMSO to make stock concentration
31.6 mM.
b. 3.2 µL of stock solution (31.6 mM) was diluted with 96.8 µL of vehicle to prepare
1 mM, 100 µL solution.
c. 4 µL of 1 mM solution was diluted with 196 µL of vehicle to prepare 0.02 mM,
200 µL solution.
d. 100 µL of 0.02 mM solution was diluted with 100 µL of wash buffer to prepare
0.01 mM, 200 µL solution. 100 µL of 0.01 mM PMs solution was added to assay
plate using automated liquid handler.
e. Concentration of DMSO:
(

3.2 µ𝐿, 31.6 𝑚𝑀 𝑠𝑡𝑜𝑐𝑘
4 µ𝐿, 1 𝑚𝑀
100 µ𝐿, 0.02 𝑚𝑀
)∗(
)∗(
) ∗ 100%
100µ𝐿 𝑣𝑒ℎ𝑖𝑐𝑙𝑒
200 µ𝐿 𝑤𝑎𝑠ℎ 𝑏𝑢𝑓𝑓𝑒𝑟
200 µ𝐿 𝑤𝑎𝑠ℎ 𝑏𝑢𝑓𝑓𝑒𝑟
= 0.032% 𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐷𝑀𝑆𝑂 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑠𝑠𝑎𝑦

Preparation of 1 µM solution of Vorapaxar.

a. 1.5 mg of vorapaxar was dissolved in 100% DMSO to make stock concentration
10 mM.
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b. 1 µL of stock solution (10 mM) was diluted with 99 µL of vehicle to prepare 0.1
mM, 100 µL solution.
c. 4 µL of 0.1 mM solution was diluted with 196 µL of vehicle to prepare 0.002
mM, 200 µL solution.
d. 100 µL of 0.002 mM solution was diluted with 100 µL of wash buffer to prepare
0.001 mM, 200 µL solution. 100 µL of 0.001 mM PMs solution was added to
assay plate using automated liquid handler.
e. Concentration of DMSO:
(

1 µ𝐿, 10 𝑚𝑀 𝑠𝑡𝑜𝑐𝑘
4 µ𝐿, 0.1 𝑚𝑀
100 µ𝐿, 0.002 𝑚𝑀
)∗(
)∗(
) ∗ 100%
100µ𝐿 𝑣𝑒ℎ𝑖𝑐𝑙𝑒
200 µ𝐿 𝑤𝑎𝑠ℎ 𝑏𝑢𝑓𝑓𝑒𝑟
200 µ𝐿 𝑤𝑎𝑠ℎ 𝑏𝑢𝑓𝑓𝑒𝑟
= 0.01% 𝑓𝑖𝑛𝑎𝑙 𝑐𝑜𝑐𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑎𝑠𝑠𝑎𝑦

Preparation of 5 µM solution of agonist.

0.2 mg of TFLLRN-NH2 in was dissolved into 524.3 µL of water to make stock
concentration of 0.5 mM.

Running the assay.

Basic plate reader info and settings:
h. Instrument: Perkin Elmer EnSpire plate reader
i.

Temperature: 37°C

j.

Excitation wavelength: 485 nm

k. Emission wavelength: 525 nm
l.

Measurement height: 7.8 mm (optimized)
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m. Number of flashes: 100
n. Number of repeats: 50, every 5 sec. Experiment was halted after the emission
signal starts to decrease from the maximum.
Vehicle or antagonists (0.01 mM, 100 μL) were added to each well (according to
the plate map, Table 7.1) using automated liquid handler, and the plate was incubated in
the plate reader for 5 min at 37 °C. Response to agonists was measured 2 columns at a
time, since this plate reader scanned wells individually, but plate readers that measure
wells concurrently could optionally support assays with all agonists added concurrently,
for higher throughput. Upon starting the assay, the basal level of the 2 columns was
measured (20 scans) prior to the addition of the agonist. The agonist (2 μL) was then
added (over 30 seconds with a multichannel pipette), and the wells were analyzed with
the plate reader using the settings above.
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Table 7.1 Assay map for screening:
1
A Vehicle +
Agonist

2
Vehicle +
Agonist

3
Vehicle +
Agonist

4
Vehicle +
Agonist

5
Vehicle +
Agonist

6
Vehicle +
Agonist

7
Vehicle +
Agonist

8
Vehicle +
Agonist

9
Vehicle +
Agonist

10
Vehicle +
Agonist

11
Vehicle +
Agonist

12
Vehicle +
Agonist

B

Vorapaxa
r, 1 µM +
Agonist
C PM a, 10
µM +
Agonist
D PM b, 10
µM +
Agonist
E PM c, 10
µM +
Agonist
F PM d, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM a, 10
µM +
Agonist
PM b, 10
µM +
Agonist
PM c, 10
µM +
Agonist
PM d, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM a, 10
µM +
Agonist
PM b, 10
µM +
Agonist
PM c, 10
µM +
Agonist
PM d, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM a, 10
µM +
Agonist
PM b, 10
µM +
Agonist
PM c, 10
µM +
Agonist
PM d, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM g, 10
µM +
Agonist
PM h, 10
µM +
Agonist
PM i, 10
µM +
Agonist
PM j, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM g, 10
µM +
Agonist
PM h, 10
µM +
Agonist
PM i, 10
µM +
Agonist
PM j, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM g, 10
µM +
Agonist
PM h, 10
µM +
Agonist
PM i, 10
µM +
Agonist
PM j, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM g, 10
µM +
Agonist
PM h, 10
µM +
Agonist
PM i, 10
µM +
Agonist
PM j, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM m, 10
µM +
Agonist
PM n, 10
µM +
Agonist
PM o, 10
µM +
Agonist
PM p, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM m, 10
µM +
Agonist
PM n, 10
µM +
Agonist
PM o, 10
µM +
Agonist
PM p, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM m, 10
µM +
Agonist
PM n, 10
µM +
Agonist
PM o, 10
µM +
Agonist
PM p, 10
µM +
Agonist

Vorapaxa
r, 1 µM +
Agonist
PM m, 10
µM +
Agonist
PM n, 10
µM +
Agonist
PM o, 10
µM +
Agonist
PM p, 10
µM +
Agonist

G PM e, 10
µM +
Agonist

PM e, 10
µM +
Agonist

PM e, 10
µM +
Agonist

PM e, 10
µM +
Agonist

PM k, 10
µM +
Agonist

PM k, 10
µM +
Agonist

PM k, 10
µM +
Agonist

PM k, 10
µM +
Agonist

PM q, 10
µM +
Agonist

PM q, 10
µM +
Agonist

PM q, 10
µM +
Agonist

PM q, 10
µM +
Agonist

H PM f, 10
µM +
Agonist

PM f, 10
µM +
Agonist

PM f, 10
µM +
Agonist

PM f, 10
µM +
Agonist

PM l, 10
µM +
Agonist

PM l, 10
µM +
Agonist

PM l, 10
µM +
Agonist

PM l, 10
µM +
Agonist

PM r, 10
µM +
Agonist

PM r, 10
µM +
Agonist

PM r, 10
µM +
Agonist

PM r, 10
µM +
Agonist
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8.6

P-Selectin Expression Assay.169

Blood from healthy donors who had not ingested aspirin in the 2 weeks prior to
donation was collected by veinpuncture into 0.4% sodium citrate. Citrate-anticoagulated
blood was centrifuged at 200g for 20 minutes to prepare platelet-rich plasma. Washed
platelets were subsequently prepared from platelet-rich plasma by centrifugation at
1,000g in the presence of 0.15 µM PGE1. For analysis of P-selectin expression, 20 μL
washed platelets (0.5-1 x 108/mL) were incubated with the indicated agonists. Platelet
activation was measured by P-selectin surface expression using PE-antihuman P-selectin
(BD) and flow cytometry.1 Results are expressed as percent inhibition of P-selectin
surface expression.

8.7

General comments on synthetic procedures

All reagents and solvents, including anhydrous solvents, were purchased from
commercial vendors and used as received. Deionized water was purified by charcoal
filtration and used for reaction workups and in reactions with water. NMR spectra were
recorded on Varian 300 MHz or 400 MHz spectrometers as indicated. Proton and carbon
chemical shifts are reported in parts per million (ppm; δ) relative to tetramethylsilane (1H
δ 0), or CDCl3 (13C δ 77.16), (CD3)2CO (1H δ 2.05,
13

C δ 39.5), or CD3OD (1H δ 3.31,

13

13

C δ 29.84), d6-DMSO (1H δ 2.50,

C δ 49.00). NMR data are reported as follows:

chemical shifts, multiplicity (obs = obscured, app = apparent, br = broad, s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet, comp = complex overlapping signals);
coupling constant(s) in Hz; integration. Unless otherwise indicated, NMR data were
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collected at 25 °C. Filtration was performed by vacuum using VWR Grade 413 filter
paper, unless otherwise noted. Flash chromatography was performed using Biotage
SNAP cartridges filled with 40-60 µm silica gel on Biotage Isolera automated
chromatography systems with photodiode array UV detectors. Analytical thin layer
chromatography (TLC) was performed on Agela Technologies 0.25 mm glass plates with
0.25 mm silica gel. Visualization was accomplished with UV light (254 nm) and KMnO 4
stain, unless otherwise noted. Chemical names were generated and select chemical
properties

were

calculated

using

either

ChemAxon

Marvin

suite

(https://www.chemaxon.com) or ChemDraw Professional 15.1. NMR data were
processed using either MestreNova or ACD/NMR Processor Academic Edition
(http://www.acdlabs.com) using the JOC report format. High-resolution mass spectra
(HRMS) were obtained either at the University of Wisconsin-Milwaukee Mass
Spectrometry Laboratory with a Shimadzu LCMS-IT-TOF with ESI and APCI ionization
or from the University of Cincinnati with an Agilent 6540 Accurate-Mass with Q-TOF
LC/MS.

LC-MS Characterization Methods

Tandem liquid chromatography/mass spectrometry (LC-MS) was performed on a
Shimadzu LCMS-2020 with autosampler, photodiode array detector, and singlequadrupole MS with ESI and APCI dual ionization using a Peak Scientific nitrogen
generator.
Method A
Column: Phenomenex Gemini C18 (100 x 4.6 mm, 3 µm particle size, 110 Å pore size)
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Column temperature: 40 °C
Sample Injection: 1–5 µL of sample in MeCN or MeOH
Chromatographic monitoring: UV absorbance at 210 or 254 nm
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic
acid
Flow Rate:

1.0 mL/min

Gradient:

0 to 0.5 min: 25% MeCN
0.5 min to 5 min: 25% to 95% MeCN
5 min to 7.3 min: 95% MeCN
7.3 min to 7.5 min: 95% to 25% MeCN

Method B
Column: Phenomenex Gemini C18 (100 x 4.6 mm, 3 µm particle size, 110 Å pore size)
Column temperature: 40 °C
Sample Injection: 1–5 µL of sample in MeCN or MeOH
Chromatographic monitoring: UV absorbance at 210 or 254 nm
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic
acid
Flow Rate:

1.0 mL/min

Gradient:

0 to 0.5 min: 25% MeCN
0.5 min to 5 min: 25% to 95% MeCN
5 min to 7.3 min: 95% MeCN
7.3 min to 7.5 min: 95% to 25% MeCN
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Method C
Column: Phenomenex Gemini C18 (100 x 4.6 mm, 3 µm particle size, 110 Å pore size)
Column temperature: 40 °C
Sample Injection: 1–5 µL of sample in MeCN or MeOH
Chromatographic monitoring: UV absorbance at 210 or 254 nm
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic
acid
Flow Rate:

1.0 mL/min

Gradient:

0 to 0.5 min: 25% MeCN
0.5 min to 5 min: 25% to 95% MeCN
5 min to 7.3 min: 95% MeCN
7.3 min to 7.5 min: 95% to 25% MeCN

Preparative HPLC Purification Methods

Preparative liquid chromatography was performed on a Shimadzu LC-20AP
preparative HPLC with autosampler, dual wavelength detector, and fraction collector.

Method A
Column: Phenomenex Gemini C18 Semi Preparative Column (250 x 10 mm, 5 µm
particle size, 110 Å pore size)
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeOH w/ 0.1% formic
acid
Peak collection: measured by UV absorbance at 210 or 254 nm
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Sample Injection: 0.1–1.9 mL (2 mL sample loop) of sample in DMSO
Flow Rate:

6.0 mL/min

Gradient:

0 to 1.5 min: 25% MeOH
1.5 min to 8 min: 25% to 95% MeOH
8 min to 10.5 min: 95% MeOH

Method B
Column: Phenomenex Gemini C18 Semi Preparative Column (250 x 10 mm, 5 µm
particle size, 110 Å pore size)
Mobile Phase: Solvent A: H2O w/ 0.1% formic acid; Solvent B: MeCN w/ 0.1% formic
acid
Peak collection: measured by UV absorbance at 210 or 254 nm
Sample Injection: 0.1–1.9 mL (2 mL sample loop) of sample in DMSO
Flow Rate:

6.0 mL/min

Gradient:

0 to 1.5 min: 25% MeCN
1.5 min to 8 min: 25% to 95% MeCN
8 min to 10.5 min: 95% MeCN

8.8

Experimental protocol for Chapter 4

Method A: Peptide Coupling using EDC

To a round bottom flask with stir bar under nitrogen were added the appropriate
carboxylic acid and anhydrous DCM/DMF (85:15; 0.2-0.6 M). The amine HCl salt to be
coupled (1.2 eq.), HOBt (1.2 eq.), EDC•HCl (1.2 eq.), and DIPEA (2.1 eq.) were added
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and the reaction was stirred under nitrogen. The reaction was diluted with DCM (75
mL), washed with saturated NaHCO3, 1M HCl (30 mL), brine, dried over Na2SO4,
filtered, and concentrated under reduced pressure to give crude product.

Method B: Conversion to the Acid Chloride for Subsequent Acylation

To an oven-dried round bottom flask with stir bar under nitrogen were added the
carboxylic acid, dry DCM, and 3Å molecular sieves. Oxalyl chloride (1.2 eq.) and a
catalytic amount of DMF (1–2 mol %) were added and the reaction was stirred while
attached to a bubbler (to monitor production of CO2) at 20 °C for 2–3 h. The amine HCl
salt (1 eq.) in DCM and DIPEA (2 eq.) were added and the reaction was stirred under
nitrogen for 3–6 h. The reaction was diluted with EtOAc and washed with half-saturated
aqueous NaHCO3, 1M HCl (30 mL), brine, dried over Na2SO4, filtered, and concentrated
under reduced pressure to give crude material.

Method C: Acylation

To an oven-dried round bottom flask with stir bar and under nitrogen were added
the acid chloride, dry DCM, and 3Å molecular sieves. The amine HCl salt (1 eq.) in
DCM and DIPEA (2 eq.) were added and the reaction was stirred under nitrogen for 3–6
h. The reaction was diluted with EtOAc and washed with half-saturated aq. NaHCO3, 1M
HCl (30 mL), brine, dried over Na2SO4, filtered, and concentrated under reduced pressure
to give crude product.
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Method D: Peptide Coupling using HATU

To a round bottom flask with stir bar under nitrogen was added the carboxylic
acid and anhydrous DCM. The amine (1.2 eq.), HATU (1.2 eq.), and DIPEA (1.2 eq.)
were added and the reaction was stirred under nitrogen. The reaction was diluted with
DCM (75 mL) and washed with saturated NaHCO3, 1M HCl (30 mL), brine, dried over
Na2SO4, filtered, and concentrated under reduced pressure to give crude material.

Method E: Boc removal

To an 8 mL scintillation vial with stir bar and under nitrogen was added the bocprotected amine, dry DCM, and a large excess of TFA. The reaction was allowed to stir
at 20°C for 1–2 h. The reaction mixture was concentrated under reduced pressure (passed
through a base trap) to give crude material that was suspended in EtOAc and washed with
half-saturated aq. NaHCO3, and brine. The reaction was dried over Na2SO4, filtered, and
concentrated under reduced pressure to give crude material that was carried onto the next
peptide coupling step without further purification.
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8.9

Experimental procedures for the selected Parmodulins (specifically central

heterocycles and photoaffinity azide ligands) from Chapter 4

2-bromo-N-(3-nitrophenyl)benzamide (4.2). 4.2 was synthesized according to a
previously published protocol.1
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N-(3-aminophenyl)-2-bromobenzamide hydrochloride (4.3). To a round bottom flask
with stir bar was added a solution of SnCl2•2H2O (6.15 g, 0.03 mol) in conc. HCl (5 mL).
To this solution was added a solution of 2-bromo-N-(3-nitrophenyl)benzamide (4.2, 1.75
g, 0.01 mol) in ethanol (50 mL), and the resulting suspension was stirred at 55 °C for 2 h.
A sample aliquot was taken from the reaction, made basic with 2M aq. NaOH, filtered
and the filtrate was concentrated under reduced pressure, dissolved in a minimal amount
of HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion. The
reaction was cooled to 20 °C, made basic with 2 M aq. NaOH (until pH 9), then filtered.
The filtrate was concentrated under reduced pressure to half volume and then extracted
with DCM (150 mL). The organic layer was washed with brine, dried over Na 2SO4,
filtered, and concentrated under reduced pressure to give crude product. The crude
material was dissolved in DCM and added to 0.9 M HCl in ether (20 mL), and stirred for
5 min. at 20 °C to form a precipitate. The precipitate was filtered, washed with DCM,
collected, and dried to give aniline HCl salt 4.31 (1.6 g, 81%) as a yellow solid.
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N-(3-nitrophenyl)butanamide (4.27). 4.27 was synthesized according to a previously
published protocol.1

N-(3-aminophenyl)butanamide hydrochloride (4.28). A solution of nitroarene 4.27
(5.95 g, 28.7 mmol) in MeOH (85 mL) was flushed with nitrogen for 5 min. To a 10 mL
scintillation vial under nitrogen was suspended 10% Pd/C (0.95 g, 0.88 mmol) in
MeOH/H2O (4:1) and the resultant suspension was added to the solution of 4. A balloon
was filled with H2 gas and inserted into the flask and the reaction was purged with H 2 gas
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for 2 min. The reaction was left to stir under a full balloon of H 2 for 16 h, after which an
aliquot was taken from the reaction, filtered through Celite and cotton, and concentrated
under reduced pressure. The aliquot was dissolved in a minimal amount of HPLC grade
MeCN, and analyzed with LCMS to confirm reaction completion. The reaction was
filtered through a funnel packed with Celite. The filter cake was washed with MeOH and
the filtrate was concentrated under reduced pressure, to give crude material that was
dissolved in DCM and added to 0.9 M HCl in ether (40 mL). The reaction was stirred for
5 min. at 20 °C to give a precipitate that was filtered and washed with excess DCM. The
precipitate was dried to give 4.28 (5.6 g, 92%) as a grey solid.

2-Azido-N-(3-butyramidophenyl)benzamide (4.31).
Part 1: Diazotization. To a round bottom flask with stir bar was added 2aminobenzoic acid 4.29 (1.50 g, 10.9 mmol) and deionized H2O (100 mL). The reaction
was cooled to 0 °C and conc. aq. HCl (5 mL) was added dropwise over 5 min. A solution
of NaNO2 (0.75 g, (11 mmol) in H2O (1 mL) was added, and the reaction was stirred for
10 min. at 2 °C. A solution of NaOAc (0.63 g, 11 mmol) in H 2O (1 mL) and a solution of
NaN3 (0.71 g, 10.9 mmol) in H2O (1 mL) were added consecutively and the reaction was
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stirred for 30 min at 2 °C. A sample aliquot was taken from the reaction, diluted with
TBME, extracted and the organic phase was separated, concentrated under reduced
pressure, dissolved in a minimal amount of HPLC grade MeCN, and analyzed with
LCMS to confirm reaction completion. The reaction was extracted with TBME (100 mL)
and the organic layer was washed with brine, dried over Na2SO4, filtered, and
concentrated under reduced pressure to give 2-azidobenzoic acid 25 (1.5 g) as a yellow
solid in 85% yield. TLC: mobile phase: ethyl acetate/hexanes/formic acid (25/25/1), Rf =
0.4; 1H NMR (300 MHz, CDCl3) δ = 8.19 - 8.14 (m, 1 H), 7.67 - 7.59 (m, 1 H), 7.29 (dd,
J = 2.0, 7.3 Hz, 2 H).
Part 2: Acylation. Crude azide analogue 4.31 was synthesized by acylation of
aniline•HCl salt 4.28 with 2-azidobenzoic acid 4.30 according to general method B. The
crude material was dissolved in a minimal amount of DCM, loaded onto a 25 g column,
and purified with flash chromatography (EtOAc/hexanes, 0–80%) to give 4.31 (160 mg,
80%) as a colorless oil. TLC: mobile phase: ethyl acetate/hexanes (50:50), Rf: 0.6;
LC/MS tR = 5.01 min (characterization method A); m/z = 323.80 (M + H+) 368.00 (M +
formate); 1H NMR (400 MHz, CDCl3) δ = 9.36 (br. s., 1 H), 8.26 - 8.19 (m, 1 H), 7.98
(br. s., 1 H), 7.61 - 7.50 (m, 1 H), 7.41 (d, J = 7.6 Hz, 2 H), 7.36 - 7.23 (m, 5 H), 2.33 (t, J
= 7.4 Hz, 2 H), 1.76 (sxt, J = 7.4 Hz, 2 H), 0.99 (t, J = 7.3 Hz, 3 H); 13C NMR (101
MHz, CDCl3) δ = 162.7, 138.6, 138.4, 136.9, 132.1, 129.6, 125.4, 118.4, 115.6, 111.6,
39.7, 19.0, 13.7; HRMS calcd. for C17H17N5O2 (M + H+) 324.1455, found 324.1415.
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6-nitro-2-propyl-1H-benzimidazole (4.11). To an oven dried 50 mL round bottomed
flask with stir bar and under N2 was added was added 4-nitrobenzene-1,2-diamine 4.10
(0.29 g, 1.87 mmol), POCl3 (3 mL) and butyric acid (0.2 mL, 2.2 mmol). The flask was
attached to a reflux condenser, sealed with a septum, and placed under positive pressure
of N2, then the reaction was refluxed at 105 °C (oil bath temp.) for 3 h. A sample aliquot
was taken from the reaction, made basic with 2N NH4OH solution, extracted with EtOAc
and concentrated under reduced pressure, dissolved in a minimal amount of HPLC grade
MeOH, and analyzed with LC-MS to confirm reaction completion. The reaction was
slowly cooled to room temperature, and then to 10 °C in an ice water bath. The reaction
was made basic with dropwise addition of 2N NH4OH solution over 10 min. to pH 9.
After that, the reaction was extracted with EtOAc (30 mL x 2), washed with brine, dried
over Na2SO4, filtered and concentrated under reduced pressure to give the crude nitrobenzimidazole 4.11 (90 mg, 23%) as a yellow solid.
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N
N
H
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NH2

2-propyl-1H-benzimidazol-6-amine (4.12). To a 25 mL round bottom flask with stir bar
and under N2 was added nitro-benzimidazole 4.11 (54.0 mg, 0.24 mmol) and MeOH (4
mL). The flask was flushed well with nitrogen. Then, 10% Pd/C (5.4 mg, 0.0048 mmol, 2
mol%,

pre-wetted

with

0.5

mL

of

H2 O)

was

added

to

the

reaction.

The flask was sealed with rubber septum; the reaction was evacuated and back-filled with
hydrogen 3-4 times from a large hydrogen gas balloon inserted via needle, while stirring
vigorously. The reaction was stirred under a hydrogen balloon for 1 h, after which time
the reaction was passed through a funnel packed with cotton and Celite. The filter cake
was washed with MeOH, and the combined filtrate was concentrated under reduced
pressure to give the crude aniline 4.12 (50.0 mg) as a brown solid, which was used in the
next step without purification. LC-MS (ESI+APCI): m/z 176 (M+H+).

N

O

N
H

Br

N
H
4.13

2-bromo-N-(2-propyl-1H-benzimidazol-6-yl)benzamide (4.13). Benzimidazole 4.13
was synthesized from acylation of aniline 4.12 (50.0 mg, 0.29 mmol) and 2bromobenzoyl chloride (37 µL, 0.29 mmol) according to general method C. The crude
material was wet loaded using DCM onto a 10 g silica gel column and purified by flash
chromatography (MeOH : DCM, 0–10%) to give 4.13 as a pale yellow solid (45 mg,
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44%). LC-MS tR = 4.47 min (Characterization Method A); m/z = 348.70 (M + H); 1H
NMR (400 MHz ,DMSO-d6) δ = 8.11 - 7.89 (m, 1 H), 7.70 (dd, J = 0.8, 8.0 Hz, 1 H),
7.54 (dd, J = 1.7, 5.8 Hz, 1 H), 7.51 - 7.34 (m, 3 H), 7.30 - 7.18 (m, 1 H), 2.80 - 2.67 (m,
2 H), 1.76 (sxt, J = 7.4 Hz, 2 H), 0.92 (t, J = 7.4 Hz, 3 H); 13C NMR (75 MHz ,DMSOd6) d = 166.2, 166.1, 140.1 (d, J = 3.2 Hz), 133.3, 131.7, 129.5, 128.4, 119.8, 31.2, 21.6,
14.4.
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NO2

6-nitro-1H-indazole (4.15). To a 250 mL round bottom flask with stir bar was added 2methyl-5-nitro-aniline 4.14 (1.01 g, 6.64 mmol) and glacial acetic acid (150 mL). The
reaction was cooled to 0 °C (ice bath temp.) and then a pre-cooled solution of NaNO2
(490 mg, 7.102 mmol) in 2.5 mL of water was added dropwise at 0⁰C via a separatory
funnel over 5 min., then the reaction was warmed to room temperature and stirred for 3
days. The reaction was concentrated under reduced pressure (with base trap attached to
rotary evaporator), to give crude material that was suspended in EtOAc (50 mL), passed
through a silica plug, and concentrated again under reduced pressure. The crude was wet

181
loaded in minimal DCM onto a 100 g silica gel column and purified by flash
chromatography (0-100% EtOAc:hexanes) to yield nitro-indazole 4.15 (940 mg, 87%).
1H NMR (300 MHz, DMSO-d6) d = 8.44 (s, 4 H), 8.31 (s, 1 H), 8.03 - 7.97 (m, 1 H),
7.95 - 7.89 (m, 1 H).

+

N
N

NO2

N
N

NO2

4.17
4.16

1-butyl-6-nitro-1H-indazole (4.16) and 2-butyl-6-nitro-2H-indazole (4.17). To an
oven dried 15 mL round bottom flask with stir bar was added nitro-indazole 4.15 (0.10 g,
0.61 mmol), 3A⁰ molecular sieves (0.5 g), dry DMF (3 mL) and freshly powdered K2CO3
(0.17 g, 1.23 mmol). The reaction was stirred vigorously at room temperature for 1.5 h,
after which time 1-bromobutane (66 µL, 0.61 mmol) was added. The flask was sealed
with a rubber septum and the reaction was heated to 60 °C (oil bath temp.) for 25 h. A
sample aliquot was taken from the reaction, diluted with water, extracted with EtOAc,
concentrated under reduced pressure, re-dissolved in HPLC grade MeOH, and analyzed
by LC-MS to confirm reaction completion. The reaction was then cooled to room
temperature, diluted with water (30 mL) and extracted with 30:10 EtOAc:MTBE (30 mL
x 2). The combined organics were washed with brine, dried over Na2SO4, filtered and
concentrated under reduced pressure to give a yellow crude that was wet loaded with
minimal DCM onto a 10 g silica gel column and purified by flash chromatography
(EtOAc:hexanes, 0 – 60%) to yield 37% (75 mg) of 4.16 and 37% (75 mg) of 4.17.
Isomer 4.16 was fully characterized by NOSEY, COSY, HMBC, HMQC, 1HNMR and
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13C NMR, and only 1H NMR was taken for isomer 4.17. Characterization of 4.16: 1H
NMR (400 MHz ,CDCl3) δ = 8.36 (m, 1 H), 8.08 (d, J = 1.0 Hz, 1 H), 7.96 (dd, J = 1.9,
8.9 Hz, 1 H), 7.79 (dd, J = 0.6, 8.9 Hz, 1 H), 4.44 (t, J = 7.1 Hz, 2 H), 1.96 - 1.87 (m, 2
H), 1.32 (sxt, J = 7.5, 15.1 Hz, 2 H), 0.92 (t, J = 7.4 Hz, 3 H).

13

C NMR (101MHz,

CDCl3) δ = 146.3, 138.1, 133.1, 126.9, 121.8, 115.2, 105.8, 49.3, 31.9, 20.0, 13.6.

N
N
4.18A

NH2

2-butyl-2H-indazol-6-amine (4.18A). To a 25 mL round bottom flask with stir bar was
added nitro-indazole 4.17 (70 mg, 0.32 mmol), the flask was sealed with septum under
N2 and MeOH (6 mL). The flask was flushed well with nitrogen. Then, 10% Pd/C (34
mg, 0.032 mmol, 10 mol%, pre-wetted with 1 mL of H2O) was added to the reaction. The
flask was sealed with a septum and evacuated and back-filled with hydrogen 4 times from
a large hydrogen gas balloon inserted via needle, while stirring vigorously. The reaction
was stirred under the hydrogen balloon for 4 h, after which time, the reaction was passed
through a funnel packed with cotton and Celite. The filter cake was washed with MeOH,
and the filtrate was concentrated to give brown colored crude aniline 4.18A (50.0 mg).
Aniline 20 was wet loaded with minimal DCM onto a 10 g silica gel column and purified
by flash chromatography (EtOAc:hexanes, 10 – 100%) to give 4.18A (40 mg, 60%) with
minor impurities. The aniline was immediately used in the subsequent acylation reaction.

183

N
N

NH2
4.18B

1-butyl-1H-indazol-6-amine (4.19B). Aniline 4.19B(40 mg, 66%) was synthesized from
nitro-indazole 4.17 using same protocol for 4.19.

O

N
N

Br

N
H
4.19A

2-bromo-N-(2-butyl-2H-indazol-6-yl)benzamide

(4.19A).

Amide

4.19A

was

synthesized by coupling of aniline 4.18A (25 mg, 0.13 mmol) with 2-bromobenzoyl
chloride (19 µL, 0.15 mmol) according to general method C. The crude material was wet
loaded with minimal DCM onto a 10 g silica gel column and purified by flash
chromatography (EtOAc:hexanes, 0–60%) to give 4.19A as a colorless oil (40 mg, 49%).
1H NMR (300 MHz ,DMSO-d6) δ = 10.46 (s, 1 H), 8.29 (s, 1 H), 8.15 (s, 1 H), 7.71 (d, J
= 7.2 Hz, 1 H), 7.63 (d, J = 8.9 Hz, 1 H), 7.59 - 7.53 (m, 1 H), 7.52 - 7.37 (m, 2 H), 7.20
(dd, J = 1.5, 9.0 Hz, 1 H), 4.36 (t, J = 6.9 Hz, 2 H), 1.93 - 1.79 (m, 2 H), 1.29 - 1.14 (m, 2
H), 0.87 (t, J = 7.1 Hz, 3 H). 13C NMR (75 MHz, DMSO-d6) δ = 166.6, 148.7, 140.0,
136.8, 133.4, 131.8, 129.6, 128.4, 124.4, 121.4, 119.7, 119.1, 117.0, 106.0, 53.0, 32.7,
19.9, 14.1.
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2-bromo-N-(1-butyl-1H-indazol-6-yl)benzamide

(4.19B).

Amide

4.19B

was

synthesized by coupling of aniline 4.18B (25 mg, 0.13 mmol) with 2-bromobenzoyl
chloride (19 µL, 0.14 mmol) according to general method C. The crude material was wet
loaded with minimal DCM onto a 10 g silica gel column and purified by flash
chromatography (MeOH:DCM, 0–10%) to give 4.19B as a white solid (40 mg, 81%). 1H
NMR (400 MHz ,CD3CO) δ = 9.77 (br s, 1 H), 8.41 (br s, 1 H), 7.95 (apparent d, J = 1.0
Hz, 1 H), 7.75 - 7.65 (m, 2 H), 7.60 (dd, J = 1.7, 7.5 Hz, 1 H), 7.47 (dt, J = 1.1, 7.5 Hz, 1
H), 7.42 - 7.36 (m, 1 H), 7.33 (dd, J = 1.7, 8.7 Hz, 1 H), 4.39 (t, J = 7.0 Hz, 2 H), 1.94 1.85 (m, 2 H), 1.33 (sxt, J = 7.5 Hz, 2 H), 0.93 (t, J = 7.4 Hz, 3 H). 13C NMR (101 MHz
,CD3CO) δ = 166.0, 139.8, 139.3, 137.4, 133.0, 132.3, 131.2, 129.0, 127.6, 121.2, 120.9,
119.2, 114.3, 99.0, 48.0, 31.7, 19.8, 13.1.
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N-(2-hydroxy-5-nitrophenyl)butanamide (4.21). To an oven dried 50 mL round bottom
flask with stir bar was added 2-amino-4-nitro-phenol (0.75 g, 4.8 mmol) and dry THF (10
mL). The flask was sealed with septum and flushed well with N2. The reaction was
cooled to 5 °C, and pyridine (0.47 mL, 5.8 mmol) was added followed by dropwise
addition of butanoyl chloride (0.6 mL, 5.3 mmol) via 1 mL syringe over 5 min. The
reaction was warmed to room temperature, the flask was connected to a reflux condenser,
and the reaction was refluxed for 68 h under a positive pressure of N2. A sample aliquot
was taken from the reaction, washed with 1 M HCl, extracted with EtOAc, concentrated
under reduced pressure, dissolved with HPLC grade MeOH and analysed by LC-MS to
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confirm reaction completion. The reaction was cooled to room temperature, diluted with
EtOAc (50 mL), washed with 1 M aqueous HCl (50 mL x 2) and brine, then dried over
Na2SO4, filtered, and concentrated under reduced pressure to give a brown colored crude.
The crude was wet loaded with minimal DCM onto a 10 g silica gel column and purified
by flash chromatography (EtOAc:hexanes, 0 – 60%) to yield amide 4.21 (0.79 g, 72%).
1H NMR (300 MHz , CD3CO) δ = 9.10 (br. s., 1 H), 8.85 (d, J = 2.7 Hz, 1 H), 7.92 (dd, J
= 2.8, 8.9 Hz, 1 H), 7.06 (d, J = 8.9 Hz, 1 H), 2.54 (t, J = 7.3 Hz, 2 H), 1.74 (sxt, J = 7.4
Hz, 2 H), 0.98 (t, J = 7.4 Hz, 14 H). 13C NMR (75 MHz, CD3CO) δ = 173.3, 153.4,
140.7, 127.5, 120.8, 116.8, 116.3, 38.5, 18.9, 13.3

TfO
O
N
H

NO2
4.22

2-(butanoylamino)-4-nitrophenyl trifluoromethanesulfonate (4.22). To an oven dried
250 mL round bottom flask with stir bar was added sodium hydride (60%, 0.18 g, 4.6
mmol), the flask was sealed with septum, flushed under N2 and dry MeCN (20 mL). The
reaction was cooled to 5 °C, and a suspension of phenol 4.21 (0.75 g, 3.34 mmol) in dry
MeCN (70 mL) was added slowly. After 30 min., triflic anhydride (0.67 mL, 4.01 mmol)
was added dropwise over 2 min. using a 1 mL syringe. The reaction was stirred for 6 h at
5 °C, and then warmed to room temperature and stirred for another 16 h. The reaction
was quenched with water (20 mL), and solvent volume was reduced under pressure. The
reaction was diluted with water (30 mL) and extracted with EtOAc (2 x 30 mL). The
combined organics were washed with half saturated NaHCO3 (30 mL) and brine, then
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dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude was wet
loaded with minimal DCM onto a 100 g silica gel column and purified by flash
chromatography (EtOAc:hexanes, 0 – 80%) to yield of triflate 4.22 as a yellow solid
(0.55 g, 46%). 1H NMR (300 MHz, CDCl3) δ = 8.04 (dd, J = 2.8, 9.1 Hz, 1 H), 7.72 (s, 1
H), 7.49 (d, J = 9.1 Hz, 1 H), 2.47 (t, J = 7.4 Hz, 2 H), 1.88 - 1.71 (m, 2 H), 1.03 (t, J =
7.4 Hz, 3 H).

O
N
H

NO2
4.23

N-[5-nitro-2-(pent-1-yn-1-yl)phenyl]butanamide (4.23). To an oven dried 250 mL
round bottom flask with stir bar and under N2 was added triflate 4.22 (0.51 g, 1.43 mmol)
and dry MeCN (10 mL). The flask was sealed under N2. Pd(PPh3)4 (165 mg, 0.143
mmol), tetrabutylammonium;iodide (793.14 mg, 2.147 mmol) and iodocopper (90 mg,
0.47 mmol) were added, respectively. The flask was immediately sealed with rubber
septum and flushed well with N2 over 2 min, and then TEA (2 mL) and pent-1-yne (0.1 g,
1.43 mmol), were added respectively. The reaction was stirred at room temperature for 2
h. A sample aliquot was taken from the reaction, quenched with half saturated NH4Cl
solution, extracted with EtOAc, cocncntrated, dissolved in HPLC MeOH grade, and
analyzed to LC-MS to confirm reaction completion. The reaction was quenched with half
saturated NH4Cl solution (25 mL) and then extracted with EtOAc (2 X 30 mL). The
combined organic extracts were then washed with brine, dried over Na 2SO4, filtered and
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concentrated under reduced pressure. The crude was wet loaded with minimal DCM to 25
g silica gel column and purified by flash chromatography (EtOAc:Hexane, 0 – 80%) to
yield 70% (0.28 g) of alkyne 4.24 as an yellow solid. 1H NMR (300 MHz, CDCl3) δ =
9.29 - 9.22 (m, 1 H), 8.03 (br. s., 1 H), 7.85 - 7.76 (m, 1 H), 7.47 - 7.39 (m, 1 H), 2.56 2.46 (m, 2 H), 2.46 - 2.35 (m, 2 H), 1.83 - 1.61 (m, 4 H), 1.11 - 0.95 (m, 6 H).

N
H

NO2
4.24

6-nitro-2-propyl-1H-indole (4.24). To an oven dried 20 mL scintillation vial with stir
bar and under N2 was added alkyne 4.23 (0.28 g, 1.01 mmol), t-BuOK (0.15 g, 1.38
mmol) and NMP (2.3 mL). The vial was flushed well with N2 and the reaction was heated
at 70 °C for 24 h. The reaction was cooled to room temperature, added 1 equivalent of tBuOK (0.15 g, 1.38 mmol) and the reaction was heated again at 70 °C for 5 h. The
reaction was then cooled again to room temperature, quenched with water (10 mL), and
stirred for 10 min. The reaction was diluted with water (30 mL), extracted with EtOAc
(50 mL), washed with brine, dried over Na2SO4, filtered, and concentrated. The crude
was wet loaded with minimal DCM to a 25 g silica gel column and purified by flash
chromatography (EtOAc:hexanea, 0 – 80%) to yield nitroindole 4.24 (0.082 g, 40%) as a
yellow solid. 1H NMR (300 MHz, CDCl3) δ = 9.04 (br s, 1 H), 8.35 (s, 1 H), 7.99 (dd, J
= 1.9, 8.8 Hz, 1 H), 7.51 (d, J = 8.8 Hz, 1 H), 6.35 (s, 1 H), 2.80 (t, J = 7.5 Hz, 2 H), 1.79
(sxt, J = 7.4 Hz, 2 H), 1.02 (t, J = 7.1 Hz, 3 H).
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2-propyl-1H-indol-6-amine (4.25). To a 50 mL round bottom flask with stir bar and
under N2 was added nitroindole 4.24 (82 mg, 0.37 mmol) and MeOH (3 mL). The flask
was flushed well with nitrogen. Then, 10% Pd/C (5.4 mg, 0.0048 mmol, 2 mol%, prewetted with 1 mL of H2O) was added to the reaction. The flask was sealed with a septum
and evacuated and back-filled with hydrogen 4 times from a hydrogen gas balloon
inserted via needle, while stirring vigorously. The reaction was stirred under a hydrogen
balloon for 3 h. The mixture was filtered through a funnel packed with cotton and Celite
and washed with MeOH, and the filtrate was concentrated to give brown colored crude
aniline 4.25 (78.0 mg) as solid. Aniline 4.25 was pushed to next step without any attempt
of purification.
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2-bromo-N-(2-propyl-1H-indol-6-yl)benzamide (4.26). Analogue 4.26 was synthesized
by coupling of aniline 4.25 (70 mg, 0.4 mmol) with 2-bromobenzoyl chloride (52 µL, 0.4
mmol) according to general method C. The crude material was wet loaded with minimal
DCM onto a 10 g silica gel column and purified by flash chromatography
(EtOAc:hexanes, 0 – 80%) to give 4.26 as a pale yellow solid (20 mg, 20%). 1H NMR
(400 MHz, CDCl3) δ = 8.60 (br. s., 1 H), 8.24 (s, 1 H), 7.83 (s, 1 H), 7.65 - 7.59 (m, 2
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H), 7.45 - 7.41 (m, 1 H), 7.41 - 7.35 (m, 1 H), 7.33 - 7.26 (m, 1 H), 6.87 (dd, J = 1.9, 8.3
Hz, 1 H), 6.18 - 6.13 (m, 1 H), 2.58 (t, J = 7.6 Hz, 2 H), 1.63 (sxt, J = 7.4 Hz, 2 H), 0.90
(t, J = 7.5 Hz, 3 H); 13C NMR (101 MHz ,CD3CO) δ = 165.7, 140.5, 140.1, 136.7,
133.2, 131.1, 129.1, 127.8, 126.1, 119.5, 119.3, 112.5, 102.6, 98.9, 30.2, 22.6, 13.5.
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Characterisation data for the selected Parmodulins (specifically central

heterocycles and photoaffinity azide ligands) from Chapter 4

1

H NMR (400 MHz, CDCl3) of Compound 4.31
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13

C NMR (101 MHz, CDCl3) ) of Compound 4.31
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LC/MS of 4.31(+ Mode)
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LC/MS of4.31(- Mode)
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H NMR (400 MHz, d6-DMSO) of Compound 4.13
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C NMR (400 MHz, d6-DMSO) of Compound 4.13
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H NMR (400 MHz, CD3CO) of Compound 4.19B
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C NMR (101 MHz, CD3CO) of Compound 4.19B
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C NMR (75 MHz, CD3CO) of Compound 4.21
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Experimental procedures for the PAR1 antagonist RWJ-58259

from

Chapter 6

(9H-Fluoren-9-yl)methyl

tert-butyl

(4-(benzylamino)-4-oxobutane-1,3-diyl)(S)-

dicarbamate (6.13). To a round bottom flask with stir bar under nitrogen was added
carboxylic acid 6.12 (500 mg, 1.13 mmol) and anhydrous DCM (25 mL). Benzylamine
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(0.15 mL, 1.4 mmol), HOBt (229 mg, 1.50 mmol), and EDC•HCl (433 mg, 2.26 mmol)
were added and the reaction was stirred under nitrogen for 2 h. A sample aliquot was
taken from the reaction, concentrated under reduced pressure, dissolved in a minimal
amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion.
The reaction was diluted with DCM (75 mL) and washed with saturated NaHCO3 (30
mL), 1M HCl (30 mL), brine, dried over MgSO4, filtered, and concentrated under
reduced pressure to give 6.13 (588 mg) as a white solid in 98% yield. mp = 154–156 °C;
LC/MS tR = 6.09 min (Characterization Method A); m/z = 530.05 (M + H+); 1H NMR
(300 MHz, CDCl3) δ = 7.76 (d, J = 7.6 Hz, 2 H), 7.61 - 7.49 (overlapping signals, 3 H),
7.43 - 7.22 (m, 9 H), 5.96 (d, J = 6.7 Hz, 1 H), 5.11 (br. m., 1 H), 4.50 - 4.13 (overlapping
m, 6 H), 3.48 - 3.32 (br. s., 1 H), 3.04 - 2.90 (br. m., 1 H), 1.97 - 1.71 (overlapping
signals, 2 H), 1.45 - 1.37 (m, 9 H); 13C NMR (75 MHz, CDCl3) δ = 171.2, 157.2, 156.3,
143.9, 141.5, 138.0, 128.8, 127.9, 127.8, 127.6, 127.3, 125.3, 120.2, 80.1, 67.2, 52.2,
47.3, 43.8, 37.0, 34.9, 28.6.

tert-butyl((S)-3-((S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(3,4difluorophenyl)propanamido)-4-(benzylamino)-4-oxobutyl)carbamate (6.15).
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Part 1: Fmoc removal. Dicarbamate 6.13 (550 mg, 1.03 mmol) was added to a
round bottom flask with stir bar and sealed under nitrogen, then MeCN (25 mL), DCM
(10 mL), and piperidine (0.220 mL, 2.22 mmol) were added. The reaction was stirred for
2 h. A sample aliquot was taken from the reaction, concentrated under reduced pressure,
dissolved in a minimal amount of HPLC grade MeCN, and analyzed with LCMS to
confirm reaction completion. The reaction was concentrated under reduced pressure and
then re-dissolved in (CHCl3/EtOAc, 1:1, 75 mL), washed with H2O (2 x 20 mL) and
brine (20 mL). The organic phase was dried over MgSO4, filtered, and concentrated
under reduced pressure to give crude material (496 mg) as a white solid that was carried
onto the next reaction without further purification.
Part 2: Coupling. To a round bottom flask with stir bar already containing crude
material from Part 1 (496 mg crude material, max. yield is 319 mg) was added anhydrous
MeCN

(30

mL)

and

anhydrous

DCM

(15

mL).

(S)-2-((((9H-Fluoren-9-

yl)methoxy)carbonyl)amino)-3-(3,4-difluorophenyl)propanoic acid (300 mg, 0.709
mmol), HOBt (191 mg, 1.41 mmol), and EDC•HCl (272 mg, 1.41 mmol) were added,
and the resulting white suspension was stirred for 2 h. A sample aliquot was taken from
the reaction, concentrated under reduced pressure, dissolved in a minimal amount of
HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion. The
reaction was concentrated under reduced pressure, re-suspended in EtOAc (100 mL), and
washed with H2O (20 mL), 0.5 M HCl (20 mL), saturated NaHCO3 (20 mL), and brine.
The organic phase was dried over MgSO4, filtered, and concentrated under reduced
pressure to give crude material (yellow oil) that was dry loaded using silica onto a 5 g
silica gel column and purified with flash chromatography (EtOAc/hexanes, 1–100%) to
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give 3 (368 mg, 49%) as a white solid over 6.15 steps. m.p. = 183–185 °C; LC/MS tR =
6.43 min (Characterization Method A); m/z = 713.15 (M + H+), m/z = 757.35 (formic
acid adduct); 1H NMR (300 MHz, DMSO-d6) δ = 8.43 (dd, J = 5.0, 5.9 Hz, 1 H), 8.22
(d, J = 7.9 Hz, 1 H), 7.86 (d, J = 7.6 Hz, 2 H), 7.68 - 7.53 (m, 2 H), 7.52 - 7.43 (br. s., 1
H), 7.43 - 7.07 (m, 11 H), 6.74 (br. s., 1 H), 4.28 (br. d, J = 5.6 Hz, 4 H), 4.15 (br. s, 3 H),
3.05 - 2.85 (overlapping br. s, 3 H), 2.73 (app. t, J = 12.0 Hz, 1 H), 1.86 - 1.73 (m, 1 H),
1.73 – 1.58 (m, 1H), 1.34 (s, 9 H); 13C NMR (75 MHz, DMSO-d6) δ = 171.8, 171.7,
156.4, 156.1, 150.8 (dd, J = 45.2, 13 Hz), 147.6 (dd, J = 45.8, 12.1 Hz), 144.4, 144.3,
141.35, 141.33, 139.8, 136.6, 128.9, 128.2, 127.7, 127.6, 127.4, 126.7, 125.9, 120.7,
118.9, 118.6, 117.6, 117.4, 78.3, 66.3, 56.4, 51.5, 47.2, 42.7, 37.5, 37.1, 33.1, 28.9

tert-butyl((S)-3-((S)-2-Amino-3-(3,4-difluorophenyl)propanamido)-4-(benzylamino)4-oxobutyl)carbamate (6.16). Carbamate 6.15 (250 mg, 0.351 mmol) was added to a
round bottom flask with stir bar and sealed under nitrogen, then anhydrous MeCN (30
mL) and piperidine (2 mL) were added and the reaction was stirred for 90 min. A sample
aliquot was taken from the reaction, concentrated under reduced pressure, dissolved in a
minimal amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction
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completion. The reaction was concentrated under reduced pressure to give crude material
(light yellow solid) that was triturated with 75/25 hexanes/ether. The material was then
dry loaded using silica onto a 10 g silica gel column and purified with flash
chromatography (IPA/DCM, 0 to 20%) to give 6.16 (86 mg) as a white solid in 50%
yield. mp = 216–219 °C; LC/MS tR = 3.15 min (Characterization Method A); m/z =
491.35 (M + H+), m/z = 489.30 (M - H+), 535.30 (formic acid adduct); 1H NMR (300
MHz, CDCl3) δ = 8.06 (d, J = 7.9 Hz, 1 H), 7.72 (br. t, J = 5.0 Hz, 1 H), 7.37 - 7.20 (m, 5
H), 7.14 - 6.95 (m, 2 H), 6.94 - 6.83 (br. m, 1 H), 5.37 (app. t. J = 5.3, 6.2 Hz, 1 H), 4.56 4.47 (m, 1 H), 4.47 - 4.35 (m, 2 H), 3.53 - 3.42 (m, 1 H), 3.39 - 3.25 (br. m, 1 H), 3.09
(dd, J = 3.8, 9.7 Hz, 1 H), 3.02 - 2.89 (br. m, 1 H), 2.66 (dd, J = 4.7, 9.1 Hz, 1 H), 2.00 1.85 (br. m, 1 H), 1.84 - 1.67 (br. m, 1 H), 1.54 (br. m., 2 H), 1.43 (s, 9 H); 13C NMR (75
MHz, CDCl3) δ = 174.4, 171.2, 156.9, 151.6 (dd, J = 53.5, 12.7 Hz), 148.4 (dd, J = 52.1,
12.4 Hz), 138.1, 134.8 (dd, J = 5.3, 3.9 Hz), 128.8, 127.9 (partially obs.) 127.8, 127.6,
125.4 (dd, J = 6.2, 3.6 Hz), 117.9 (J = 28.5, 17.3 Hz), 79.8, 56.4, 50.4, 43.7, 40.3, 37.0,
34.5, 28.6.

6-Nitro-1H-indazole-3-carbaldehyde (6.18). To a 500 mL round bottomed flask with
stir bar was added NaNO2 (6.38 g, 92.5 mmol) and H2O (150 mL). 6-Nitro-1H-indole
(6.17, 1.5 g, 9.3 mmol) was added to the above solution at 20 °C and the resultant
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mixture was stirred vigorously until evenly suspended (over 5 min.). To this bright
yellow suspension was added 6 M HCl (14 mL) via addition funnel over 30 min. at 20
°C, and the resultant suspension was stirred for 90 min. A sample aliquot was taken from
the reaction, filtered, and the precipitate was dissolved in a minimal amount of HPLC
grade MeCN. Analysis with LCMS confirmed reaction completion. The product was
vacuum filtered and the precipitate was washed with additional H2O (50 mL). The
precipitate was dried to give 6.18 (1.37 g) as an orange solid in 77% yield. m.p.: changed
color from orange to brown between 120 and 160 °C, decomposed after 200 °C; LC/MS
tR = 2.40 min (Characterization Method A); m/z = 190.05 (M - H+); 1H NMR (400
MHz, DMSO-d6) δ = 10.22 (s, 1 H), 8.57 (d, J = 1.5 Hz, 1 H), 8.29 (dd, J = 0.5, 8.9 Hz, 1
H), 8.13 (dd, J = 2.0, 8.9 Hz, 1 H); 13C NMR (100 MHz, DMSO-d6) δ = 187.7, 146.9,
124.0, 122.4, 118.7, 108.6.

6-Nitro-3-(pyrrolidin-1-ylmethyl)-1H-indazole (6.19). Aldehyde 6.18 (1.3 g, 6.80
mmol) was added to a round bottom flask with stir bar and sealed under nitrogen. A premixed solution of anhydrous DCE:DMF:AcOH (300:30:0.3 mL), and pyrrolidine (2.8
mL, 34.01 mmol) was then added. The resulting yellow suspension became a reddish
brown solution immediately after the addition of pyrrolidine, and the reaction was stirred
for 20 min. Sodium triacetoxyborohydride (8.32 g, 39.24 mmol) was added in 3 portions
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at 5 min. intervals, and the resultant suspension was stirred at 20°C for 4 h. A sample
aliquot was taken from the reaction, diluted with DCM, and washed with half saturated
Na2CO3.

The organic layer was separated, concentrated under reduced pressure,

dissolved in a minimal amount of HPLC grade MeCN, and analyzed with LCMS to
confirm reaction completion. The reaction was diluted with DCM (100 mL), washed with
aqueous NaHCO3 solution (100 mL), brine, dried over Na2SO4, vacuum filtered, and
concentrated under reduced pressure to give 2.2 g of dark brown solid. The crude
material was dissolved in minimal DCM and loaded onto a 50 g SiO 2 column and
purified by flash chromatography (1N NH3 in MeOH/DCM, 0–18%) to give 6.19 (1.09
g) as an orange brown shiny solid in 65% yield. mp = 37–40°C; LC/MS tR = 0.91 min
(Characterization Method A); m/z = 247.05 (M + H+); m/z= 245.15 (M - H+); 1H NMR
(400 MHz , CD3OD) δ = 8.44 (d, J = 1.5 Hz, 1 H), 8.05 (d, J = 8.8 Hz, 1 H), 7.99 (dd, J =
2.0, 7.0 Hz, 1 H), 4.16 (s, 2 H), 2.78 - 2.71 (m, 4 H), 1.84 (spt, J = 3.3 Hz, 4 H); 13C
NMR (75 MHz, CD3OD) δ = 147.0, 142.8, 140.1, 125.2, 121.3, 114.9, 106.8, 53.9, 50.6,
23.1.

1-(2,6-Dichlorobenzyl)-6-nitro-3-(pyrrolidin-1-ylmethyl)-1H-indazole (6.20). Amine
6.19 (1.06 g, 4.30 mmol) and 2-(bromomethyl)-1,3-dichlorobenzene (1.03 g, 4.30 mmol)
were added to a round bottom flask with stir bar and sealed under nitrogen. Anhydrous
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THF (50 mL) was added, followed by Cs2CO3 (1.4 g, 4.30 mmol) added in 3 portions (1
portion every 5 min.), and the flask was flushed with nitrogen. The resultant orange
solution was stirred for 16 h at 20 °C. A sample aliquot was taken from the reaction,
diluted with EtOAc, and washed with H2O. The organic phase was separated,
concentrated under reduced pressure, dissolved in CDCl3 and analyzed with NMR to
confirm reaction completion. The reaction was diluted with EtOAc (200 mL), washed
with H2O (200 mL) and brine, dried over Na2SO4, vacuum filtered, and concentrated
under reduced pressure. The brown crude (1.5 g) was dissolved in minimal DCM and
loaded onto a 50 g column and purified with flash chromatography (MeOH/DCM, 018%) to give 6.20 (1.33 g) as an orange brown shiny solid (containing ~10%
dibenzylated side-product) in 76% yield. 8 was carried forward to the next step without
additional purification. LC/MS t R = 3.15 min (Characterization Method A); m/z = 404.80
(M + H+); for dibenzylated impurity LC/MS t R = 3.63 min (Characterization Method A);
m/z = 579.95 (M + H+).

1-(2,6-Dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-6-amine (6.21). To an
oven dried pressure tube with stir bar was added indazole 6.20 (18 mg, 0.044 mmol) and
MeOH (5 mL). FeCl3•6H2O (25 mol%, 2.6 mg), hydrazine monohydrate solution (65%
active hydrazine, 0.05 mL, 0.7 mmol) and activated charcoal (20 mg) were added, the
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tube was capped tightly, and the reaction was stirred at 100 °C for 2 h. A sample aliquot
was taken from the reaction, concentrated under reduced pressure, dissolved in a minimal
amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction
completion. The reaction was filtered, the charcoal and filtered solids were washed with
MeOH (10 mL), and the filtrate was concentrated under reduced pressure to give crude
material that was dry loaded using silica onto a 5 g silica column and purified with flash
chromatography (0 to 20% MeOH/DCM) to give 6.21 (11.5 mg) as a white solid in 69%
yield. LC/MS tR = 1.44 min (Characterization Method A); m/z = 374.95 (M + H +); 1H
NMR (300 MHz, CDCl3) δ = 7.57 (d, J = 8.5 Hz, 1 H), 7.37 (d, J = 8.2 Hz, 2 H), 7.31 7.20 (s, 1 H), 6.63 (d, J = 8.8 Hz, 1 H), 6.58 (s, 1 H), 5.63 (s, 2 H), 4.29 (s, 2 H), 3.96 (br.
s., 2 H), 3.13 (br. s., 4 H), 1.84 (br. s., 4 H); 13C NMR (75 MHz, CDCl3) δ = 146.5, 142.5,
137.0, 131.6, 130.3, 128.8, 121.0, 117.7, 113.7, 92.2, 52.3, 48.5, 48.2, 23.9.

(S)-4-Amino-N-benzyl-2-((S)-2-(3-(1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)1H-indazol-6-yl)ureido)-3-(3,4-difluorophenyl)propanamido)butanamide (6.23a-b)

Part 1: Coupling reaction. Aniline 6.21 (40 mg, 0.11 mmol) was added to an
oven-dried round bottom flask with stir bar and sealed under nitrogen, then dry THF (16
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mL) was added. The solution was cooled in a NaCl/H2O bath (–5 °C) for 15 min., and
then both DMAP (34.6 mg, 0.282 mmol) and triphosgene (12 mg, 0.04 mmol) were
added consecutively. Immediately the reaction became a light orange suspension. The
reaction was stirred at –5°C for 8 min., and then amine 6.16 (35 mg, 0.071 mmol) was
added and the reaction was stirred at –5°C for 1 h, then for an additional 1 h while
warming to room temperature. A sample aliquot was taken from the reaction,
concentrated under reduced pressure, dissolved in a minimal amount of HPLC grade
MeCN, and analyzed with LCMS to confirm reaction completion. The reaction was
concentrated under reduced pressure to give crude material 6.22 that could be either
carried onto the next reaction without purification, or triturated with DCM/hexanes (1:1)
to provide purer material.
Part 2: Boc removal. The round bottom flask already containing either the crude
or triturated material 6.22 was cooled in a NaCl/H2O bath for 10 min (–5°C), and then
HCl in dioxane (4 M, 3 mL) was slowly added. The reaction immediately became a
heterogeneous dark red mixture and was stirred for 40 min. at –5° C. A sample aliquot
was taken from the reaction, concentrated under reduced pressure, dissolved in a minimal
amount of HPLC grade MeCN, and analyzed with LCMS to confirm reaction
completion. The reaction was concentrated under reduced pressure to give a red-orange
solid that was free-based with 0.075 N NH3 in MeOH and concentrated under reduced
pressure. The crude product was dissolved in a minimal amount of DCM, loaded onto a
10 g normal phase silica column, and purified with flash chromatography (0–18% (0.75
N NH3 in MeOH)/DCM,) to give amine 6.23 (free base) as a light pink oily solid. The
product was converted to the bis HCl salt 6.23a by adding 1N HCl (1 mL) and
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lyophilizing overnight to give bis HCl salt as a light pink solid. LCMS Data t R =
(Characterization Method A); m/z = 396.65 [(M/2) + H+], 835.30 (M - H+, formic acid
adduct); 1H NMR (400 MHz, CD3OD, free base) δ = 7.98 (s, 1 H), 7.75 (d, J = 8.7 Hz, 1
H), 7.45 - 7.38 (m, 2 H), 7.37 - 7.05 (m, 10 H), 5.56 (br. s., 2 H), 4.64 (s, 2 H), 4.60 4.48 (m, 2 H), 4.40 (d, J = 4.5 Hz, 2 H), 3.57 - 3.45 (m, 2 H), 3.29 - 3.12 (m, 3 H), 3.12 2.93 (m, 3 H), 2.35 - 2.20 (m, 1 H), 2.15 - 1.85 (m, 5 H); 13C NMR (75 MHz, CD3OD,
free base) δ = 173.3, 171.0, 156.2, 141.7, 139.0, 138.2, 136.6, 135.1, 134.3, 131.4,
130.3, 128.3, 128.1, 126.9, 126.7, 125.6, 119.7, 118.3, 118.1, 117.8, 117.0, 116.7, 115.2,
97.4, 55.6, 53.5, 51.0, 48.8, 42.6, 36.8, 36.6, 29.5, 22.6. Alternatively, the crude product
could be dissolved in DMSO and purified in batches with preparative HPLC (method A).
Pooled fractions were concentrated under reduced pressure in lukewarm water (to remove
MeCN) and lyophilized overnight to give 6.23b (36.3 mg) as a light pink oil in 58% yield
over 2 steps.
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N-((S)-4-(Benzylamino)-3-((S)-2-(3-(1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1ylmethyl)-1H-indazol-6-yl)ureido)-3-(3,4-difluorophenyl)propanamido)-4oxobutyl)pent-4-ynamide (6.24)

Note: If using 6.23b, it is necessary to convert this compound to the bis HCl salt
(6.23a) prior to performing this EDC coupling reaction as it has been seen that the
formate salt will give a mixture of products. To a 5 mL scintillation vial with stir bar was
added 6.23b (5.5 mg, 6.4 μmol). The vial was purged with N2 for 5 min and then dry
dioxane (0.5 mL) and 4 M HCl in dioxane (0.3 mL, 172 eq.) was added. The reaction was
stirred for 5 min, concentrated under reduced pressure, and then lyophilized to give the
bis HCl salt (6.23a). The vial containing 6.23a was purged with nitrogen and then
dissolved in dry DMF (0.5 mL). 4-Pentynoic acid (1 mg, 10 µmol), HOBt (1.2 mg, 8.9
µmol), EDC•HCl (3 mg, 12 µmol), and DIPEA (9.6 μL, 55 µmol) were added
consecutively and the reaction was stirred for 5 h under N2. A sample aliquot was taken
from the reaction, concentrated under reduced pressure, dissolved in a minimal amount of
HPLC grade MeCN, and analyzed with LCMS to confirm reaction completion. The
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reaction was diluted with EtOAc (5 mL) and washed with saturated NaHCO 3 (5 mL) and
brine (5 mL). The organic layer was dried over MgSO4, filtered, and concentrated under
reduced pressure to give crude material that was dissolved in DMSO and purified with
preparative HPLC (method A) to give 6.24 (2.4 mg) as a colorless oily residue in 43%.
1

H NMR (600 MHz, CD3OD) δ = 8.54 (br. s, 1 H, formate CHO), 7.94 (d, J = 1.2 Hz, 1

H), 7.67 (d, J = 8.8 Hz, 1 H), 7.44 (s, 1 H), 7.42 (s, 1 H), 7.33 (dd, J = 1.2, 7.6 Hz, 1 H),
7.28 - 7.11 (m, 7 H), 7.09 - 7.05 (br. m, 1 H), 6.99 (dd, J = 1.8, 7.0 Hz, 1 H), 5.61 (dd, J =
14.1, 2.3 Hz, 2 H), 4.55 (dd, J = 2.9, 5.3 Hz, 1 H), 4.44 - 4.41 (m, 1 H), 4.39 (s, 2 H),
4.37 - 4.34 (br. m, 2 H), 3.58 (dd, J = 4.7, 6.5 Hz, 1 H), 3.51 (dd, J = 4.7, 6.5 Hz, 1 H),
3.20 - 3.13 (m, 2 H), 3.12 - 3.04 (br. s, 3 H), 2.99 (dd, J = 5.9, 8.2 Hz, 1 H), 2.41 - 2.37
(m, 2 H), 2.34 - 2.29 (m, 2 H), 2.21 - 2.20 (m, 1 H), 2.07 - 1.98 (m, 2 H), 1.93 - 1.86 (m,
4 H). LC/MS tR = 3.46 min (Characterization Method A); m/z = 871.15 (M + H+), m/z =
915.30 (M - H+, formic acid adduct). HRMS (ESI-TOF) calcd. for C45H47Cl2F2N8O4 (M +
H+) 871.3060, found 871.2988.
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(S)-N-benzyl-2-((S)-2-(3-(1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1Hindazol-6-yl)ureido)-3-(3,4-difluorophenyl)propanamido)-4-(3-(1-(31-(4-(6-(4fluorophenyl)-8-isopropylimidazo[1,2-b]pyridazine-2-carbonyl)-3,3dimethylpiperazin-1-yl)-28,31-dioxo-3,6,9,12,15,18,21,24-octaoxa-27azahentriacontyl)-1H-1,2,3-triazol-4-yl)propanamido)butanamide (6.31c).

To a 5 mL vial with stir bar was added 6.24 (1.7 mg, 2.0 µmol) and 6.30c (2.0 mg, 2.2
µmol). In a second 5 mL vial was added sodium ascorbate (1.2 mg, 6.1 µmol), TBTA (1.0 mg,
1.9 µmol), and CuSO4 (50 mol%, 49 µL of a 0.02 M solution in H2O). This suspension was
diluted with DMSO (0.2 mL) and nitrogen gas was bubbled through the resulting solution for 1
min. This solution was then added to the first vial, the reaction was further diluted with DMSO
(0.2 mL), N2 gas was bubbled through the reaction for 10 seconds, and the reaction was stirred
under N2 for 1 h. A sample aliquot was taken from the reaction, diluted with a minimal amount
of HPLC grade MeOH, and analyzed with LCMS to confirm reaction completion. The reaction
was filtered (0.2 µm syringe filter) and purified with preparative HPLC (method A). Product
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fractions were pooled together, concentrated under reduced pressure in room temperature H2O (to
remove MeOH), and lyophilized overnight to give 6.31c (2.9 mg) as a white solid in 83% yield.
LC/MS tR = 3.85 min (Characterization Method B); m/z = 895.05 [(M + H+)/2], 1785.00 (M - H+),
1831.90 (formic acid adduct); HRMS (ESI-TOF) calcd. for C89H112N17O15F3Cl2 (M – H+)
1784.7780, found 1784.7653.
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8.12

Characterization data for the PAR1 antagonist RWJ-58259 from Chapter 6
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H NMR of 6.13 (300 MHz, CDCl3)
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C NMR of 6.13 (75 MHz, CDCl3)
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LC/MS of 6.13 (+ mode)
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H NMR of 6.15 (300 MHz, DMSO-d6)
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LC/MS of 6.15 (+ mode)
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LC/MS of 6.15 (- mode)
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LC/MS of 6.16 (+ Mode)
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LC/MS of 6.16 (- Mode)

238

1

H NMR of 6.18 (400 MHz, DMSO-d6)
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LC/MS of 6.18 (- Mode)
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245

LC/MS of 6.20(+ Mode)
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LC/MS of 6.21 (+ Mode)
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H NMR of 6.23 (400 MHz, CD3OD, free base)
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LC/MS of 6.23 (+ Mode)
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LC/MS of 6.23 (- Mode)
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LC/MS of 6.24 (+ Mode)
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LC/MS of 6.24 (- Mode)
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LC/MS (+ mode) for compound 6.31c
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LC/MS (- mode) for compound 38c
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